<allTrials totalCount="58" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">41063599</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Family orientated early intervention enhances social-interactive behaviour of premature infants and mother-infant-interaction</title>
      <scientificTitle/>
      <acronym>PRIMA Study (Prospective Randomized Implementation of the Model-project Augsburg)</acronym>
      <studyHypothesis>Condition: Very preterm children who are at an increased risk of cognitive impairments, poor educational achievement and behavior problems and psychopathology. Most consistently, an increased risk for attention problems, hyperactivity and social or peer relationship problems have been reported across a range of hospital and geographically defined cohorts. Improvements in infant self-regulation and mother-infant-relationship may avert longterm behavioural and social relationship sequelae of very preterm birth. A first step in demonstrating such a link is to test in a randomised controlled trial whether an individualised family based approach can alter infant social-emotional regulation. 

Hypothesis: Does an individualised family-based early support intervention (case management approach) for mothers of prematurely born infants alter 1) the maternal sensitivity and 2) infant social-emotional regulation and reciprocal quality of mother-infant interaction in the first 6 months of life?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome measure was the improvement in social-interactive behaviour of the infants, mother's sensitivity and the dyadic quality of interaction. Before discharge the nurses assessed the early mother sensitivity with the Boston City Hospital Assessment of Parental Sensitivity (BCHAPS)(Timepoint 1). This questionnaire consists of 13 closed-ended items, evaluating the mother's sensitive responsivness and care giving competence. The items are ranked on 5-point scales from "poor" to "competent" and the scores totalled. 

At 6 months corrected age the infant social-interactive behaviour and mother-infant interaction were assessed with the Mother-Infant Structured Play Assessment (MISPA)(Timepoint 2). This is an 8-minute, semi-structured face-to-face play interaction which includes the Still-Face Paradigm, which provides a method to access infant regulatory capacities and illustrates central qualities of the young infant's capacities for interpersonal engagement. For the interaction records the infants were placed on a blanket or mat on the floor and mothers were asked to sit on the floor opposite their infant. A mirror was mounted at an angle, which enabled the examiner to videotape both the face and body of the infant and the face and upper torso of the mother. Standardised instructions were used to explain the procedure to the mothers. 

Episode 1 involved the mother playing with her baby with a rattle (warm-up). After 2 minutes (Episode 2) she was cued to lay aside the rattle and play (without a toy) with her baby for another 2 minutes. Then she was asked to get her baby to watch her face, which lasted for 1 minute (Episode 3). Next she was asked to make a still-face for 1.5 minutes (Episode 4) and then finally asked to resume playing with her baby for another 1.5 minutes (Episode 5). 

Three existing schemes were modified and adapted to create a suitable coding scheme: 
1. The Play Observation Scheme and Emotion Ratings (POSER)
2. The Emotional Availability Scales (EAS)
3. Tronick and Weinberg's Infant and Caregiver Engagement Phases (ICEP)

Each interaction episode was coded with 5-point scales reflecting maternal sensitivity (apart from episode 4) and infant social regulatory behaviour. Maternal Sensitivity consisted of 5 rating scales (sensitivity, positive response, negative facial emotional expression, verbal involvement, undercontrol) that were totalled to gain a measure of maternal sensitivity. Social Regulatory Behaviour was also assessed using 5 rating scales (emotional state, attentiveness, responsivness, vocalisation, clarity of signals). 

Quality of dyadic interaction consisted of 2 five-point rating scales (Harmony, Control over interaction) and the scores were totalled. Each of the five episodes in the MISPA was scored separately, and infant, maternal and dyadic behaviours were coded individually. The last episode demonstrating mother-infant reunion after perturbation of interaction was decided to be confirmative for the effect of the intervention. This episode presents the infant with a complex and demanding regulatory task: the infant needs to simultaneously cope with the resumption of the maternal behaviour, as well as the carry-over of negative affect from the still-face episode.</primaryOutcome>
      <secondaryOutcome>The demographic characters and the medical and psychosocial burden of the families were recorded with a structured mother-interview at both time points. Several items of the interview ware totalled showing a dyadic adjustment scale and a psyochosocial stress-index.</secondaryOutcome>
      <trialWebsite>http://www.betainstitut.de/fue_erg_prima_studie.php</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics board of Rheinische Friedrich Wilhelms University, Bonn, Germany. Approved on 27/11/2001 (ref: 181/01)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41063599</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, single-blind, single-center trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fb852260-e6c8-4ffe-a509-54be4fc13d92">
	  <name>Stenglinstr. 2</name>
	  <address/>
	  <city>Augsburg</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D 86156</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Families with premature births &lt;32 weeks Gestational Age (GA) or birth weight below 1500 g and cared for in the Neonatal Intensive Care Unit (NICU) of the University Children Hospital, Bonn, Germany, between 1 January 2002 and 31 December 2003.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>108</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>87 families with 108 children</totalTarget>
      <exclusion>1. Families living more than 100 km from the hospital
2. Mother did not speak German
3. Infant was transferred to another hospital
4. Infant died or suffered major malformations</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Premature infants</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Premature infants</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>43 families with 55 children were randomized in the intervention group and 44 families with 53 children in the control group.  

The aim of our individualised, family-based intervention was to integrate parents in the care of their babies from the very beginning in the NICU and to support families with social needs by providing parent education, improving care-giving competence, enhancing parent-infant interaction, evaluation of the needs and resources of the family, psychosocial care and emotional support, and establishing a network for the family. Beginning in the first week of life trained nurses, social workers and psychologists as required visited as case managers the mothers in the NICU and at home after discharge of the baby up to six months. The intervention addressed problems in four domains including 1) caregiving environment, 2) infant behaviour and characteristics, 3) home discharge and community resources, and 4) family organisation and functioning. Visiting was every two to three days during hospital stay and 1-2 weekly after discharge as needed by the family. The mean duration of the intervention was 161.9 days (45-277): 35.2 days (1-108) during hospital stay and 126.7 days (14-210) after discharge. The professions involved were: nurses in all families, social workers in 42.6% and psychologists in 4.8%.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17218-0</funderId>
      <funderId>Funder17218-1</funderId>
      <funderId>Funder17218-2</funderId>
      <funderId>Funder17218-3</funderId>
      <contactId>Contact55179_17218</contactId>
      <sponsorId>Sponsor53745</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55179_17218">
    <title>Dr</title>
    <forename>Friedrich</forename>
    <surname>Porz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Stenglinstr. 2</address>
      <city>Augsburg</city>
      <country>Germany</country>
      <zip>D 86156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53745">
    <organisation>Beta Institute for Research and Development in Social Medicine (Germany) </organisation>
    <website>http://www.betainstitut.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Kobelweg 95</address>
      <city>Augbsurg</city>
      <country>Germany</country>
      <zip>D 86156</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17218-0">
    <name>The study was internally founded by the beta Institute for Research and Development in Social Medicine (beta Institut für Sozialmedizinische Forschung und Entwicklung), Augsburg, Germany.</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-1">
    <name>The study was also supported by the following institutions:</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-2">
    <name>Köhler foundation (Köhler Stiftung), Essen, Germany (S112/10020/02)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17218-3">
    <name>Northrine-Westphalia Welfarework Foundation (Stiftung Wohlfahrtspflege Nordrhein-Westfalen), Düsseldorf, Germany (SW-620-4206-Z)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">46090514</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to compare the efficacy, safety and tolerability of PSD502, delivered topically onto the upper vagina and cervix, to placebo in controlling discomfort/pain intensity in subjects undergoing outpatient hysteroscopy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Hysteroscopy is used extensively in the evaluation of common gynaecological problems such as premenopausal menstrual disorders, infertility and postmenopausal bleeding. It allows direct visualisation of the uterine cavity and the opportunity for targeted biopsy, safe removal of endometrial polyps, and treatment of submucous fibroids, septa and adhesions. There is a general consensus that hysteroscopy is the current gold standard for evaluating intrauterine pathology, including submucous myomas, polyps, hyperplasia and cancer.

This study aims to evaluate the efficacy of PSD502 in relieving discomfort/pain at placement of the tenaculum on the anterior lip of the cervix during outpatient hysteroscopy.  Topically delivered agents have a theoretical advantage over cervical injection in terms of ease of administration and the potential for side effects with oral or systemically administered agents.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To evaluate the efficacy of PSD502 in relieving discomfort/pain at placement of the tenaculum on the anterior lip of the cervix assessed using a 100 mm VAPS in subjects undergoing hysteroscopy.</primaryOutcome>
      <secondaryOutcome>1. To evaluate the efficacy of PSD502 in relieving discomfort/pain during insertion of the hysteroscope as assessed using a VAPS in subjects undergoing hysteroscopy
2. To evaluate the efficacy of PSD502 in relieving discomfort/pain during examination of the uterine cavity as assessed using a VAPS in subjects undergoing hysteroscopy
3. To evaluate the efficacy of PSD502 in relieving the worst discomfort/pain experienced during the entire hysteroscopy procedure using a 4-point discomfort/pain scale
4. To evaluate the need for additional analgesia in the 24 hours after the procedure
5. To evaluate the safety and tolerability of PSD502 administered to the cervix and vagina</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Wojskowy Instytut Medyczny) on the 22nd August 2007 (ref: 121/WIM/2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46090514</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PSD502-UP-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A phase II, multi-centre, randomised, double-blind, placebo-controlled, parallel group, proof of concept study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c3d81f41-c69f-495a-8da2-47e687406111">
	  <name>Department of Gynaecology</name>
	  <address/>
	  <city>Warsaw</city>
	  <state/>
	  <country>Poland</country>
	  <zip>00-909</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>A subject will be invited to participate if she meets the following inclusion criteria:
1. Healthy, pre-menopausal female who requires hysteroscopy
2. Aged 18 - 50 years inclusive
3. Clinically insignificant medical history and clinical examination other than the underlying condition requiring treatment, in the opinion of the Investigator
4. Post menstruation, but prior to ovulation at the time of the procedure and has a negative pregnancy test
5. Able to understand and complete the visual analogue pain scale (VAPS) and 4-point discomfort/pain scale, in the opinion of the Investigator
6. Willing and able to provide written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>24</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>24</totalTarget>
      <exclusion>A subject will be excluded from study participation if she meets any of the following criteria:
1. Contraindication to hysteroscopy
2. Known hypersensitivity to amide-type local anaesthetics
3. Received another investigational product within the previous 3 months
4. Current history of alcohol or drug abuse such that the subject is unable to comply with the study procedures or has resulting clinically significant organ damage, in the opinion of the Investigator
5. Clinically-significant medical history or clinical finding (e.g. bleeding diathesis or coagulopathy) that would affect the subject's ability to take part in the study, in the opinion of the Investigator
6. Previous hysteroscopy with technical difficulties or side effects
7. Used lidocaine or prilocaine preparation within 6 hours before the hysteroscopy procedure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Discomfort or pain during hysteroscopy</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Discomfort or pain during hysteroscopy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Study medication (active or placebo) will be sprayed onto the cervix in 10 metered dose sprays (to give a total of 75 mg lidocaine and 25 mg prilocaine, or placebo). The first spray will be to the cervix, followed by each of the 4 vaginal fornices in clockwise fashion from the anterior fornix (anterior, left lateral, posterior, right lateral); the spraying pattern will be repeated immediately to complete 10 sprays in total. The time of final spray application will be recorded. After a minimum of 5 minutes and no more than 10 minutes, the excess fluid will be swabbed away. A tenaculum will then be used to secure the cervix and the hysteroscope will be inserted. The subject will then undergo the hysteroscopy procedure.

Product: PSD502 is a metered dose spray that delivers a eutectic mixture of lidocaine and prilocaine for topical anaesthesia. Each actuation dispenses 7.5 mg lidocaine and 2.5 mg prilocaine in their base forms. The propellant used in this spray is norflurane (HFA-134a), which also serves as a solvent. The spray provides a concentrated film of local anaesthetic base, which facilitates drug penetration and is capable of providing rapid, superficial anaesthesia of non-keratinised skin. 

Dose: Ten metered dose sprays will be used to deliver a total dose of 75 mg lidocaine and 25 mg prilocaine. 

Administration: Topical administration to the vagina and cervix approximately 10 minutes, but no sooner than 5 minutes, prior to hysteroscopy.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lidocaine, prilocaine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17292-0</funderId>
      <contactId>Contact55253_17292</contactId>
      <sponsorId>Sponsor53821</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55253_17292">
    <title>Prof</title>
    <forename>Wlodzimierz</forename>
    <surname>Baranowski</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Gynaecology
Military Institute of the Health Services
Szaserow Str 128</address>
      <city>Warsaw</city>
      <country>Poland</country>
      <zip>00-909</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)22 510 1175</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wbaranowski@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53821">
    <organisation>Plethora Solutions Limited (UK)</organisation>
    <website>http://www.plethorasolutions.co.uk/index.php </website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4th Floor
233 High Holborn</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC1V 7DN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7269 8630</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sheryl.caswell@plethorasolutions.co.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487437.b</gridId>
    <rorId>https://ror.org/02y9vw172</rorId>
  </sponsor>
  <funder id="Funder17292-0">
    <name>Plethora Solutions Limited (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">35198481</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Therapy of locally advanced rectal cancer of the upper third by quality controlled total versus partial mesorectal excision</title>
      <scientificTitle>Therapy of cUICC stage II/III rectal cancer of the upper third by quality controlled total versus partial mesorectal excision, followed by adjuvant chemotherapy</scientificTitle>
      <acronym>GAST-05</acronym>
      <studyHypothesis>The multicentric GAST-05 study aims at identifying the optimal surgical treatment of locally advanced (cUICC stage II/III) rectal cancer located 12 - 16 cm above the anocutaneous verge. Two established surgical techniques are compared: 
1. Total mesorectal excision (TME), to completely eliminate affected and surrounding tissue, bears the risk of post-surgical complications
2. Partial mesorectal excision (PME) restricts surgery to the afflicted tissue and defined surroundings

PME may be equally effective in eliminating cancer while limiting post-operative complications. No clinical data have been raised to date that show if TME or PME is oncologically superior. To answer this requires a refocus on the principles of both resection techniques, including peri- and post-operative quality control. Post-surgical chemotherapy is identical in both trial arms. Primary endpoint is the disease-free survival after 3 years. 

The GAST-05 study is an add-on study to the ongoing CAO/AIO/ARO-04 trial, which intends to optimise the pre-surgical chemoradiotherapy of cUICC stage II/III cancers in the lower two thirds of the rectum (0 - 12 cm). The comparison of the long-term outcomes of both studies (GAST-05: surgical procecures; CAO/AIO/ARO-04: intensified preoperative treatment) will influence future studies; they will apply the surgical procedure that is identified as being superior during the GAST-05 study. Additional gene expression analyses on pre-therapeutically taken tumour probes will show if gene profiling can help to predict individual prognosis. 

The identification of the oncologically superior of two standardised surgical treatments (TME and PME) of cUICC stage II/III cancers of the upper third of the rectum has not been determined. The identification is a prerequisite for further studies, needed to reduce the side effects of optimised surgical treatments. If both techniques, TME and PME, turn out to be equivalent, that technique will be regarded as superior, which promises less comorbidities, a higher qualitiy of life, and lower health care costs (i.e. PME). 

A cross-comparison of disease-free and overall survival data from the GAST-05 trial and the CAO/ARO/AIO-04 trial will further allow judgement on the need for further studies on multimodal therapies for rectal cancers of the upper third. If the rate of local and distant metastases turns out to be equal or lower in the GAST-05 trial (upper third, no neoadjuvant RT/CT, PME/TME) than in the CAO/ARO/AIO-04-trial (lower two thirds, intensified preoperative treatment), further trials may be unnecessary which test multimodal therapies in cancers of the upper third. Patients with cUICC stage II/III cancers of the upper third of the rectum will then be spared potentially ineffective preoperative radiochemotherapy with its toxicities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Disease-free survival after 3 years (local and/ or distant recurrences).</primaryOutcome>
      <secondaryOutcome>1. R0-rate of resection
2. Post-operative 30-day lethality
3. Post-operative morbidity (especially rate of anastomotic insufficiencies)
4. Cumulative incidence of local relapses and distant metastases
5. Survival after 3 and 5 years
6. Acute and late toxicity of the chemotherapy according to the Common Toxicity Criteria of the National Cancer Institute (NCI CTC version 2.0) 
7. Post-operative late complications (defaecation problems, anastomotic  stenoses, loss of sphincter function)
8. Quality of TME and PME as assessed
9. Quality of life according to the European Organisation for Research and Treatment of Cancer (EORTC)-Questionnaire QLQ-30 (3.0)

Assessment of safety: TME, PME, and adjuvant chemotherapy are established procedures.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Georg-August-University Gottingen Ethik-Kommission der Medizinischen Fakultat on the 17th January 2007 (ref: 21/11/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35198481</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, multi-centric, prospectively randomised phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fc2f1f4a-0a47-40dd-b3c1-3f911bac797e">
	  <name>Georg-August University of Gottingen</name>
	  <address/>
	  <city>Göttingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>37075</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Histologically confirmed advanced primary rectum carcinoma at a level 12 - 16 cm above the anocutaneous verge (as measured by rigid endoscopy), endosonographically classified as uT3-4 or uN+ carcinomas, no evidence for synchronous distant metastases
2. Patients aged 18 - 85 years, either sex 
3. No preliminary treatment of rectum carcinoma</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>1. Successfully treated secondary malignoma with the exception of basal cell carcinoma of the skin and in situ cervix carcinoma, respectively, The inclusion of patients with other tumours, that have been treated successfully and have not reappeared during the last 5 years, has to be discussed with the principal investigator 
2. Simultaneous therapy with other anti-cancer drugs 
3. Chronic colonic diseases</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Rectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For all procedures, standard operating procedures (SOPs) are available.  

Experimental intervention:
1. Arm A: total mesorectal excision (TME) including surgical and pathological quality control, followed by standard adjuvant chemotherapy. The mesorectum is completely excised downwards to the pelvic floor:
1.1. Dorsally: entire retro-rectal fat body with the lymph tissue under consideration of the fascial system
1.2. Ventrally: including the spatium prerectale along the Denonvilliers-fascia
1.3. Laterally: entire area up to pelvis

2. Arm B: Partial mesorectal excision (PME) including surgical and pathological quality control, followed by adjuvant chemotherapy. PME follows the same surgical principles as in TME with the following exception: the mesorectum is transected at a right angle to the rectal wall 5 cm beyond the gross distal margin of the tumour, as measured in situ

In both trial arms, surgery is followed by adjuvant chemotherapy: 
1. Folinic acid: 400 mg/m^2, 2-hour infusion, day 1
2. Oxaliplatin: 100 mg/m^2 2-hour infusion in 500 ml glucose 5%, day 1
3. 5-Fluorouracil: 2400 mg/m^2 as 46-hour infusion

Perioperative assessment of mesorectal excision (TME/PME):
Staining of the specimen via inferior mesenteric artery, photo-documentation:
Class 1: no leakage, optimal TME/PME
Class 2: punctual leakage(s), good TME/PME
Class 3: extensive leakage(s), incomplete TME/PME

Standardised pathological assessment of TME/PME (in addition to established TNM/UICC criteria): 
Extent: TME/PME?
In case of PME: 
1. Distance between macroscopically visible distal margin of tumour and distal transection margin measured in centimetres. Measuring method: 
1.1. Fresh, non-stretched specimen
1.2. After fixation (non-pinned)
1.3. After fixation (pinned, non-stretched) 
2. Coning (distal transaction in a plane at 90° to the rectal wall): no, yes
3. Macroscopic assessment of the specimen surface in all cases:
3.1. Intact, smooth (lipoma-like)
3.2. Circumscribed defect(s) no greater than 5 mm
3.3. Extensive defect(s), muscular layer of the rectum invisible
3.4. Extensive defect(s), muscular layer of the rectum visible
3.5. Incision into the tumour or tumour torn open

Pathological quality assessment of the specimens after TME/PME:
1. Complete: intact mesorectum, no defects larger than 5 mm, no PME-coning, smooth circumferential resection margin on slicing
2. Moderate: irregular mesorectal surface, moderate PME-coning, muscularis propria invisible with the exception of area of insertion of levator muscles, moderate irregularity of the circumferential resection margin
3. Incomplete: little bulk of mesorectum with defects down into mucularis and/or very irregular circumferential resection margin, PME-coning

Control intervention: 
None

Duration of intervention per patient: 32 weeks  
Follow-up per patient: 3 years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Folinic acid, oxaliplatin, 5-Fluorouracil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17442-0</funderId>
      <contactId>Contact55403_17442</contactId>
      <sponsorId>Sponsor53973</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55403_17442">
    <title>Dr</title>
    <forename>Torsten</forename>
    <surname>Liersch</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Georg-August University of Gottingen
Department of General and Visceral Surgery
Robert-Koch-Strasse 40</address>
      <city>Göttingen</city>
      <country>Germany</country>
      <zip>37075</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)5513 983 23</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tliersc@gwdg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53973">
    <organisation>Georg-August University of Gottingen (Georg-August-Universitat Gottingen, Universitatsmedizin) (Germany) </organisation>
    <website>http://www.uni-goettingen.de/en/sh/1.html </website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof. Dr. med. H. Becker and Dr. med. Torsten Liersch
Department of General and Visceral Surgery 
Robert-Koch-Strasse 40</address>
      <city>Göttingen</city>
      <country>Germany</country>
      <zip>37075</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)5513 983 23</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">tliersc@gwdg.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7450.6</gridId>
    <rorId>https://ror.org/01y9bpm73</rorId>
  </sponsor>
  <funder id="Funder17442-0">
    <name>German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) (ref: 518)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-13T00:00:00.000Z">06098697</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A one month study of the efficacy and safety of SVS20 versus carbomer and saline in patients with bilateral moderate dry eye syndrome: a randomised, double blind, controlled, parallel group, pilot, phase II study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the efficacy and safety of SVS20 versus saline (as a basic standard reference product) and carbomer (as a standard treatment with a marketing authorisation in most EU countries) in patients with bilateral moderate dry eye syndrome due to Sjogren's syndrome (immune exocrinopathy) or diagnosed as a primary syndrome.

Please note that the results of this study were used to calculate the sample size of a more recent phase III multicentre study conducted in France and UK. For more details on this phase III study, please visit the ISRCTN record at http://www.controlled-trials.com/ISRCTN91412460.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Since this study was a phase II there were no primary or secondary outcomes. Our aim was to analyse the efficacy and safety of SVS20 versus saline and carbomer and to find a parameter that could be used as the primary criterion for the following pivotal phase III study (ISRCTN91412460). Therefore, the following parameters were assessed:
1. Efficacy and tolerability:
1.1. Number of instillations
1.2. Staining with lissamine green
1.3. Symptom intensity and frequency
1.4. Repercussion of symptoms on activities of daily life
1.5. Comfort of the eye drops (presence and duration of blurred vision after instillation)
1.6. Slit lamp examination
1.7. Tear volume (Schirmer I test)
1.8. Tear film BUT
1.9. Corneal staining with fluorescein
1.10. Global evaluation of efficacy

2. Safety: 
2.1. Comfort of the eye drops (presence and duration of blurred vision)
2.2. BCVA
2.3. Impairment of dry eye symptoms
2.4. Ocular adnexa examination 
2.5. Adverse events reporting

Parameters were measured at V1 (Day-16 to Day-12), V2 (Day 0) and V3 (Day 28).</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. The National Ethics Committee for Clinical Pharmacology (KFEB) on the 29th June 2005
2. The Ministry of Health on the 14th July 2005

Thereafter, local Institutional Review Board (IRB) at each centre gave favourable opinions on 13 September 2005 (Dr. Deák), 5 October 2005 (Dr. Sohajda), 18 October 2005 (Dr. Márta), 21 November 2005 (Dr. Zeher) and 2 December 2005 (Dr. Bereczki).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06098697</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>SVS20-HUN-05-01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, controlled, parallel group, pilot, phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hungary</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73a693e1-5579-4240-9240-b80fc77959d8">
	  <name>Szent János Kórház</name>
	  <address/>
	  <city>Budapest</city>
	  <state/>
	  <country>Hungary</country>
	  <zip>1125</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Signed informed consent
2. Male and female patients aged 18 years and over
3. Patients with at least a three-month documented history of bilateral moderate dry eye due to Sjogren's syndrome (immune exocrinopathy) or diagnosed as a primary syndrome
4. Patients with total score of staining with lissamine green of at least 5/12 and not more than 10/12 for each eye
5. Patients with at least two symptoms of dry eye among soreness, scratchiness, dryness, grittiness and burning each:
5.1. Occurring at least often and
5.2. Rated at least 30 mm and not more than 70 mm on the 0 to 100 mm visual analogue scale (VAS)
6. Patients with at least two out of three following objective parameters:
6.1. Schirmer test less than or equal to 10 mm wetting/5 minutes for each eye
6.2. Tear film break-up time (BUT) less than or equal to 10 seconds for each eye
6.3. Staining with fluorescein with a total score greater than or equal to 3/7 for each eye
7. Eligible patients using the following medications should have been taking them continuously for the two months before the screening visit and the dose should not have changed during the whole trial:
7.1. Tricyclic antidepressive agents
7.2. Anti-histaminic agents
7.3. Phenothiazines
7.4. Cholinergic agents
7.5. Antimuscarinic agents
7.6. Non-steroidal anti-inflammatory drugs (NSAIDs)
7.7. Beta-blockers
7.8. Immunomodulators
7.9. Anti-acneic agents
7.10. Diuretic agents
8. Female patients should be post-menopausal or be using a recognised, reliable method of contraception for at least three months before selection
9. Patients complying with the local regulations (e.g. social security system)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>72</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>72 patients were planned for 1:1:1 randomisation to SVS20 (n = 24), saline (n = 24) and carbomer (n = 24)</totalTarget>
      <exclusion>1. Patients who respond to Unilarm® during or at the end of the run-in period so that their inclusion criteria are not met at D0 examinations
2. Patients with unilateral dry eye
3. Severe dry eye syndrome, defined as:
3.1. Staining with fluorescein with a depth score less than 3 in any eye and/or
3.2. Severe bulbar conjunctival hyperaemia (score of 4) in any eye and/or
3.3. Severe limbal hyperaemia (score of 4) in any eye and/or
3.4. Severe palpebral observation (score of 4) in any eye and/or
3.5. Severe blepharitis in any eye
4. Patients who underwent:
4.1. Refractive surgery within the last 12 months before selection and/or
4.2. Any other ocular surgery or ocular trauma within the last four months before selection
5. Patients taking the following systemic concomitant medications within the last two months before selection:
5.1. Corticosteroids and/or
5.2. Tetracyclines
6. Patients requiring concomitant in-eye medication for the whole trial, except Unilarm® during the selection period only
7. Patients with abnormality of the nasolacrimal drainage apparatus
8. Patient with permanent occlusion of lacrimal puncta in any eye
9. Patient with temporary punctal plug within two months before selection in any eye
10. Patients with other diseases or characteristics judged by the investigator to be incompatible with the frequent assessments needed in this study or with reliable instillation of the products (for example disability of the upper limbs)
11. Patients who participated in any other clinical trial within the last 30 days before selection
12. Patients with known hypersensitivity to hyaluronic acid or any component or procedure used in the study
13. Patients who need or intend to wear contact lens during the whole trial
14. Patients with best corrected visual acuity (BCVA) less than 1/10 in any eye
15. Pregnant or lactating females
16. Known human immunodeficiency virus (HIV) positive patients, if they belong to an anamnestic known risk group like drug addicts, etc., or if there is any reasonable doubt about HIV a validated test must be performed
17. Patients with a concomitant diagnosis of sarcoidosis, non-hodgkin lymphoma, bone marrow transplant or any secondary Sjogren's syndrome due to rheumatoid diseases or as an adverse event possibly of any other prior of concomitant medication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Dry eye syndrome</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Disorders of lacrimal system</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There were three arms: 
1. SVS20
2. Saline 
3. Carbomer

Patients instilled 2 - 4 times a day one of these eye drops. Treatment duration was 1 month with a previous period of wash-out of 112 to 16 days.

The following parameters were measured at V1 (day 16 to day 12), V2 (day 0) and V3 (day 28):
1. BUT
2. Schirmer I test
3. Lissamine and fluorescein staining
4. BCVA
5. Slit lamp examination
6. Symptoms intensity and frequency</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>SVS20, carbomer</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17492-0</funderId>
      <contactId>Contact55454_17492</contactId>
      <sponsorId>Sponsor54034</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55454_17492">
    <title>Prof</title>
    <forename>Margrit</forename>
    <surname>Zeher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Szent János Kórház
1 Diósárok u.</address>
      <city>Budapest</city>
      <country>Hungary</country>
      <zip>1125</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor54034">
    <organisation>TRB Chemedica International SA (Switzerland) </organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>12 rue Michel-Servet </address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487371.e</gridId>
    <rorId>https://ror.org/012pz6314</rorId>
  </sponsor>
  <funder id="Funder17492-0">
    <name>TRB Chemedica International SA (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-08T00:00:00.000Z">86152982</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of Haemate HS for the treatment of severe intraoperative hemorrhage during aortic-valve replacement in patients with aortic-valve stenosis</title>
      <scientificTitle/>
      <acronym>HAVAS-Study</acronym>
      <studyHypothesis>Evaluation of the efficacy and safety of Haemate HS in this clinical setting</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Intra- and postoperative transfusion requirements according to defined transfusion thresholds.</primaryOutcome>
      <secondaryOutcome>1. Requirement of rethoracotomy, assessed during patients stay at the intensive care unit 
2. Surgeons' subjective rating of therapeutic efficacy after application of Haemate HS or placebo (classification of bleeding after therapy as "better", "equal" or "worse") 
3. Survival (perioperative mortality, mortality during hospital stay, mortality within a 90 day period following surgery) 
4. Duration of treatment on intensive care ward 
5. Adverse events and therapy-related side effects, assessed within the first 10 days after surgery. A second assessment is carried out after 3 month (at day 90)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee of the Heinrich Heine University Medical Center (Duesseldorf, Germany) on 25 April 2007. First amendment approved on 28 November 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86152982</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BI8021_5101</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Two-arm, randomised, double-blind controlled clinical study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-19T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7fa4256a-350f-48e8-a0ae-2fa2ec0d217f">
	  <name>Department of Hemostasis and Transfusion Medicine</name>
	  <address/>
	  <city>Duesseldorf</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-40225</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with isolated valvular aortic stenosis or combined aortic-valve defect with prevailing stenosis (mean transvalvular gradient &gt;50 mmHg) with severe bleeding during aortic-valve replacement 
2. Age &gt;18 years. 
3. Written informed consent. 
4. All patients that fulfill at least one of the following criteria 15 minutes after the end of extracorporal circulation and application of protamine: 
4.1. Excessive bleeding without surgical explanation according to the surgeons' impression (Classification of bleeding as "normal", "moderate" or "excessive" by the surgeon. Classification as "excessive" bleeding leads to recruitment to the study). 
4.2. Drainage volume &gt;40 ml in 5 minutes following application of protamine and thorax closure.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 patients (20 per arm)</totalTarget>
      <exclusion>1. Participation in other interventional studies that potentially impair the interpretation of results 
2. History suggestive for inherited or acquired bleeding disorder 
3. Written informed consent not to be obtained 
4. Active endocarditis 
5. Concomitant coronary heart disease 
6. Agents impairing platelet function at the time of surgery 
7. Pregnancy 
8. Known or suspected intolerance against Haemate HS 
9. Previous thromboembolic complications 
10. Known hepatitis B, hepatitis C or HIV infection 
11. Known or suspected intolerance against standard medication (e.g., heparin) 
12. Emergency surgery within the last 7 days 
13. Previous chemotherapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-10-19T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Severe intraoperative hemorrhage during aortic-valve replacement</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Severe intraoperative hemorrhage during aortic-valve replacement</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Intraoperative infusion Haemate HS 500/1000 IU (vWF/F VIII:C concentrate), time of infusion according to inclusion criteria.  
Control group: Intravenous infusion of 0.9% NaCl solution (100 ml)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Haemate HS (intraoperative infusion)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17333-0</funderId>
      <contactId>Contact55294_17333</contactId>
      <sponsorId>Sponsor53862</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55294_17333">
    <title>Dr</title>
    <forename>Rainer</forename>
    <surname>Zotz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Hemostasis and Transfusion Medicine
Heinrich Heine University Medical Center 
Moorenstrasse 5 </address>
      <city>Duesseldorf</city>
      <country>Germany</country>
      <zip>D-40225 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49(0)211 8117474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Nicola.Moeller@med.uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53862">
    <organisation>Heinrich Heine University Duesseldorf (Germany) </organisation>
    <website/>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>c/o Dr Rainer B. Zotz
Department of Hemostasis and Transfusion Medicine
Heinrich Heine University Medical Center
Moorenstrasse 5</address>
      <city>Duesseldorf </city>
      <country>Germany</country>
      <zip>D-40225</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)211 8117474</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">zotz@med.uni-duesseldorf.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411327.2</gridId>
    <rorId>https://ror.org/024z2rq82</rorId>
  </sponsor>
  <funder id="Funder17333-0">
    <name>CSL Behring GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2008-02-06T00:00:00.000Z">88422298</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the effectiveness of a nursing intervention aiming at facilitating the hospital to home transition within a cardiologic Emergency Room (ER) [Évaluation de l&#146;efficacité d&#146;un modèle d&#146;interventions infirmières de soutien à la transition hôpital-domicile dans une urgence cardiologique]</title>
      <scientificTitle/>
      <acronym>TRANSIT-ER [TRANSIT-URGENCE]</acronym>
      <studyHypothesis>We are studying the nursing discharge interventions modalities provided in the Emergency Room (ER) of a cardiology tertiary care centre where an important proportion of patients make repeated visits to the ER in the year following their discharge to home (24% of the patients).

It is hypothesised that the return rates to the ER in the month following discharge to home will be less important in the group receiving the intervention than in the control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>'Return to ER: the occurrence of any visits to the cardiologic ER in the month following randomisation. This will be measured using the hospital patient's registry.</primaryOutcome>
      <secondaryOutcome>The secondary outcomes will be measured at baseline and one month following randomisation by a telephone interview and are as followed: 
1. Health care continuity using the Heart Continuity of Care Questionnaire (HCCQ), a 41-item questionnaire using a 5 points Likert scale (score 1 to 5, 1 = strongly disagree, 5 = strongly agree) measuring the patients' perception of continuity of care in regard to eight different dimensions. A higher score indicate a better continuity of care process according to the patient.
2. Patient's self-care management using the Therapeutic Self-Care Tool (TSCT), a 12-item questionnaire using a 5 points Likert scale (score 0 to 5, 0 = not at all, 5 = very much so) measuring the patients' ability to initiate and perform activities aiming at maintaining health, managing health problems and restoring functioning. A higher score indicate better self-care capacities in the patient.
3. Medication adherence scale using the Self-Reported Medication-Taking Scale (SR-MTS), a 4-item questionnaire using a dichotomous (yes or no) scale measuring patients' adherence to prescribed medication. A higher score indicate a poorer adherence to medication.
4. Patients' perception of control over the disease and of its consequences using three subscales of the Illness Perception Questionnaire - Revised (IPQ-R), a 38-item questionnaire using a 5 points Likert scale (score 1 to 5, 1 = totally agree, 5 = totally disagree) measuring the patients' perception of his disease. The three subscales used are: 
4.1. Consequences (6 items)
4.2. Personal control (6 items) 
4.3. Treatment control (5 items)
Higher scores on the consequences subscale represent strongly held beliefs about the negative consequences of the disease. Higher scores on the control subscales represent positive beliefs about the controllability of the illness. 
5. Anxiety and depressing feelings using the Hospital Anxiety and Depression Scale (HADS), a 14-item questionnaire using a 4 points ordinal rating scale and composed of two subscales (anxiety and depression - each score from 0 to 21). A higher score to each of the subscales indicate a higher degree of symptoms (anxiety or depression).
6. Health services utilisation using the medicare provincial registry (Régie de l&#146;assurance maladie du Québec). The occurence of ER visits, hospitalisation or medical consultations by the patient within the province of Québec will be collected at 1, 3, 6 and 12 months following discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the research ethics committee of the Institut de Cardiologie de Montréal on the 7th September 2007 (ref: 07-963).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88422298</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>FRSQ 10187</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial - one ER (single centre)</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0aa2b2c1-59d5-4402-b6cb-14c7920a19ab">
	  <name>R-1520</name>
	  <address/>
	  <city>Montreal, Quebec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>H1T 1C8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female aged 18 years old or more presenting both of the following repeated visits to the ER criterion: 
1.1. Taking six medications or more a day
1.2. Having made one visit or more to the cardiologic ER in the last 12 months
2. Visiting the ER for an unplanned visit (i.e. not coming to the ER on a planned basis, e.g. to receive a laboratory or diagnosis procedure result)
3. Being discharged from the ER directly to their home
4. Having the physical and cognitive capacities to answer a written questionnaire and to communicate by telephone
5. Being able to communicate in French or in English</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>462</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>462</totalTarget>
      <exclusion>1. Having already another nursing follow-up in the 10 days following discharge (e.g. from another research project or from a specialised clinic) to avoid duplication of the nursing interventions being provided to the patient
2. Having already been recruited in the study in a precedent visit to the cardiologic ER</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Facilitation of hospital to home transition after a visit to the ER</description>
	<diseaseClass1>Other</diseaseClass1>
	<diseaseClass2>Facilitation of hospital to home transition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All eligible patients will meet with the research nurse after discharge care. Then, the study will be presented to the patient. After informed consent, the participants will be randomly assigned to the intervention or control group. The two groups will answer a questionnaire about the secondary outcomes and the baseline characteristics will be recorded.

Intervention group: 
After randomisation, the nurse will proceed with an assessment of the patient's risks of repeated visits to the ER following discharge to home. The evaluation will include the following themes: 
1. Patient's perception in regard to his discharge to home
2. Patient's self-management of his disease, symptoms and co-morbidities
3. Patient's self-management of his treatment
4. Patient's self-management of his daily living and domestic activities
5. Patient's self-management of his emotions and cognitions
6. Patient's external resources management 
7. Patient's health-services utilisation management

Following the assessment, the nurse will propose tailored interventions to the patient aiming at managing the repeated emergency department visits risk factors identified. Those interventions include: 
1. Teaching
2. Legitimisation and normalisation
3. Listening and empathy
4. Reassurance
5. Reframing
6. Confrontation
7. Recommendations
8. Warnings
9. Reinforcement
10. Referral to external resources 
11. Support to external resources already in place

The research nurse will proceed with this assessment-intervention process thrice: 
1. In person at the patient's discharge from the ER
2. By telephone 4 ± 3 days following discharge 
3. By telephone 10 ± 3 days following discharge

Finally, the patient will be able to contact the nurse by telephone during working hours in the 30 days following discharge for any concerns he would like to address her. 

Control group: 
No specific intervention by the research nurse, the patient will return to home.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17232-0</funderId>
      <contactId>Contact55193_17232</contactId>
      <sponsorId>Sponsor53759</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55193_17232">
    <title>Dr</title>
    <forename>Sylvie </forename>
    <surname>Cossette</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>R-1520
5000, Belanger Street</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H1T 1C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 376 3330 ext. 4012</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sylvie.cossette.inf@umontreal.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53759">
    <organisation>Montreal Heart Institute (MHI) Research Centre (Canada)</organisation>
    <website>http://www.icm-mhi.org/en/index.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>5000, Belanger Street</address>
      <city>Montreal, Quebec</city>
      <country>Canada</country>
      <zip>H1T 1C8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 514 376 3330</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Richard.Maheu@icm-mhi.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.482476.b</gridId>
    <rorId>https://ror.org/03vs03g62</rorId>
  </sponsor>
  <funder id="Funder17232-0">
    <name>Quebec Health Research Fund (Fonds de recherche en Santé du Québec [FRSQ]) (Canada) (ref: 10187)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">27058472</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in chronic staphylococcal osteomyelitis: a long-term follow-up trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Oral rifampin-cotrimoxazole combination may be as useful as the standard intravenous cloxacillin therapy against chronic osteomyelitis by Staphylococcus aureus.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Treatment failure rate, defined as the number of cases with clinical relapse (appearance or recurrence of local inflammatory signs or sinus tract drainage, with or without microbiological confirmation) during follow-up.</primaryOutcome>
      <secondaryOutcome>1. Treatment tolerability and compliance (number of patients who did not fulfil protocol treatment and reason), from patient inclusion to the end of antibiotic therapy (8 weeks)
2. Length of hospital stay (days) for each treatment schedule; defined as hospitalisation during the diagnosis and treatment of the episode</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Investigation Committee of Hospital de Bellvitge in January 1991.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27058472</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre interventional randomised, active controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1991-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="36d5acd5-06a6-4943-92d7-dda5e4b64ab5">
	  <name>Hospital de Bellvitge</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08907</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adult patients (greater than 18 years old) of any gender with chronic osteomyelitis by Staphylococcus aureus treated with surgery.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Exploratory study. Fifty patients included</totalTarget>
      <exclusion>1. Prosthetic joint infection
2. Methicillin resistant Staphylococcus aureus
3. Allergy to protocol antibiotics
4. Strain resistance to cotrimoxazole or rifampin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1991-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Non-axial chronic osteomyelitis due to Staphylococcus aureus</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Chronic osteomyelitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After surgery and identification of Staphylococcus aureus upon surgical samples, randomisation of patients for antibiotic therapy: 
Group A: intravenous cloxacillin (2 g every four hours [q4h]) for 6 weeks followed by oral cloxacillin (500 mg every six hours [q6h]) for 2 weeks
Group B: oral rifampin-cotrimoxazol combination for 8 weeks (rifampin 600 mg every 24 hours [q24h] plus 7 - 8 mg/kg per day of trimethoprim component, equivalent to three simple strength cotrimoxazole capsules, every 12 hours [q12h])

The total duration of the protocol treatment was 8 weeks for both groups (6 intravenous [iv] and 2 oral [po] in the cloxacillin group and 8 po in the rifampin-cotrimoxazole group). The duration of the follow-up is from the end of antibiotic therapy until 2007 (a median of 10 years).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Cloxacillin, rifampin-cotrimoxazole, trimethoprim</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17382-0</funderId>
      <contactId>Contact55343_17382</contactId>
      <sponsorId>Sponsor53913</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55343_17382">
    <title>Prof</title>
    <forename>Javier</forename>
    <surname>Ariza Cardenal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hospital de Bellvitge
Feixa Llarga s/n
L'Hospitalet de Llobregat</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53913">
    <organisation>Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain) </organisation>
    <website>http://www.idibell.es </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr. Javier Ariza Cardenal
Hospital de Bellvitge 
Feixa Llarga s/n
L'Hospitalet de Llobregat </address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08907</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418284.3</gridId>
    <rorId>https://ror.org/0008xqs48</rorId>
  </sponsor>
  <funder id="Funder17382-0">
    <name>Hospital de Bellvitge (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">06127083</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of post-caesarean infections in low resource countries: is a single dose as adequate as a multiple dose antibiotic regiment? A randomised controlled trial</title>
      <scientificTitle>Is the administration of a single prophylactic dose of ampicillin and metronidazole before caesarean section as effective as a multiple day regimen of these antibiotics to prevent postpartum maternal infection in a low resource setting? A randomised controlled trial</scientificTitle>
      <acronym/>
      <studyHypothesis>Single dose antibiotic prophylaxes is as effective as a multiple dose scheme in women undergoing a caesarean section in low resource setting in preventing postoperative infections.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The presence of fever, endometritis, urinary tract infection, wound infection or other serious infections (such as pelvic abscess, peritonitis, sepsis). 

Timepoint of evaluation is on discharge (see interventions section): an independent doctor will review the wound and score the wound healing and record if any complication arose or additional antibiotics were given.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Instritute for Medical Research, Dar es Salaam (Tanzania) on the 12th November 2007 (ref: NIMR/HQ/R.8a/Vol.IX/633).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06127083</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Evaluator-blind randomised controlled non-inferiority trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-01-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="15602248-b215-4db9-ba1c-22ed0b319ee2">
	  <name>PO Box 228</name>
	  <address/>
	  <city>Lindi</city>
	  <state/>
	  <country>Tanzania</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Delivery through caesarean section
2. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>160</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>160</totalTarget>
      <exclusion>1. Use of antibiotics in the last week
2. Known allergy for any of the antibiotics used
3. Greater than 24 hour rupture of membranes
4. Evident infection or fever pre- or during operation</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet (only in Kiswahili)</patientInfoSheet>
      <recruitmentStart>2008-01-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-01-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Post-operative infection after caesareans</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Post-operative infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: ampicillin 1000 mg and metronidazole 500 mg intravenous 20 minutes prior to caesarean section 
Group 2: ampicillin 1000 mg and metronidazole 500 mg intravenous 20 minutes prior to caesarean section followed by ampicillin 500 mg 8-hourly for two more doses and metronidazole 500 mg 8-hourly for two more doses. After completion of the intravenous (iv) doses the patients will receive oral medication for four days (total 12 doses) of amoxicillin 500 mg and metronidazole 400 mg. 

The follow up will be until the patients are discharged: for uncomplicated lower segment caesarean section (LSCS) this will be on day five (in case of pfannenstiel incision) and day seven (in case of median incision). When complications arise, the patient will be followed up longer, until discharge.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17448-0</funderId>
      <contactId>Contact55409_17448</contactId>
      <sponsorId>Sponsor53979</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55409_17448">
    <title>Dr</title>
    <forename>Heleen</forename>
    <surname>van Beekhuizen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>PO Box 228</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53979">
    <organisation>Sokoine Regional Hospital (Tanzania)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>PO Box 1011</address>
      <city>Lindi</city>
      <country>Tanzania</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17448-0">
    <name>Sokoine Regional Hospital (Tanzania)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-05T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-02-05T00:00:00.000Z">90960030</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Functional milk product On the Metabolic Syndrome II</title>
      <scientificTitle>Randomised, controlled, double-blind clinical study on the effect of a functional milk-product on metabolism of men with diagnosed metabolic syndrome: study with extended sample size</scientificTitle>
      <acronym>EFOMS II</acronym>
      <studyHypothesis>The goal of the investigation is the question, to what extent the risk of the metabolic syndrome may be reduced by substances naturally occurring in milk. The pathophysiology of the metabolic syndrome is characterised by an insulin resistance, a dyslipidaemia, an essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus and atherosclerosis. Such metabolic disturbances increase in the industrialised countries and in the developing countries, too, and represent an important economical and public-health cost factor. It is necessary to identify the relevant factors of human nutrition and to develop potential avoidance strategies, e.g. by development of functional food. 

The cow-milk derived substances, which will be used in this study have had influenced individual components of the metabolic syndrome and lowered the risk of components of the metabolic syndrome in own animal and human trials. 

This study is an extension of a previous human study (ISRCTN41474531 - see http://www.controlled-trials.com/ISRCTN41474531).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change of HOMeostasis model Assessment of Insulin Resistance (HOMA-IR) during the intervention period.</primaryOutcome>
      <secondaryOutcome>1. Blood pressure 
2. Body mass index (BMI), waist-to-hip ratio
3. Mean blood glucose during continuously glucose monitoring
4. Postprandial concentration of several hormones and blood parameters linked mainly to carbohydrate metabolism</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University of Kiel (Germany) on the 26th October 2007 (ref: A171/06 - extended sample size).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN90960030</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study is a randomised double-blind placebo-controlled intervention study over 8 weeks.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d31222f0-eb82-4940-bf84-52b9b9dca0c1">
	  <name>Institute for Physiology and Biochemistry of Nutrition</name>
	  <address/>
	  <city>Kiel</city>
	  <state/>
	  <country>Germany</country>
	  <zip>24103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men, 45 - 70 years old
2. A metabolic syndrome as defined by the International Diabetes Federation, 2006 (A new IDF worldwide definition of the metabolic syndrome: the rationale and the results - Diabetes Voice, Vol. 50 Issue 3, 2005)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240 volunteers (120 for each the verum and control group)</totalTarget>
      <exclusion>1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination 
2. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure 
3. Known metabolic or gastro-intestinal diseases, which affects the absorption, metabolism or excretion of food or food components 
4. Condition after operation of the gastro-intestinal tract, which affect gastro-intestinal motility 
5. Haemoglobin less than 12 g/dL 
6. Malfunction of blood coagulation or drugs, leading to malfunction of blood coagulating diabetes 
7. Operation within the last 3 months, which still affects the current state of health 
8. Illness of thyroid gland, which has metabolic and/or cardiovascular effects 
9. Known hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection or chronic liver damage 
10. Kidney insufficiency 
11. Hypercalcaemia 
12. Drug or alcohol abuse 
13. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal tract 
14. Intake of hormone preparations 
15. Vegetarianism, anorexia, bulimia 
16. Known milk protein allergy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic syndrome</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The volunteers of the verum group will take one portion of the functional milk-product (product code 966125, a non-registered product) once a day after lunch with a dessert for 56 days. The product of the control group is based on meat protein and is isoenergetic and isonitrogenous. 

Primary and secondary outcome measures will be analysed before and at the end of the intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Functional milk-product (product code 966125, a non-registered product)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17367-0</funderId>
      <contactId>Contact55328_17367</contactId>
      <sponsorId>Sponsor53897</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55328_17367">
    <title>Prof</title>
    <forename>Juergen</forename>
    <surname>Schrezenmeir</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Physiology and Biochemistry of Nutrition
Federal Reserach Centre for Nutrition and Food
Hermann-Weigmann-Str. 1</address>
      <city>Kiel</city>
      <country>Germany</country>
      <zip>24103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)431 609 2220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juergen.schrezenmeir@bfel.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53897">
    <organisation>Humana GmbH (Germany) </organisation>
    <website>http://www.humana.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bielefelder Strasse 66</address>
      <city>Herford</city>
      <country>Germany</country>
      <zip>32051</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17367-0">
    <name>Humana GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2008-01-29T00:00:00.000Z">88931004</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The learning curve for vitreous surgery</title>
      <scientificTitle>The learning curve for primary vitrectomy without scleral buckling for pseudophakic retinal detachment</scientificTitle>
      <acronym/>
      <studyHypothesis>Pseudophakic retinal detachment is a complication in patients after cataract surgery. Although rare, this represents a high number of patients since the number of cataract extractions is on the rise (500,000 in France). This complication may lead to a severe loss of visual acuity. 

In this study we aim to evaluate the learning curve of junior surgeons in performing primary vitrectomy without scleral buckling for pseudophakic retinal detachment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Reattachment rate with a single procedure at 6-month follow-up</primaryOutcome>
      <secondaryOutcome>1. Number of final successes
2. Number of reoperations and complications</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for the Protection of Human Subjects in Biomedical Research, Bourgogne (Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale de Bourgogne). Date of approval: 4 Marth 2004 (ref: 2004/19)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88931004</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Retrospective interventional case series in two academic centers.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d3108ae-881b-4038-8d13-d4ebb1d7fa08">
	  <name>Service d'Ophtalmologie</name>
	  <address/>
	  <city>Dijon</city>
	  <state/>
	  <country>France</country>
	  <zip>21000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients presenting with a pseudophakic retinal detachment and a Proliferative VitreoRetinopathy (PVR) grade A and B</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>280</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>280</totalTarget>
      <exclusion>Patients presenting with a pseudophakic retinal detachment and a PVR grade C and D</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pseudophakic retinal detachment</description>
	<diseaseClass1>Eye Diseases</diseaseClass1>
	<diseaseClass2>Pseudophakic retinal detachment</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Surgical procedure with pars plana vitrectomy under local anesthesia. Drainage of subretinal fluid through the retinal break or a retinotomy. External cryotherapy on the retinal tears. At the end of the procedure, air-gas exchange with inexpansible gas mixture. No scleral buckling added.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17399-0</funderId>
      <contactId>Contact55360_17399</contactId>
      <sponsorId>Sponsor53930</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55360_17399">
    <title>Prof</title>
    <forename>Catherine</forename>
    <surname>Creuzot-Garcher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Service d'Ophtalmologie
CHU General Hospital </address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53930">
    <organisation>Burgundy Association for Research in Ophthalmology (ABPRO) (France) </organisation>
    <website>http://www.chu-dijon.fr</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Service d'Ophtalmologie
CHU General Hospital</address>
      <city>Dijon</city>
      <country>France</country>
      <zip>21000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder17399-0">
    <name>University Hospital Dijon (CHU), General Hospital (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-29T00:00:00.000Z">34357360</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Better Efficacy in Lowering events by General practitioner's Intervention Using remote Monitoring in Heart Failure</title>
      <scientificTitle/>
      <acronym>BELGIUM-HF Registry &amp; Trial</acronym>
      <studyHypothesis>To test the hypothesis that general practitioner's intervention triggered by an alarm generated by an algorithm based on non-invasive vital sign home telemonitoring measurements in moderate to severe heart failure patients may reduce the rate of hospitalisations for heart failure, mortality or both. 

The BELGIUM-HF Registry and Trial is a study that will be conducted in two steps. 
The primary objective of the registry is to identify predictors of death, heart failure recurrence requiring hospitalisation, or both, and to validate simple and robust interventional algorithms based on weight, blood pressure and pulse transmitted by a telemonitoring system and to test those algorithms in subgroups of patients. 

The primary objective of the subsequent randomised trial is to demonstrate a reduction in the incidence of Heart Failure (HF)-related hospitalisations or all-cause mortality in HF subjects managed with the the telemonitoring/interventional algorithm strategy as compared with HF subjects managed with the telemonitoring/usual care strategy over a period of 6 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary outcome measures in the Randomised Trial: 
1. Incidence of HF-related hospitalisations (Duration of follow-up: 6 months) 
2. All-cause mortality (Duration of follow-up: 6 months)</primaryOutcome>
      <secondaryOutcome>The following secondary end-points in the Randomised Trial will be assessed at 3 and 6 months except the cost-effectiveness evaluation, which will be carried out after the trial: 
1. To demonstrate a reduction in the combined end-point of cardiac death, HF-related hospitalisations and cardiac-related urgent visits and interventions whichever comes first in HF subjects managed with the TeleMonitoring (TM) strategy compared to the Usual Care (UC) strategy 
2. To demonstrate a reduction in HF-related hospitalisations in the TM arm compared to the UC arm 
3. To demonstrate a reduction in all-cause mortality in the TM arm compared to the UC arm 
4. To demonstrate a reduction in cardiac mortality in the TM arm compared to the UC arm 
5. To demonstrate a reduction in the number of days spent at the hospital for HF-related conditions in the TM arm compared to the UC arm 
6. To determine whether TM intervention improves functional status as assessed by a 6-minute walk test 
7. To demonstrate an improvement in quality of life as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in the TM arm compared to the UC arm 
8. To report a shift from "in-patient" to "out-patient" healthcare utilisation in the TM arm compared to the UC arm 
9. To conduct a cost-benefit comparison between the two strategies</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee for Clinical Trials at the Saint-Jean Clinic (Commission d'éthique Expérimentation Humaine de la Clinique Saint-Jean), Brussels. Date of approval: 10/10/2007 (ref: 2007-284)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34357360</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Parallel-group, prospective, single-centre, phase III, randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-12-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Belgium</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="75ad38d6-9e3c-4f1b-98b2-198c29fb8b98">
	  <name>Boulevard du Jardin Botanique 32</name>
	  <address/>
	  <city>Brussels</city>
	  <state/>
	  <country>Belgium</country>
	  <zip>1000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>BELGIUM-HF will be conducted in two steps: a prospective registry and a subsequent randomised trial. The BELGIUM-HF Registry will be completed before the BELGIUM-HF Randomised Trial starts. Patients who have been included in the Registry are eligible for the subsequent randomised trial if they meet the inclusion criteria at that time and have signed an informed consent regarding the randomised trial. 

Inclusion criteria for both BELGIUM-HF Registry and Randomised Trial: 
1. Subject with left ventricular systolic dysfunction, defined as a left ventricular ejection fraction &lt; or = 40%, documented by echocardiography, contrast ventriculography or radionuclide angioscintigraphy within 6 months prior to inclusion 
2. Subject has been hospitalised within the past 6 months for mild to severe heart failure defined as New York Heart Association (NYHA) class II to IV 
3. Subject has received loop diuretics within 2 weeks prior to inclusion 
4. Subject is at least 18 years of age 
5. Subject or subject's legally representative has signed and dated the study informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>500</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Registry: 200 patients; Randomised trial: 500 patients</totalTarget>
      <exclusion>1. Subject who is scheduled for corrective valve surgery or coronary revascularisation, i.e. Coronary Artery Bypass Grafting (CABG) or Percutaneous Coronary Intervention (PCI) in a near future 
2. Subject who has significant concurrent illness or condition not related to heart failure (i.e. terminal malignancy), associated with a life expectancy that is anticipated to be shorter than the expected duration of the trial 
3. Subject on chronic renal dialysis 
4. Pregnancy 
5. Subject who has a health condition or psychic condition associated with poor compliance, including active alcoholism, mental illness or drug dependence 
6. Subject directly involved in the execution of this protocol</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet</patientInfoSheet>
      <recruitmentStart>2007-12-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Systolic heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Systolic heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>BELGIUM-HF Registry: No intervention. Duration of the Registry: 6 months. Follow-up visits will take place at 3 and 6 months. 

BELGIUM-HF Trial: General practitioner's intervention based on an alarm generated by a predefined algorithm applied to the telemonitoring system and based on daily measured blood pressure, pulse and weight versus usual care (control). Types of intervention: none, medication changes, cardiologist referral, out-patient clinic referral, emergency room referral, hospitalisation. 

Duration of intervention: 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17314-0</funderId>
      <contactId>Contact55275_17314</contactId>
      <sponsorId>Sponsor53843</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55275_17314">
    <title>Dr</title>
    <forename>Marc</forename>
    <surname>Castadot</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Boulevard du Jardin Botanique 32</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53843">
    <organisation>Saint-Jean Clinic, Department of Cardiology (Belgium)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Boulevard du Jardin Botanique 32</address>
      <city>Brussels</city>
      <country>Belgium</country>
      <zip>1000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.490685.6</gridId>
    <rorId>https://ror.org/01dd1x730</rorId>
  </sponsor>
  <funder id="Funder17314-0">
    <name>Institute for the Encouragement of Scientific Research and Innovation of Brussels (Public funding) (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-25T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-25T00:00:00.000Z">83077547</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>ALAP-1 for the attenuation of nasal provocation with histamine in seasonal allergic rhinitis: a randomised, double-blind, placebo-controlled, three-day dosing, cross-over study and dose finding one month cross-over study</title>
      <scientificTitle/>
      <acronym>BB100A and BB100B</acronym>
      <studyHypothesis>1. To evaluate the ability of ALAP-1 compared with placebo to reduce the signs and symptoms of allergic rhinitis (AR) in the presence of a nasal histamine challenge
2. To evaluate the efficacy of chronic dosing of ALAP-1 compared with placebo on reducing the symptoms of AR induced by nasal histamine challenge</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Peak nasal inspiratory flow meter, measured at 0, 10, 20, 30, 45 and 60 minutes post-histamine challenge on the study visit days.</primaryOutcome>
      <secondaryOutcome>Sneeze score, measured at 0, 10, 20, 30, 45 and 60 minutes post-histamine challenge on the study visit days.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Copernicus Group Institutional Review Board (IRB) on the 19th September 2006 (ref: MED4-06-238).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83077547</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>BB100A and BB100B</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double-blind placebo controlled crossover study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5f1ebd8f-02a4-4741-b745-c8b519fe7177">
	  <name>18250 Roscoe Blvd.</name>
	  <address/>
	  <city>Northridge</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>91325</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 18 - 59 years, either sex
2. A history of seasonal allergic rhinitis</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Atrophic rhinitis
2. Rhinitis medicamentosa
3. Nasal polyps
4. Septal deviation
5. Active bacterial or viral sinusitis
6. Severe asthma
7. Peptic ulcer disease or active gastroesophageal reflux disease (GERD)
8. History of anaphylaxis to any allergen
9. Pregnancy
10. Active bacterial or viral rhinitis
11. Nasal surgery within the last eight weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Seasonal allergic rhinitis</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Seasonal allergic rhinitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>ALAP-1 (herbal combination) versus placebo. ALAP-1 is an herbal combination formulated to prevent and reduce AR symptoms. This proprietary formula is a standardised blend of the following eleven botanical extracts: Cullen corylifolium (Psoralea fruit), Xanthium sibiricum (Xanthium fruit), Scutellaria baicalensis (Chinese skullcap root), Gardenia augusta (Gardenia fruit), Bupleurum chinense (Bupleurum root), Chrysanthemum x moriflolium (Chrysanthemum flower), Areca catechu (Areca husk), Schisandra spp. (Schisandra fruit), Ziziphus jujuba var. spinosa (Jujube seed), Nepeta tenuifolia (Schizonepeta aerial parts) and Plantago asiatica (Asian plantain seed).

Three-day study:
Subjects will consume three capsules of ALAP-1 (1350 mg) or placebo per day for two days and return to the research office on the third day for evaluation. Subjects undergo their baseline peak nasal inspiratory flow (PNIF) measurement and then consume four capsules of ALAP-1 (1800 mg) or placebo. Fifteen minutes later, the nasal histamine provocation is performed. Shortly after the histamine challenge, subjects consume an additional 4 capsules of ALAP-1 (1800 mg) or placebo. This dosing regimen simulates the method in which the formula would be used in practice: daily preventive doses during allergy season and a treatment dose in the event of direct exposure to an environmental allergen. Subjects then wash out for 1 week and are then enrolled into the opposite arm (active or placebo). 

One month study:
Subjects will receive ALAP-1 or placebo for 4 weeks total. Initally, ALAP-1 (or placebo) is provided for 2 weeks at a high dose (1350 mg/day) and subjects undergo nasal histamine provocation and peak nasal inspiratory flow (PNIF) measurements. Then subjects are given ALAP-1 or placebo for 2 weeks at a low dose (900 mg/day). Subjects washout for 1 week and then are enrolled in the opposite arm.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>ALAP-1</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17379-0</funderId>
      <contactId>Contact55340_17379</contactId>
      <sponsorId>Sponsor53910</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55340_17379">
    <title>Dr</title>
    <forename>Jay</forename>
    <surname>Udani</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>18250 Roscoe Blvd.
Suite 240</address>
      <city>Northridge</city>
      <country>United States of America</country>
      <zip>91325</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53910">
    <organisation>Radix Bioscience (USA) </organisation>
    <website>http://www.radixbioresearch.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>4436 Reeves Road</address>
      <city>Ojai</city>
      <country>United States of America</country>
      <zip>93023</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.505150.4</gridId>
    <rorId>https://ror.org/024hp8310</rorId>
  </sponsor>
  <funder id="Funder17379-0">
    <name>Radix Bioscience (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-23T00:00:00.000Z">37803178</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of perioperative patients with obstructive sleep apnoea</title>
      <scientificTitle/>
      <acronym>OSAS</acronym>
      <studyHypothesis>Polysomnographic parameters in patients with obstructive sleep apnoea are influenced by the type of surgery and the type of anaesthesia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Apnoea-hypopnoea index, based on the following: 
1. Continuous polysomnographic measurement. This will be carried out at the following timepoints:
1.1. The night before surgery from 23:00 pm to 7:00 am
1.2. For 2 hours in the recovery room after extubation
1.3. After returning from the recovery room to the ward, until 7:00 am next day 
2. The patients will be asked to rate the intensity/recreative power of the night sleep on a scale, from 1 (not recreative) to 5 (very recreative) the first and second morning 7:00 am</primaryOutcome>
      <secondaryOutcome>1. Patient satisfaction, based on the following: 
1.1. The patients will be asked to rate his contentedness with the anaesthesia on a scale, from 1 (very content) to 5 (not content) the next morning after surgery
1.2. The patients will be asked to rate the pain on a scale from 0 (no pain) to 10 (strongest pain) at the following timepoints:
1.2.1. At the beginning of the anaesthesia
1.2.2. Immediately after extubation
1.2.3. After the first hour in the recovery room
1.2.4. After the second hour in the recovery room
1.2.5. Next morning after surgery
2. Heart rate and blood pressure, measured as part of the continuous polysomnographic measurement (see primary outcome measures)
3. Circulating mediators 
4. Validity of screening</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Charité - Berlin Medical University Ethics Committee on the 18th May 2006 (ref: EA1/016/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37803178</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EA1/016/06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eb81e125-6361-4ac6-8c55-ee6a4d0fa1df">
	  <name>Chariteplatz 1</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Obstructive sleep apnoea (the Epworth Sleepiness Scale [ESS] score greater than 9) 
2. Elective surgery with either general or regional anaesthesia, or airway surgery 
3. Aged greater than 18 years, either sex
4. American Society of Anaesthesiologists (ASA) classification I - III</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Significant cardiovascular or pulmonary disease 
2. Significant liver or renal disease 
3. Significant psychiatric disease rendering the subject unable to participate in the trial 
4. Drug dependency 
5. Chronic opioid therapy 
6. Chronic BiPAP (Bi-level Positive Airway Pressure) ventilator therapy</exclusion>
      <patientInfoSheet>Not available in web format, please use the contact details below to request a patient information sheet.</patientInfoSheet>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obstructive sleep aponea</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Obstructive sleep aponea</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 20 patients with surgery with general anaesthesia
Group 2: 20 patients with surgery with regional anaesthesia
Group 3: 20 patients with surgery on the upper airway with general anaesthesia

Randomisation of participants will be carried out between groups 1 and 2. There is no randomisation in group 3.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17209-0</funderId>
      <contactId>Contact55170_17209</contactId>
      <sponsorId>Sponsor53736</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55170_17209">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53736">
    <organisation>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder17209-0">
    <name>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-18T00:00:00.000Z">84220089</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An interventional, randomized, double-blind, placebo-controlled, parallel-assignment, safety/efficacy study for treatment of chronic middle ear infection in adult patients with the antimicrobial peptide OP-145</title>
      <scientificTitle/>
      <acronym>OP-145</acronym>
      <studyHypothesis>The purpose of this study is to determine the safety, tolerability, and efficacy of OP-145 eardrops to the middle ear of patients with chronic otitis media. We hypothesize that OP-145 will improve the middle ear mucosa in patients with chronic otitis media.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety of OP-145 eardrops, which will be determined by the following at baseline and week 1, 2, 4, 8, and 12 (for both Part I and II of the trial): 
1. Hearing levels
2. Blood analysis
3. Antibody detection
4. Bacterial culture of ear and throat swabs
5. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey)</primaryOutcome>
      <secondaryOutcome>Efficacy of OP-145 eardrops, assessed by the following at baseline and week 1, 2, 4, 8, and 12: 
1. Mucosal endoscopic scores (for both Part I and II of the trial)
2. Quality of life questionnaires (the 36-item Short Form health survey (SF-36), the Brief Illness Perception Questionnaire and the Chronic Ear Survey) (only for Part II of the trial)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Committee of the Leiden University Medical Center. Approved on the 19th December 2003 (Ref: P02.216/YR/yr)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN84220089</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P02.216</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Phase I/II, double-blind, parallel-assignment, safety/efficacy, randomized placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f78f205a-9198-4106-8aaa-1954d67ac7ff">
	  <name>Leiden University Medical Center</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2333 ZA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Inclusion criteria for the Part I dose finding study: 
1. Adults &gt;= 18 years, males and females 
2. Legally competent, no psychiatric history 
3. Chronic otitis media with a clear perforation of the tympanic membrane &gt;3 months 
4. Chronic proliferative mucosal changes (confirmed by Computerised Tomography (CT) scan) 
5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for &gt;6 weeks) 

Inclusion criteria for the Part II randomised controlled study: 
1. Adults, both males and females, over 18 years of age 
2. Legally competent, with no history of psychiatric disorders 
3. Chronic otitis media with a clear perforation of the tympanic membrane, lasting longer than 6 months 
4. Chronic proliferative mucosal changes  (confirmed with CT scan)
5. Antibiotic therapy resistant (Adequately treated with at least 2 different eardrops for &gt;6 weeks)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Part I: 16 patients; Part II: 52, with an interim analysis after 26 patients.</totalTarget>
      <exclusion>Exclusion criteria for the Part I dose finding study: 
1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan) 
2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte') 
3. Pregnant and breastfeeding women 
4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days 
5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days 
6. Patients with serious headaches 
7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract 
8. Immunocompromized patients or patients with auto-immune disorders 
9. History of seizures 
10. Patients with deficits at the nervus facialis 

Exclusion criteria for the Part II randomised controlled study: 
1. Presence of cholesteatoma in the treated ear (confirmed with CT-scan)
2. History of mastoidectomy in the treated ear (resulting in a 'radicaalholte')
3. Pregnant and breastfeeding women 
4. Patients that have been using topical, oral or parenteral antibiotics or steroids in the last 30 days
5. Patients that have been using prednison or any other immunosuppressive agent in the last 30 days
6. Patients with serious headaches
7. Patients with Down syndrome or other congenital anomalies in the upper respiratory tract
8. Immunocompromized patients or patients with auto-immune disorders
9. History of seizures
10. Patients with deficits at the nervus facialis
11. Patients who were included in the Part I dose finding study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic otitis media</description>
	<diseaseClass1>Ear, Nose and Throat</diseaseClass1>
	<diseaseClass2>Chronic otitis media</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Part I dose finding study: 

The participants were allocated into four trial arms in the order of inclusion timepoints i.e. the first four participants were allocated to the lowest dose group, second four in the next dose group, etc. 

Arm 1: 0.25 mg/ml OP-145 eardrops twice a day
Arm 2: 0.5 mg/ml OP-145 eardrops twice a day
Arm 3: 1.0 mg/ml OP-145 eardrops twice a day
Arm 4: 2.0 mg/ml OP-145 eardrops twice a day

Duration of intervention: 2 weeks
 
Part II randomised controlled study: 
Based on the results of the Part I study the Part II study was executed with 0.5 mg/ml OP-145 eardops twice a day (control: placebo twice a day) for 2 weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I/II</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16955-0</funderId>
      <contactId>Contact54916_16955</contactId>
      <sponsorId>Sponsor53481</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54916_16955">
    <title>Dr</title>
    <forename>Nanno</forename>
    <surname>F.A.W. Peek</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Center
Albinusdreef 2</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 ZA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53481">
    <organisation>OctoPlus N.V. (The Netherlands)</organisation>
    <website>http://www.octoplus.nl/index.cfm/site/OctoPlus/pageid/821DEDEC-E30E-0D4E-CC80F8CDD400753F/index.cfm</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Ewoud-Jan van Hoogdalem 
Zernikedreef 12</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2333 CL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476342.0</gridId>
    <rorId>https://ror.org/01dn4wg45</rorId>
  </sponsor>
  <funder id="Funder16955-0">
    <name>OctoPlus Inc. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2008-01-18T00:00:00.000Z">74707125</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Does Acamprosate Decrease Cue-induced Alcohol Craving?</title>
      <scientificTitle>A randomised placebo-controlled trial of acamprosate effects on alcohol cue reactivity and alcohol priming in dependent patients</scientificTitle>
      <acronym>DADCAC</acronym>
      <studyHypothesis>1. Acamprosate attenuates cue-induced subjectively experienced and physiolological correlates of craving
2. Acamprosate attenuates alcohol-induced subjectively experienced and physiolological correlates of craving</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. The difference in subjectively experienced craving post exposure to non-alcohol related stimuli versus alcohol related stimuli
2. The difference in subjectively experienced craving between pre- and post-consumption of an alcoholic drink

For both measures comparisons are made between acamprosate versus placebo treated patients. Measures are collected post 22 days of treatment. Patients then come to the clinic and go through a series of sessions where they are exposed to alcohol versus non-alcohol related stimuli, and also take part in a alcohol priming paradigm. Present alcohol craving is measured in connection to each exposure.</primaryOutcome>
      <secondaryOutcome>Physiological measures of craving:
1. Pulse
2. Blood-pressure
3. Cortisol in blood
4. Galvanic skin response
5. Skin temperature

Measures are collected post 22 days of treatment. Patients then come to the clinic and go through a series of sessions where they are exposed to alcohol versus non-alcohol related stimuli, and also take part in an alcohol priming paradigm. Present alcohol craving is measured in connection to each exposure.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The trial was approved by:
1. The Regional Ethical Review Board in Stockholm on the 23rd March 2005 (ref: 2005/30-31/3)
2. The Swedish Medical Products Agency on the 5th April 2005 (EudraCT number: 2004-004514-17)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74707125</doi>
      <eudraCTNumber>2004-004514-17</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EudraCT number: 2004-004514-17</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study used a randomised, double blind, single-site, placebo-controlled design comparing cue- and alcohol-induced craving for acamprosate and placebo treated patients</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-05T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c942a0cf-9319-4efa-bb72-44bcbf1a268c">
	  <name>Department of Clinical Neuroscience</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>17176</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A male or a non-pregnant/non-nursing female between 18 and 65 years of age
2. A goal of controlled drinking
3. An intact sense of smell
4. Fulfilling the criteria for alcohol dependence according to Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
5. Willingness to give informed consent and comply with study procedures
6. Alcohol consumption in 15 of the last 90 days</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>1. Seeking complete alcohol abstinence
2. Current use of any medication that interferes with salivation
3. A diagnosis of an Axis I psychiatric disorder according to DSM-IV criteria (including all forms of substance dependence other than nicotine and alcohol)
4. A current use of psychoactive medications to manage schizophrenia, bipolar disorder, or major depression
5. Inpatient alcohol detoxification within the last 4 days
6. Acamprosate medication during the last year
7. Use of illegal drugs during the course of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-05T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Alcohol dependence</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Alcohol dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were assigned to 22 days of either acamprosate (1998 mg/day) or placebo treatment according to a randomisation process conducted by the Karolinska University Hospital pharmacy. Medication (150 tablets containing 333 mg acamprosate or placebo) was dispensed once per patient, at the start of the trial, with instructions to intake 6 tablets per day (2 in AM, 2 midday, 2 in PM).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Acamprosate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17269-0</funderId>
      <funderId>Funder17269-1</funderId>
      <funderId>Funder17269-2</funderId>
      <funderId>Funder17269-3</funderId>
      <contactId>Contact55230_17269</contactId>
      <sponsorId>Sponsor53798</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55230_17269">
    <title>Dr</title>
    <forename>Johan</forename>
    <surname>Franck</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Clinical Neuroscience
Section for Alcohol and Drug dependence Research
Karolinska University Hospital, M4:02</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>17176</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">johan.franck@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53798">
    <organisation>Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)</organisation>
    <website>http://www.beroendecentrum.com</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Box 17914</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>118 95 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476028.f</gridId>
    <rorId>https://ror.org/04g380834</rorId>
  </sponsor>
  <funder id="Funder17269-0">
    <name>AFA insurances (AFA försäkringar) (Sweden) - http://www.afaforsakring.se</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-1">
    <name>Systembolagets Council for Alcohol Research (Systembolagets råd för alkoholforskning) (Sweden) - http://www.can.se/sa/node.asp?node=1663</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-2">
    <name>Milan Valverius Foundation (Sweden) - http://www.salusansvar.se/info/default.aspx?FolderID=3063a24d-26b2-416d-b00a-1d4d06810b2e</name>
    <fundRef/>
  </funder>
  <funder id="Funder17269-3">
    <name>Foundation for Research on Psychiatric Diseases (Psykiatrifonden) (Sweden) - http://www.psykiatrifonden.se</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-11T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-01-11T00:00:00.000Z">18010960</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Amniocentesis Before rescue Cerclage</title>
      <scientificTitle/>
      <acronym>ABC Trial</acronym>
      <studyHypothesis>We hypothesise that the use of a diagnostic amniocentesis and testing for rapid markers of chorioamnionitis (amniotic fluid lactate dehydrogenase or glucose level) will identify a subset of women without subclinical chorioamnionitis for whom the cerclage is more likely to prolong pregnancy to a viable gestational age and decrease the risk of neonatal and maternal complications.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary comparison will be the prolongation of gestation to greater than 34 weeks of gestation, defined as rescue cerclage success.</primaryOutcome>
      <secondaryOutcome>1. Maternal morbidity: will include complications of cerclage insertion, through gestation and at the time of the delivery
2. Neonatal morbidity: will include complications during the initial admission to the nursery following the delivery</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval is pending as of 31/10/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18010960</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MSH Reference Number # 07-0080-A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7612215e-3013-4743-a54d-c1960b0f3e06">
	  <name>RM 3201</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M5G 1X8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Singleton gestation 
2. Presence of cervical dilatation 
3. Membranes visible at or protruding through the cervical opening 
4. Absence of any uterine activity 
5. Absence of any overt signs of maternal infection:
5.1. Maternal temperature greater than 37.8°C
5.2. Diffuse abdominal pain
5.3. Foul/pus like discharge
5.4. Maternal or foetal tachycardia</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>46</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>46</totalTarget>
      <exclusion>1. Intrauterine foetal demise or distress 
2. Intrauterine growth restriction 
3. Foetal anomaly 
4. Poly- or oligo-hydramnious 
5. Ruptured foetal membranes 
6. Current history of significant antepartum haemorrhage</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cervical incompetence</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Maternal care for cervical incompetence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Women will be randomised to either:
1. Cerclage group 
2. Amniocentesis and cerclage group

Randomisation will be organised by a random numbers table and assigned by telephone. Women randomised to the amniocentesis group will undergo an aseptic aspiration of amniotic fluid under ultrasound guidance by a single operator. Briefly, the abdomen will be prepared with antiseptic solution and draped with sterile towels. The ultrasound transducer probe will be draped with a sterile plastic cover. Using a sterile water-based ultrasound gel to facilitate visualisation, the operator will identify a pocket of amniotic fluid suitably away from the foetus and placenta. A sterile 22 gauge needle will be passed into the uterine cavity under direct visualisation and approximately 15 cc of amniotic fluid will be aspirated. 

Post procedure, Rhogam™ will be administered to Rhesus negative patients as indicated. Amniotic fluid will be tested for lactate dehydrogenase level (2 cc), glucose level (2 cc), cell count (2 cc), haemoglobin level (2 cc) and Gram staining (2 cc). Amniotic fluid will be sent for confirmatory aerobic, anaerobic and myoplasma/ureaplasma culture (4 cc per culture). 

All tests will be performed by the respective Departments of Biochemistry, Haematology and Microbiology (Mount Sinai Hospital, Canada) using established protocols. While waiting for the fluid test results (approximately 90 - 120 minutes), a tocodynometer will be placed over the uterine fundus to confirm the absence of uterine activity. Those women without evidence of subclinical infection following amniocentesis and those women who were randomised to the cerclage group will have a rescue cerclage placed. 

Rescue cerclage placement will be performed under general anaesthesia. Women will be placed in the lithotomy position with a steep Trendelenberg tilt. The prolapsed membranes will be gently pushed back into the uterine cavity with an inflated Foley catheter. A single purse string suture (#5 Ticron™) will be performed using the technique described by MacDonald. Perioperative tocolysis (indomethacin 100 mg per rectum [pr] followed by 25 mg orally every 6 hours for 48 hours) to prevent the uterine contractions that can be precipitated by cervical manipulation and cerclage insertion and prophylactic antibiotics (clindamycin 900 mg intravenous [iv] three times a day [TID] for 7 days) will be administered. A transvaginal ultrasound to evaluate the cervical placement will be done 48 hours postoperatively. 

Following cerclage insertion, women will be restricted to bedrest until 30 weeks of gestation. Cerclages will be removed electively at 36 weeks or before based on foetal or maternal indication. Thromboprophylaxis with enoxaparin (40 mg subcutaneously [sc] once daily [od]) will be administered to all women on prolonged bed rest.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17236-0</funderId>
      <contactId>Contact55197_17236</contactId>
      <sponsorId>Sponsor53763</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55197_17236">
    <title>Dr</title>
    <forename>Wendy</forename>
    <surname>Whittle</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>RM 3201 
700 University Avenue</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wwhittle@mtsinai.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53763">
    <organisation>Mount Sinai Hospital (Canada) </organisation>
    <website>http://www.mtsinai.on.ca/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Dr Wendy Whittle
Department of Obstetrics and Gynaecology
Rm 3201 Ontario Power Generation Building
700 University Avenue </address>
      <city>Toronto </city>
      <country>Canada</country>
      <zip>M5G 1X8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wwhittle@mtsinai.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416166.2</gridId>
    <rorId>https://ror.org/05deks119</rorId>
  </sponsor>
  <funder id="Funder17236-0">
    <name>Mount Sinai Hospital (Canada) - Department of Obstetrics and Gynaecology Research Fund ($5000)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">56178790</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The MRS study</title>
      <scientificTitle>Sorafenib (NEXAVAR®) monotherapy in patients with inoperable/recurrent germ cell carcinoma refractory to chemotherapy</scientificTitle>
      <acronym>MRS</acronym>
      <studyHypothesis>Sorafenib prolongs Progression-Free Survival (PFS) in patients with inoperable/recurrent germ cell carcinoma refrectory to chemotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Progression Free Survival (PFS)</primaryOutcome>
      <secondaryOutcome>1. Overall Relapse Rate (ORR)
2. Overall Survival (OS)
3. Toxicity
4. Evaluation of panel of biomarkers, will be assessed every 4 weeks
5. Quality of Life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ-C30] version 3.0 pol and testicular cancer module), will be assessed every 12 weeks</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Submitted, not reviewed yet as of 06/12/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN56178790</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>12602</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single arm, non-randomised, single institution, phase II trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Poland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8902808c-99d9-4f78-a4ef-24c2b5b14b66">
	  <name>Roentgena 5</name>
	  <address/>
	  <city>Warsaw</city>
	  <state/>
	  <country>Poland</country>
	  <zip>02781</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male patients greater than 18 years of age
2. Patients with histologically proven germ cell neoplasm (gonadal or extragonadal primary)
3. Patients must have the disease not amendable to cure with either surgery or chemotherapy 
4. Patients must have failed at least two cisplatin-based combination chemotherapy regimens
5. Failure on prior regimens will be defined as either:
5.1. A greater than or equal to 25% increase in sum of target lesions, new lesions, or
5.2. An increasing Alpha Fetoprotein (AFP) or Human Chorionic Gonadotropin (HCG) above the nadir level
6. Patients with at least one measurable lesion by Computed Tomography (CT) scan or Magnetic Resonance Imaging (MRI) according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria  
7. Adequate bone marrow, liver and renal function, assessed no longer than 14 days before treatment start, defined by the following laboratory test limits: 
7.1. White Blood Cells (WBC) greater than 2.0 x 10^9/l and platelets greater than 60 x 10^9/l
7.2. Total bilirubin less than 2 x Upper Limit of Normal (ULN)
7.3. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 5 x ULN
7.4. Serum creatinine less than 2 x ULN
8. World Health Organization (WHO) performance status 0, 1, 2 
9. No concurrent chemotherapy or radiotherapy
10. Life expectancy of at least 12 weeks
11. Absence of any physiological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
12. A signed informed consent must be obtained prior to any study specific procedures 
13. All patients must agree to use adequate contraception during the whole study period</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Patients not fulfilling of inclusion criteria 	
2. Primary radiotherapy in the field of target lesion
3. Major surgery (Retroperitoneal Lymph Node Dissection [RPLND]) within 4 weeks before the start of study drug or concurrent serious non-healing wounds, ulcers or bone fractures.
4. Known serious and active bacterial, viral or fungal infection (greater than grade II Common Terminology Criteria for Adverse Events [CTC-AE]) including Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) carrier state
5. Previous or concurrent malignancy except for basal cell carcinoma of the skin
6. Uncontrolled hypertension
7. Thrombotic or embolic event in last 6 months prior to inclusion
8. Impairment of Gastrointestinal (GI) tract, or GI disease that may influence the bioavailability of oral sorafenib
9. Substance and alcohol abuse (nicotine use is allowed)
10. Known or suspected hypersensitivity to sorafenib
11. Participance in any other clinical trial using investigational drug within 4 weeks prior to study entry
12. Prior use of investigational or licensed angiogenesis and Raf kinase or Mitogen-activated Extracellular-signal-Regulated Kinase (ERK) (MEK) inhibitors
13. Patient unwilling or unable to give informed consent
14. Any condition that may in the investigator&#146;s opinion jeopardize the safety of the patient or his compliance in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Testicular cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Testicular cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>There is only one treatment arm, therefore all participants will receive sorafenib 400 mg (2  tablets of 200 mg twice daily orally) continuously in 4-week cycles till progression or unacceptable toxicity. All patients will be followed/contacted after discontinuation of protocol every 3 months.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Sorafenib (NEXAVAR®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17331-0</funderId>
      <contactId>Contact55292_17331</contactId>
      <sponsorId>Sponsor53860</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55292_17331">
    <title>Dr</title>
    <forename>Iwona</forename>
    <surname>Skoneczna</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Roentgena 5</address>
      <city>Warsaw</city>
      <country>Poland</country>
      <zip>02781</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)22 5462098</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.skoneczna@coi.waw.pl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53860">
    <organisation>Prof. Grzegorz Madej Memorial Foundation "Win the health" (Fundacja "Wygrajmy Zdrowie" im Prof. Grzegorza Madeja) (Poland)</organisation>
    <website>http://www.wygrajmyzdrowie.pl</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 20</address>
      <city>Warsaw 10</city>
      <country>Poland</country>
      <zip>00956</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+48 (0)510 723 802</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">i.skoneczna@wygrajmyzdrowie.pl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17331-0">
    <name>Bayer Pharmaceuticals Poland Sp. z.o.o. (Poland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2008-01-07T00:00:00.000Z">99715969</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Immediate in-hospital reactivation of patients with an exacerbation of Chronic Obstructive Pulmonary Disease (COPD): Pulmofit-MST</title>
      <scientificTitle/>
      <acronym>PULMOFIT-MST</acronym>
      <studyHypothesis>Chronic Obstructive Pulmonary Disease (COPD) is a major cause of disability and mortality worldwide. Morbidity and mortality among COPD-patients are strongly related to acute exacerbations of COPD, which can be defined as sustained worsening of the patient&#146;s condition, from stable state and beyond normal day-to-day variations, that is acute in onset and may warrant additional treatment in a patient with underlying COPD. Severe exacerbations may lead to hospital admissions and have a major impact on disease evolution and costs.

Pulmofit-MST, an immediate reactivation programme, will induce a reduction of the length of stay in the hospital, by preventing loss of peripheral muscle force and exercise capacity and thereby initiating a faster recovery of activities of daily living.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Length of hospital stay, defined as number of days between day of admission and day of medical discharge. Day of medical discharge was distinguished from the actual day of discharge because some patients remain in hospital longer than medically necessary (e.g. patients could not yet be referred to a nursing home).</primaryOutcome>
      <secondaryOutcome>1. Walking distance (3 minutes walking test)
2. Dyspnoea (Borg scale)
3. Health status (Clinical COPD Questionnaire)
4. Activities of daily living (Barthel Index)
5. Readmissions due to a COPD-exacerbation (less than 28 days), measured at 28 days

Measurements take place at the day of admission, day 4 and the day of medical discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medisch Etische Toetsingscommissie Medisch Spectrum Twente) on the 16th January 2006 (ref: P06-05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN99715969</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NT1101</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, two armed trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-02-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9995600e-9a5b-46d4-8e0a-4fe5a58e5961">
	  <name>Haaksbergerstraat 55</name>
	  <address/>
	  <city>Enschede</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>7513 ER</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A clinical diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
2. A clinical diagnosis of an exacerbation of COPD for which hospitalisation was required
3. (Ex-) smoker
4. Age above 40 years
5. A life expectancy of at least 3 months
6. Able to understand and read Dutch
7. An informed consent from the subject prior to participation</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Pneumonia
2. Fever (greater than 38.5°C)
3. Severe confusion
4. Severe heart failure, New York Heart Association (NHYA) class III or IV
5. Relevant co-morbidity seriously influencing mobility</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-02-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Obstructive Pulmonary Disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The protocol of the programme aimed at an active role of COPD-patients during their stay in the hospital. Patients in the intervention group were asked to perform three daily training sessions of 15 minutes each. One daily session was assisted by a physiotherapist, while the other two had to be performed by the patients themselves. 

PULMOFIT-MST consists of four levels of increasing difficulty. Within four hours after admission, level I was started by the nurse who distributed the workbook with the description of all exercises and who instructed the first exercises to the patient. Within 24 hours after admission, the physiotherapist visited the patient and continued the programme by choosing the appropriate follow-up level and determining the intensity of the exercises. Every day the physiotherapist evaluated the exercises and the appropriateness of the training level and training intensity. A workbook functioned as a daily diary in which the intensities of training exercises were noted by the physiotherapist and daily experiences and improvements by the patient. All disciplines (chest physicians, nurses, and physiotherapists) stimulated patients to perform all three daily PULMOFIT-MST sessions. 

Patients in the control group received usual care, meaning treatment the patients would have received prior to this study. 

The duration of the treatment depends on the length of the hospitalisation. Patients of the intervention group are treated according to the PULMOFIT-MST protocol during the whole hospitalisation period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17272-0</funderId>
      <contactId>Contact55233_17272</contactId>
      <sponsorId>Sponsor53801</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55233_17272">
    <title>Mrs</title>
    <forename>Tanja </forename>
    <surname>Effing</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Haaksbergerstraat 55
Poli 12</address>
      <city>Enschede</city>
      <country>Netherlands</country>
      <zip>7513 ER</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53801">
    <organisation>Dutch Asthma Foundation (The Netherlands) </organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Postbus 5 </address>
      <city>Leusden</city>
      <country>Netherlands</country>
      <zip>3830 AA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.483859.b</gridId>
    <rorId>https://ror.org/00ddgbf74</rorId>
  </sponsor>
  <funder id="Funder17272-0">
    <name>Dutch Asthma Foundation (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-03T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2008-01-03T00:00:00.000Z">48092875</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>N3 fatty acids as adjuvant therapy in rheumatoid arthritis (N3-fettsäuren als adjuvante therapie bei rheumatoider arthritis)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Omega-3 fatty acids infusions may show earlier and superior antiinflammatory effects in patients with rheumatoid arthritis than oral administered ones (as shown in earlier trials), and we presumed the beneficial effects may be maintained by following oral omega-3 fatty acid administration.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were assessed at baseline, during infusion phase (after week 1 and after week 2) and during capsule phase (after two weeks [end of month 1] and then monthly until the end of month 6):
1. Swollen joints
2. Tender joints
3. Erythrocyte Sedimentation Rate (ESR)
4. C-Reactive Protein (CRP)</primaryOutcome>
      <secondaryOutcome>The following were assessed at baseline, during infusion phase (after week 1 and after week 2) and during capsule phase (after two weeks [end of month 1] and then monthly until the end of month 6):
1. Disease Activity Score (DAS)
2. Rheumatoid Arthritis Disease Activity Index (RADAI) 
3. Health Assessment Questionnaire (HAQ)
4. 36-item Short Form health survey (SF-36)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This trial was approved by the ethics committee of the Medical University of Graz on 10th July 2000.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48092875</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>10-184 ex 99/00</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, double-blinded, placebo-controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Austria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a9dfa791-fddb-48e3-9746-7c5965360601">
	  <name>State Hospital Muerzzuschlag</name>
	  <address/>
	  <city>Muerzzuschlag</city>
	  <state/>
	  <country>Austria</country>
	  <zip>8680</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients at least 19 years of age and should not be older than 85 years
2. Patients suffering from Rheumatoid Arthritis (RA), according to American College of Rheumatology (ACR) criteria, for at least (&gt;=) 6 months 
3. Patients with active RA who meet following criteria:    
3.1. &gt;= 6 swollen joints 
3.2. &gt;= 6 tender joints
3.3. &gt;= 1 of following criteria: 
a. Joint morning stiffness &gt;= 45 minutes 
b. Erythrocyte Sedimentation Rate (ESR) &gt;= 28 mm 
c. C-Reactive Protein (CRP) &gt;=  20 mg/l (normal range: 0 - 9)
4. No pregnant or breast feeding women allowed; monthly negative pregnancy test in women of reproductive age 
5. Participant doesn't have a severe concomitant physical or mental illness  
6. Participant has to be able to follow the study procedures   
7. No severe malfunctioning of the liver, kidneys, bone marrow, blood clotting system 
8. Stable dosages of RA medication for at least 1 month prior to baseline:  
8.1. DMARD therapy with methotrexate of at least 10 mg per week over 4 months
8.2. Prednisone &lt;=10 mg daily 
9. No injection of glucocorticoids into a joint within 3 month prior to baseline 
10. Participant must not have legal conflict 
11. Participant must not have alcohol or drug abuse problems 
12. Written informed consent signed by the participant</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known allergy against fish oil or any other substance of the study medication 
2. Participant is younger than 19 years of age 
3. Patient simultaneously participates in another trial  
4. Participant doesn't sign the written informed consent. 
5. No stable dosage of RA medication 1 month prior to baseline 
6. Injection of glucocorticoids into a joint within 3 month prior to baseline 
7. Pregnant or breast feeding women; positive pregnancy test in women of reproductive age 
8. Patient has legal conflicts
9. Patient has alcohol or drug abuse problems 
10. Severe concomitant physical or mental illness  
11. Participant is physically or mentally unable to follow the study procedures  
12. Hereditary disorder of lipid metabolism 
13. Blood triglyceride levels &gt;300 mg/dl 
14. Patients with uncontrolled diabetes mellitus
15. Severe malfunctioning of the liver, kidneys, bone marrow, blood clotting system: 
15.1. Creatinin clearance &lt;=30 ml/min
15.2. Elevated levels of ALanine aminoTransferase (ALT) 2 fold above the upper normal range 
15.3. Leucopenia &lt;=2,500/ml, red blood cells &lt;=2.5 mill/ml, hemoglobin &lt;=9 mg/dl, platelets &lt;=70,000/ml 
16. Severe cardiovascular disease 
17. Known neoplasms</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Rheumatoid arthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Infusions of omega-3 fatty acids once daily for 14 days (Infusion speed: 0.5 ml/kg body weight and hour), followed by oral administration of omega-3 fatty acids up to 6 months. 

Control group: Placebo infusions once daily for 14 days (Infusion speed: 0.5 ml/kg body weight and hour), followed by oral administration of placebo up to 6 months. 

Verum:   
Infusions: Fish oil emulsion (Omegaven® Fresenius). 100 ml Omegaven® contained 10 g fish oil with 2.03 g EicosaPentaenoic Acid (EPA) and 2.26 g DocosaHexaenoic Acid (DHA) (and 0.02 mg a-tocopherol as antioxidat) 
Capsules: Fish oil. One capsule contained 1 g fish oil with 0.20 g EPA and 0.23 g DHA (and 0.02 mg a-tocopherol as antioxidant) 

Placebo: 
Infusions: NaCl 0.9% (physiological sodium chloride solution)
Capsules: Paraffin wax

Randomisation was done by a hospital pharmacist who prepared the bottles and other infusion material, so that neither the patients nor the staff could identify them as verum or placebo. Additionally, the study conducting staff was not allowed to enter the inpatient area while the patients received their infusions.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Omega-3 fatty acids</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17316-0</funderId>
      <funderId>Funder17316-1</funderId>
      <contactId>Contact55277_17316</contactId>
      <sponsorId>Sponsor53845</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55277_17316">
    <title>Dr</title>
    <forename>Babak</forename>
    <surname>Bahadori</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>State Hospital Muerzzuschlag
Department of Internal Medicine
Grazerstr. 63-65</address>
      <city>Muerzzuschlag</city>
      <country>Austria</country>
      <zip>8680</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.bahadori@gmx.at</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53845">
    <organisation>Medical University of Graz (Austria)</organisation>
    <website>http://www.meduni-graz.at/englisch/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Universitätsplatz 3</address>
      <city>Graz</city>
      <country>Austria</country>
      <zip>A-8010 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11598.34</gridId>
    <rorId>https://ror.org/02n0bts35</rorId>
  </sponsor>
  <funder id="Funder17316-0">
    <name>Investigator-funded (This trial is a physician initiated study) (Austria)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17316-1">
    <name>Fresenius Kabi Austria (Provided Omega-3 infusions only)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-09-12T00:00:00.000Z">15330757</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To compare the efficacy and tolerability of nabilone with dihydrocodeine when used in the treatment of neuropathic pain based upon the following null hypotheses:
1. The analgesic activity of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
2. The patient tolerability of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
3. The antidepressant effect of nabilone is not different from that of dihydrocodeine when used in the treatment of neuropathic pain over a six-week period
4. Anxiety reducing effects of nabilone are not different from dihydrocodeine when used in the treatment of neuropathic pain over a six-week period</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mean pain score as measured by VAS 0 - 10 for the last two weeks on treatment.</primaryOutcome>
      <secondaryOutcome>1. Sleep was measured as hours slept and if the sleep was interrupted or not in the diary
2. Depression and anxiety were measured with the Hospital Anxiety and Depression Score (HAD) at baseline and after each treatment period
3. Quality of life was measured with the 36-item Short Form questionnaire (SF-36) at baseline and after each treatment period
4. Six psychometric tests were performed at baseline and after each treatment period on a Apple Newton device
5. Side effects were assessed every two weeks with a eight-point questionnaire rating the severity of the side effects on a five point scale plus a field for open comments</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from:
1. South Tees Local Research Ethics Committee on the 20th April 2001 (ref: 00/53)
2. West Ethics Committee Glasgow on the 23rd November 2001 (ref: 01/95)
3. Newcastle and North Tyneside Joint Ethics Committee on the 20th June 2001 (ref: 2000/137)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN15330757</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CL0014 Version 5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2441c365-7dc1-4e9c-a0fc-d2200bc2cbeb">
	  <name>Pain Management Unit</name>
	  <address/>
	  <city>Adelaide</city>
	  <state/>
	  <country>Australia</country>
	  <zip>5042</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients entering the study will be recruited following written informed consent from pain clinics at participating centres
2. Patients will be in the age range 18 - 90 years with a diagnosis of neuropathic pain made according to the criteria set out below
3. Patients may be taking stable dose regimens of paracetamol, anticonvulsants, antidepressants, opioids or Non-Steroidal Anti-Inflammatory Srugs (NSAIDs)
4. Patients taking excluded medications (see exclusion criteria below) may enter the study after a two week period without these medications

Diagnosis of neuropathic pain:
The term "neuropathic pain" is loosely applied to a variety of heterogeneous conditions and strict diagnostic criteria are difficult to apply. However, for the purposes of this study, the diagnosis will be made on the basis of the following:
1. Pain secondary to an identifiable injury or disease process where damage to the central or peripheral nervous system is suspected
2. Pain persisting for more than three months in the absence of any continuing nociceptive stimulus
3. Pain that is documented as responding poorly to either opioid analgesics or NSAIDs
4. Pain associated with at least two of the following signs/symptoms:
4.1. Abnormal sensation on clinical examination, including sensory loss, paraesthesia, dysaesthesia
4.2. Mechanical allodynia (static or dynamic)
4.3. Pain of a burning character
4.4. Pain of a stabbing or lancinating character
4.5. Signs of sympathetic dysfunction (discolouration, abnormal vasomotor activity, skin trophic changes)

Many conditions may present with neuropathic pain. However, in some conditions the
distinction between primary nociceptive and neuropathic pain is extremely difficult. An
important example of this is in mechanical low back pain where radiation of pain into the legs is commonly reported in the absence of identifiable nerve injury. Given this diagnostic difficulty, for the purpose of this study, patients with lumbar radiculopathy will not be recruited to the study.

The Central Post-Stroke Pain Syndrome seems to have features that are significantly different to other types of neuropathic pain. For this reason, patients with this syndrome will not be included in this study.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>Patients may not enter the study if they have a history of any of the following conditions:
1. Epilepsy
2. Liver disease
3. Psychosis
4. Bipolar disorder
5. Substance misuse
6. Renal failure
7. Adverse reactions to either dihydrocodeine or nabilone
8. Pregnant women, lactating women or women of childbearing potential not using effective methods of contraception
9. Patients involved in ongoing legal action against a third party in which financial compensation is being sought for personal injury alleged to be the cause of the presenting condition

Excluded medications:
Patients may not take the following medications during the study:
1. Dihydrocodeine
2. Antipsychotic drugs
3. Benzodiazepine drugs (excepting stable doses of night-time sedatives)
4. Monoamine oxidase inhibitors

Patients taking dihydrocodeine may enter the study after a washout period of two weeks. Analgesia during this time will be provided with co-proxamol. Patients taking cannabinoid preparations of any kind may not be included in the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mixed neuropathic pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The medication was given in identical tablets either containing 240 µg nabilone or 30 mg dihydrocodeine. The dose schedule was one capsule in the first week, two capsules in the third week, four capsules in the third and fourth week and then eight capsules in week five and six. After a two week washout the treatment was crossed over. If there were side effects the dose was not increased further. During the washout rescue medication in the form of eight tablets 30/500 codeine with paracetamol was permitted. So each treatment arm was six weeks with a two week washout after six weeks and in the end. Patients with benefit went then into the open label trial (see ISRCTN38408594: A one year open label assessment of the use of nabilone in the treatment of chronic neuropathic pain). Visual Analogue Scale (VAS) scores and hours slept were recorded in a diary daily and then averaged per week. Only pain scores for the last two weeks were used for the analyses.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nabilone, dihydrocodeine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18182416 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="9147c260-9dbb-48dd-8b6b-8e8ca292983e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18182416"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16745-0</funderId>
      <funderId>Funder16745-1</funderId>
      <contactId>Contact54703_16745</contactId>
      <sponsorId>Sponsor53259</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54703_16745">
    <title>Dr</title>
    <forename>Dilip</forename>
    <surname>Kapur</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Pain Management Unit
Flinders Medical Centre
Flinders Drive
Bedford Park</address>
      <city>Adelaide</city>
      <country>Australia</country>
      <zip>5042</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Dilip.Kapur@fmc.sa.gov.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53259">
    <organisation>Cambridge Laboratories Ltd (UK)</organisation>
    <website>http://www.camb-labs.com/index.html</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Deltic House Newcastle
Kingfisher Way
Silverlink Business Park</address>
      <city>Wallsend</city>
      <country>United Kingdom</country>
      <zip>NE28 9NX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487149.7</gridId>
    <rorId>https://ror.org/001zd1d95</rorId>
  </sponsor>
  <funder id="Funder16745-0">
    <name>Cambridge Laboratories Ltd (UK) - supported by a grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder16745-1">
    <name>The sponsors/funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-04T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-03-14T00:00:00.000Z">88259320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Recent studies have demonstrated the effectiveness of cisplatin-based combinations in patients with advanced Transitional Cell Carcinoma (TCC) of the urothelium. Concern over cisplatin toxicity instigated a search for alternative regimens. The aim of the study was to evaluate the activity and tolerability of gemcitabine plus carboplatin combination as first-line treatment in patients with advanced transitional cell carcinoma of the urothelium.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Objective response rate
2. Tolerability</primaryOutcome>
      <secondaryOutcome>1. Overall survival
2. Progression-free survival</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The First Affiliated Hospital Ethical Review Board, School of Medicine, Zhejiang University. Approved on 10/12/2002. Ethics Review No. 26 (2002)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88259320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ZJWST491010G20518</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An open label, multi-centre, phase II study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2f9e4fd2-a1d9-44df-b681-76546b42c0e5">
	  <name>79 Qingchun Road</name>
	  <address/>
	  <city>Hangzhou</city>
	  <state/>
	  <country>China</country>
	  <zip>310003</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with locally advanced or metastatic transitional cell carcinoma of the bladder, ureter or renal pelvis were eligible for this study
2. Patients were required to have histologically or cytologically proven locally advanced or metastatic transitional cell carcinoma of the bladder, ureter or renal pelvis
3. Prior cytotoxic treatment either in the adjuvant setting or for metastatic disease was permitted if the treatment had been completed at least six months prior to enrollment in the study
4. Prior radiotherapy was permitted but must have been completed at least six weeks prior to enrollment
5. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
6. A life expectancy at least 3 months
7. Age between 18 and 75 years
8. Adequate bone marrow: absolute neutrophil count more than or equal to 1.5  x 10^9/L, platelet count more than or equal to 100 x 10^9/L, and hemoglobin more than or equal to 100 g/L
9. Adequate hepatic functions: aspartate aminotransferase/alanine aminotransferase, AST/ALT less than or equal to 3.0 times the Upper Normal Limit (UNL) and serum bilirubin less than or equal to 1.5 x UNL
10. Adequate renal functions: serum creatinine less than or equal to 1.5 x UNL and creatinine clearance more than or equal to 30 ml/min based on the Calvert formula
11. Adequate normal cardiac function</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>39</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>39</totalTarget>
      <exclusion>1. Second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma
2. Central nervous system (CNS) involvement
3. Prior radiotherapy in parameter lesions
4. Concurrent uncontrolled medical illness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Advanced transitional cell carcinoma of the urothelium</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Advanced transitional cell carcinoma of the urothelium</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with advanced TCC were treated with gemcitabine 1200 mg/m2 on days 1 and 8 and carboplatin area under the concentration-time curve (AUC) 5 on day 1 every 21 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Gemcitabine, carboplatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17559681 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a6bf69c-46ef-4116-9272-143021f336c2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17559681"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16206-0</funderId>
      <contactId>Contact54161_16206</contactId>
      <sponsorId>Sponsor52715</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54161_16206">
    <title>Dr</title>
    <forename>Nong</forename>
    <surname>Xu</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>79 Qingchun Road</address>
      <city>Hangzhou</city>
      <country>China</country>
      <zip>310003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+86 571 56731277</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">xunong@medmail.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52715">
    <organisation>School of Medicine, Zhejiang University (China)</organisation>
    <website>http://www.cmm.zju.edu.cn/english/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>338 Yuhangtang Road</address>
      <city>Hangzhou</city>
      <country>China</country>
      <zip>310058</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+86 571 88208019</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Chyx@zju.edu.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.13402.34</gridId>
    <rorId>https://ror.org/00a2xv884</rorId>
  </sponsor>
  <funder id="Funder16206-0">
    <name>Health Bureau of Zhejiang Province (China)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-21T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-03-07T00:00:00.000Z">72245261</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomised double-blind controlled trial in patients with haematological malignancies</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Urokinase rinses will lead to less Coagulase-Negative Staphylococcal (CoNS) infections in patients with haematological malignancies and central vein catheters.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The main endpoints of the study were the occurrence of any Central Venous Catheter (CVC)-related infection by CoNS. According to previously described criteria these infections were classified as local CVC related infection (insertion site infection or significant CVC colonisation) and systemic CVC­related infections.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints in this study were:
1. CVC-related infections caused by other microbial pathogens
2. Premature CVC removal
3. Secondary CVC-related complications (metastatic infection, CVC-related thrombosis)
4. Non-CVC related septicaemia bleeding
5. Death</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72245261</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, placebo controlled, parallel group, double blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1999-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="511c64af-6c37-4de8-9359-276248c83d83">
	  <name>Leiden University Medical Centre (LUMC)</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 18 years or older
2. Admission to undergo intensive cytotoxic treatment associated with disruption of the mucosa and deep granulocytopenia (Polymorphonuclear cells [PMNs] less than 0.1 x 10^9/L) for at least 14 days</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>161</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>161</totalTarget>
      <exclusion>1. Patients with pre-existing bleeding disorders
2. Patients treated with intravenous unfractionated heparin to prevent veno-occlusive disease
3. Patients with documented septicaemia prior to the start of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1999-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coagulase-negative staphylococcal central venous catheter-related infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Central venous catheter-related infections</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Urokinase rinses of central vein catheter three times weekly (25,000 IU, 5 ml of 5,000 IU/ml).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Urokinase</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18202420 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c495c126-c7ff-4eb1-b988-a768c32f9dab" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-20T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18202420"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16286-0</funderId>
      <contactId>Contact54243_16286</contactId>
      <sponsorId>Sponsor52795</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54243_16286">
    <title>Dr</title>
    <forename>M V</forename>
    <surname>Huisman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leiden University Medical Centre (LUMC)
Department of General Internal Medicine, C2-R
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 625 9111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.v.huisman@lumc.nl </email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52795">
    <organisation>Leiden University Medical Centre (LUMC) (The Netherlands)</organisation>
    <website>http://www.lumc.nl/english/start_english.html</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Haematology
P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder16286-0">
    <name>Leiden University Medical Centre (LUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-08T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">21473387</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Biochemical efficacy and tolerability of allopurinol, benzbromarone and probenecid in GOUT</title>
      <scientificTitle/>
      <acronym>GOUT-1</acronym>
      <studyHypothesis>1. Allopurinol has a poor efficacy and tolerability profile to lower serum urate to target levels less than 0.30 mmol/l
2. Benzbromarone is more potent and is better tolerated than probenecid to lower serum urate to target levels less than 0.30 mmol/l</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Success rate on study medication consisting of patient tolerability and attainment of target level serum urate less than 0.30 mmol/l after eight weeks treatment.</primaryOutcome>
      <secondaryOutcome>1. Serum urate lowering effect (% decrease) of the antihyperuricemic agent
2. Tolerability of the antihyperuricemic agent (adverse drug reactions)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received by the Medical Centre Leeuwarden on the 7th February 2005 (ref: TPO-357).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21473387</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9dce9a50-fd9a-4ad7-99b9-c3121c4b6a77">
	  <name>Medical Centre Leeuwarden</name>
	  <address/>
	  <city>Leeuwarden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8901 BR</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Diagnosis gout based on crystal evidence or American Rheumatism Association (ARA) criteria
3. Eestimated creatinine clearance more than 50 ml/min
4. Baseline values measured: serum urate, urinary urate excretion, serum creatinine</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>96</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>96</totalTarget>
      <exclusion>1. Contra-indication for allopurinol, benzbromaron or probenecid
2. Prior treatment with allopurinol, benzbromaron or probenecid</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperuricemia, gout</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Stage 1: allopurinol 1dd 300 mg (eight weeks)
Stage 2:
1. Benzbromarone 1dd 200 mg (eight weeks), or 
2. Probenecide 2dd 1000 mg (eight weeks)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Allopurinol, benzbromarone, probenecide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2009 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18250112 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="80b02b92-3425-46a1-b3a7-1fb6fbb911c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2009-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18250112"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16226-0</funderId>
      <contactId>Contact54181_16226</contactId>
      <sponsorId>Sponsor52735</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54181_16226">
    <title>Dr</title>
    <forename>M K</forename>
    <surname>Reinders</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Medical Centre Leeuwarden
Department of Clinical Pharmacy and Pharmacology
P.O. Box 888</address>
      <city>Leeuwarden</city>
      <country>Netherlands</country>
      <zip>8901 BR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)58 286 6610</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.reinders@znb.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52735">
    <organisation>Medical Centre Leeuwarden (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Clinical Pharmacy and Pharmacology
P.O. Box 888</address>
      <city>Leeuwarden</city>
      <country>Netherlands</country>
      <zip>8901 BR</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414846.b</gridId>
    <rorId>https://ror.org/0283nw634</rorId>
  </sponsor>
  <funder id="Funder16226-0">
    <name>Medical Centre Leeuwarden (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-29T00:00:00.000Z">85092388</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of continuous femoral analgesia after anterior cruciate ligament repair on postoperative pain and range of motion: a pilot study</title>
      <scientificTitle/>
      <acronym>FemoX</acronym>
      <studyHypothesis>Patients with a catheter-based analgesia at the femoral nerve have less pain compared to patients receiving a Patient-Controlled Analgesia (PCA).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain levels.</primaryOutcome>
      <secondaryOutcome>Physiotherapeutic options.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received, no details provided as of 29/01/2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85092388</doi>
      <eudraCTNumber>2005-000237-37</eudraCTNumber>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-blinded, randomised study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b02c58be-9b59-4432-b89e-46bc5426cdbb">
	  <name>Charité Universitätsmedizin Berlin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10098</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients receiving a anterior cruciate ligament repair.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Pregnancy
2. Redo-Surgery
3. Neurologic or psychiatric diseases
4. Other diseases potentially putting the patient at risk
5. Body Mass Index of more than 35
6. Allergic to local anesthetics</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ruptured anterior cruciate ligament</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Ruptured anterior cruciate ligament</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Peripheral nerve catheter at the femoral nerve versus PCA.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15320-0</funderId>
      <contactId>Contact53236_15320</contactId>
      <sponsorId>Sponsor51781</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53236_15320">
    <title>Dr</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité Universitätsmedizin Berlin
Department of Anesthesiology and Intensive Care Medicine
Charitéplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (030) 450 531012</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anaesth@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51781">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de/ch/anaest/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o PD Dr Thomas Volk
Department of Anesthesiology and Intensive Care Medicine
Charitéplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder15320-0">
    <name>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin),  Medical School Research Grant (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">87678078</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and security of low toxicity immunosuppressive regimen using basiliximab, mycophenolate mofetil, neoral or tacrolimus and corticosteroids versus full doses of  neoral, thymoglobulin, azathioprine and corticosteroids</title>
      <scientificTitle/>
      <acronym>Immuno99</acronym>
      <studyHypothesis>To compare efficacy and security of low toxicity immunosuppressive regimen using basiliximab, mycophenolate mofetil (MMF), neoral (cyclosporin A [CsA]) or tacrolimus and corticosteroids versus full doses of  neoral, thymoglobulin, azathioprine and corticosteroids.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine renal function evaluated by calculated creatinine clearance at 6 and 12 months.</primaryOutcome>
      <secondaryOutcome>To assess acute rejection rate at 6 and 12 months, patient and graft survival rate at 12 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received in May 1999 from two sources:
1. The Ethics Committee of the University Hospital of the Canary Islands (ref: Inmuno/99)
2. Agencia Española del Medicamento from Spanish Ministry of Health (ref: 99-0296)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87678078</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, randomised, open-label, single centre, three parallel therapeutic armed trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-10-27T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-21T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5c17f9de-741d-4acf-a67e-102784d6c69e">
	  <name>Nephrology Service</name>
	  <address/>
	  <city>Tenerife</city>
	  <state/>
	  <country>Spain</country>
	  <zip>38320</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 18 years
2. Accepted informed consent
3. Primary kidney allograft 
4. Cadaveric donor</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>240</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>240</totalTarget>
      <exclusion>1. Panel Reactive Antibody (PRA) over 50%
2. History of malignancy
3. History of infection
4. Previous treatment with polyclonal antibodies or basiliximab</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-10-27T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-21T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Kidney transplant</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Kidney transplant</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one: thymoglobulin (1 to 1.5 mg/k/day for seven days), CsA (8 mg/k/day; levels: 175 to 225 ng/ml), azathioprine (1.5 mg/k/day) and corticosteroids
Group two: basiliximab (20 mg days zero and four), CsA (4 mg/k/day, levels: 125 to 175 ng/ml), MMF (2 g/day) and corticosteroids
Group three: basiliximab (20 mg days zero and four), tacrolimus (0.1 mg/k/day, levels: 8 to 12 ng/ml), MMF (2 g/day) and corticosteroids</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Basiliximab, mycophenolate mofetil (MMF), neoral (cyclosporin A [CsA]), tacrolimus, corticosteroids, thymoglobulin, azathioprine.</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17893603 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="81bb378d-5713-4945-9f1f-fdddd0a7361d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17893603"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15383-0</funderId>
      <contactId>Contact53315_15383</contactId>
      <sponsorId>Sponsor51862</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53315_15383">
    <title>Dr</title>
    <forename>Domingo</forename>
    <surname>Hernandez</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Nephrology Service
Hospital Universitario de Canarias
Ofra s/n La Laguna</address>
      <city>Tenerife</city>
      <country>Spain</country>
      <zip>38320</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 922 678 545</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">domingohernandez@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51862">
    <organisation>Hospital Universitario de Canarias (Spain)</organisation>
    <website>http://www.hecit.es</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Fundation Rafael Clavijo
Research Unit 
Ofra s/n La Laguna </address>
      <city>Tenerife</city>
      <country>Spain</country>
      <zip>38320</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 922 678 545</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">domingohernandez@gmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411220.4</gridId>
    <rorId>https://ror.org/05qndj312</rorId>
  </sponsor>
  <funder id="Funder15383-0">
    <name>Fundation Rafael Clavijo, Research Unit, Hospital Universitario de Canarias (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-12-14T00:00:00.000Z">87201238</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic sumatriptan for prevention of Acute Mountain Sickness: a double blind, randomised, placebo controlled, clinical trial</title>
      <scientificTitle/>
      <acronym>SAMS</acronym>
      <studyHypothesis>Prophylaxis with sumatriptan will slow or stop the progression of acute mountain sickness (AMS) compared to those taking a placebo.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>AMS development due to Lake Louise criteria within 24 hours (International Hypoxia Symposium)</primaryOutcome>
      <secondaryOutcome>1. AMS severity (score more than or equal to five) due to Lake Louise protocol after 24 hours (self-report and clinical assessment)
2. Altitude headache occurrence and severity</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Review Board of Neurology Research Center, Imam Hospital, Tehran University of Medical Sciences, Tehran, Iran.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87201238</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single centre, randomised, two-armed, placebo controlled, participants/outcome assessor blind, clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Iran</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="274352eb-ca1f-4dda-92e5-2fd5bb122312">
	  <name>No15, Shabtab Street</name>
	  <address/>
	  <city>Tehran</city>
	  <state/>
	  <country>Iran</country>
	  <zip>19389</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age of 18 to 60 years
2. Ascent to a high altitude of 3500 to 3900 metres above sea level from an altitude of at least 1500 metres
3. Consenting participant
4. May reasonably be expected to complete a 24 hour trial</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>102</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>102</totalTarget>
      <exclusion>1. Other neuro-vascular disease such as cerebrovascular accident, and hypoxic cerebral damage
2. Cardiovascular disease such as ischaemic heart disease, coronary artery disease, significant valvular disease, congestive heart failure, and uncontrolled hypertension with systolic pressure greater than 180 mmHg or diastolic pressure greater than 110 mmHg
3. Pregnancy 
4. Hypersensitivity to either sumatriptan or acetazolamide or their components</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute mountain sickness</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Acute mountain sickness</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Sumatriptan succinate 50 mg plus orally, once at early ascent 
2. Placebo: similar color, shape, and weight to interventional group</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sumatriptan succinate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17557349 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="434f927f-920c-4b64-bde8-af9c749e1ba2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17557349"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15862-0</funderId>
      <contactId>Contact53802_15862</contactId>
      <sponsorId>Sponsor52356</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53802_15862">
    <title>Dr</title>
    <forename>Sirous</forename>
    <surname>Jafarian</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>No15, Shabtab Street
Gheytarieh Avenue</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>19389</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52356">
    <organisation>Imam Neurology Research Center (Iran)</organisation>
    <website>http://iro.tums.ac.ir/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Tehran University of Medical Sciences
No. 23, Dameshgh Street
Vali-e Asr Street</address>
      <city>Tehran</city>
      <country>Iran</country>
      <zip>14167</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.411705.6</gridId>
    <rorId>https://ror.org/01c4pz451</rorId>
  </sponsor>
  <funder id="Funder15862-0">
    <name>Imam Neurology Research Center, Tehran University of Medical Sciences (Iran)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-07T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-12-06T00:00:00.000Z">64070727</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Augmented Community-based Perinatal Care</title>
      <scientificTitle/>
      <acronym>CPC Study</acronym>
      <studyHypothesis>It was hypothesised that additional community-based prenatal support from nurses and home visitors would improve the use of prenatal resources among women at low medical risk, including those experiencing challenges such as poverty, language barriers, abuse, and low self esteem.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Resource utilisation
2. Provision of information</primaryOutcome>
      <secondaryOutcome>1. Mental health
2. Lifestyle choices
3. Satisfaction with care</secondaryOutcome>
      <trialWebsite>http://www.calgaryhealthregion.ca/dsrt/studycpcs.htm</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Conjoint Health Ethics Research Board, Calgary Health Region and University of Calgary.  Approval date: June 7, 2001(ref: #15763).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN64070727</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>10</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="903601ca-a9ea-432a-aca3-113033576f37">
	  <name>Alberta Children's Hospital</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T3B 6A8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. More than or equal to 18 years
2. Speak English, French, Punjabi, Urdu, Arabic, Cantonese, Mandarin
3. Live in city limits
4. Not attended first prenatal class prior to intake interview</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>1800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1,800</totalTarget>
      <exclusion>1. Less than 18 years
2. Could not speak English, French, Punjabi, Urdu, Arabic, Cantonese, or Mandarin
3. Live outside city limits 
4. Attended first prenatal class prior to intake interview</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pregnancy</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pregnant women randomised to:  
1. Standard of prenatal care,
2. Standard of prenatal care plus supplementary nurse, or 
3. Standard of care plus supplementary nurse and home visitor.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16948718 Results:
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17118044 Results:
2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17617914 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="32db2230-db2b-4e6c-8832-2edb2a196bd7" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16948718"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="939a1f6d-c82b-4799-8cca-9edce804be57" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=17118044"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
      <output id="87e4b736-8e9a-4c9d-bcb2-07c0509348c1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-06T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17617914"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15744-0</funderId>
      <funderId>Funder15744-1</funderId>
      <funderId>Funder15744-2</funderId>
      <funderId>Funder15744-3</funderId>
      <funderId>Funder15744-4</funderId>
      <contactId>Contact53682_15744</contactId>
      <sponsorId>Sponsor52236</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53682_15744">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Tough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Alberta Children's Hospital
2888 Shaganappi Trail NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T3B 6A8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52236">
    <organisation>Calgary Children's Initiative (Canada)</organisation>
    <website>http://www.childrensinitiative.ca/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Suite 600
1202 Centre Street S.E.</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2G 5A5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder15744-0">
    <name>Calgary Children's Initiative (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15744-1">
    <name>Physician Partnership Steering Committee (Canada)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15744-2">
    <name>Added as of 07/02/2008:</name>
    <fundRef/>
  </funder>
  <funder id="Funder15744-3">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
  <funder id="Funder15744-4">
    <name>Child and Women's Health Portfolio, Calgary Health Region (Canada)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-03T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-12-01T00:00:00.000Z">89278733</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and efficacy of mycophenolate mofetil in pediatric renal transplantation</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Mycophenolate Mofetil (MMF)/prednisolone is as efficacious in prevention of acute rejections as Cyclosporin A (CsA)/prednisolone
2. MMF/prednisolone is safer than CsA/prednisolone, in renal function, lipids, and blood pressure</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Glomerular filtration rate
2. Incidence of acute rejections
3. Serum lipids
4. Blood pressure and number of antihypertensive drugs</primaryOutcome>
      <secondaryOutcome>1. Graft survival
2. Incidence of malignancies
3. Incidence of viral infections
4. Incidence of anemia</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN89278733</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NTR800</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre parallel armed, controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="169e4847-4c76-4659-a170-2c8bc7a1c3e4">
	  <name>Erasmus Medical Center</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 GJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. All Dutch children, receiving a first kidney transplant after 01/01/2000
2. Treated with initial immunosuppression corticosteroids, MMF and CsA, during the latter part of the study with addition of basiliximab</inclusion>
      <ageRange>Child</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>44</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>44</totalTarget>
      <exclusion>1. Not on triple therapy (prednisolone/CsA/MMF) at the end of the first year
2. More than one acute rejection episode
3. Rejection episode being not steroid sensitive
4. No written informed consent</exclusion>
      <patientInfoSheet>Nor ptovided at time of registration</patientInfoSheet>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal transplant</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Renal transplant</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Start trial is one year after transplantation. Randomisation between two groups: continuing with MMF/prednisolone or CsA/prednisolone by withdrawal over three months of the third immunosuppressive drug. 

During the three months of withdrawal, the prednisolone dosage is doubled. Follow-up is two years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mycophenolate mofetil (MMF), prednisolone and cyclosporin A (CsA)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17452893 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="f4446880-aaf1-466f-9c95-caeb7060c249" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-04-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17452893"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15879-0</funderId>
      <contactId>Contact53819_15879</contactId>
      <sponsorId>Sponsor52373</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53819_15879">
    <title>Dr</title>
    <forename>Karlien</forename>
    <surname>Cransberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Center
Sophia Children's Hospital
Dr Molewaterplein 60</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4636363</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.cransberg@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52373">
    <organisation>Erasmus Medical Center (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Sophia Children's Hospital
Dr Molewaterplein 60</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GJ </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder15879-0">
    <name>Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002997</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-18T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-09-29T00:00:00.000Z">03252849</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised trial of a vibrating bladder stimulator to induce urine flow in acute paediatrics</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does use of a vibrating bladder stimulator alter the time taken to pass urine in children?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to pass urine from taking the nappy off to urine flow.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03252849</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0264171565</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f21e0d66-08be-4006-b547-117465f815da">
	  <name>C/O Research and Effectiveness Department</name>
	  <address/>
	  <city>Bristol</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BS2 8HW</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All children to give a urine sample who are not continent of urine (by day or night) attending to the Paediatric Emergency Department at the Bristol Children's Hospital will be asked to take part.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>97</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>97</totalTarget>
      <exclusion>1. Children too unwell, in the opinion of the doctor treating
2. Those who do not need a clean sample of urine (so could have a urine bag)
3. Those who in the opinion of the consent taker, have insufficient understanding (due to language or other factors) of the trial process
4. Those who do not have a legal guardian with them
5. Those who have abnormalities in their anatomy or nerves which affect their ability to pass urine</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urological and Genital Diseases:</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>RCT:
1. Advice
2. Device

The patients will be assigned to one of two groups: the 'advice' and the 'device' groups. The advice group will be given an advice leaflet which has some tips on how to try to stimulate urine flow. The device group will be shown the use of a bladder stimulator. This is a hand-held vibrating disk which is non-painful and has no known side effects. It is pressed on to the lower abdomen and vibrates the bladder, with the aim of stimulating urine flow. The idea behind this stimulator is that the vibrations of the bladder cause a reflex reaction which leads to urine flow. 

Half of the patients will be in each group: which group the individuals go in to is decided at random. This is to minimise the possible effects of patients becoming frustrated at perceived preferential treatment within the waiting room area. Full informed consent will be obtained. 

The parents would be given a clock and asked to write down when the urine is passed. If a sample is passed and is missed by the parents, this still counts as a time to pass urine. A questionnaire is also given which will ask some questions on the child and their illness, as well as how they think the child coped with the urine collection process.

This is then the end of the study and there will be no further input for the child or their parents.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18192318 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d40b09b7-c0b0-4317-810f-f9213fca8463" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18192318"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15617-0</funderId>
      <funderId>Funder15617-1</funderId>
      <contactId>Contact53550_15617</contactId>
      <sponsorId>Sponsor52097</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53550_15617">
    <title>Dr</title>
    <forename>Patrick</forename>
    <surname>Davies</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>C/O Research and Effectiveness Department
Level 1 Old Building
Bristol Royal Infirmary
Marlborough Street</address>
      <city>Bristol</city>
      <country>United Kingdom</country>
      <zip>BS2 8HW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 0117 928 3473</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">R&amp;Eoffice@ubht.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52097">
    <organisation>Record Provided by the NHSTCT Register - 2006 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15617-0">
    <name>United Bristol Healthcare NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15617-1">
    <name>NHS R&amp;D Support Funding (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-07-10T00:00:00.000Z">26610787</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Impact of Laboratory-based Prompts on the Management of Patients with Chronic Kidney Disease</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>A laboratory prompt, which identifies a patient with chronic kidney disease (CKD) as being at high risk for cardiovascular disease and progression to kidney failure, improves the management of cardiovascular disease risk factors and kidney disease by physicians.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Use of ACEi or ARB in patients &gt;65 years of age with CKD who have a clear indication for ACEi or ARB use as defined by the presence of diabetes or significant albuminuria.</primaryOutcome>
      <secondaryOutcome>1. Use of an ACEi or ARB in patients &gt;65 years of age with CKD
2. Subsequent measurement of lipids, hemoglobin A1C (in patients with diabetes, if not done in previous six months), urine protein or urine albumin, and subsequent frequency of measurement of serum creatinine
3. Referral to a specialist
4. Addition of cholesterol-lowering drugs in patients &gt;65 years of age
5. Addition of new blood pressure medication(s) in patients &gt;65 years of age
6. Health care costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Bioethics Committess at the University of Calgary and the University of Alberta, 2005, reference number: 18050</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26610787</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomized trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a517e612-28e1-4b1f-b873-a601568c4f16">
	  <name>1403-29th St NW</name>
	  <address/>
	  <city>Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T2N 2T9</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients &gt;18 years of age who are registered with one of the participating general practices and have a GFR measured at &lt;60 ml/min during the one-year study period will be included.  All participating general practices will be geographically separated (not located in the same office building), and staffed by &gt;1 full time practitioners who do not see outpatients in another general practice unit (to reduce the risk of contamination).</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>92</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>46 Family Practices per group (92 total)</totalTarget>
      <exclusion>Those patients not meeting the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic kidney disease</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Kidney disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The following prompt will be added to laboratory reports for patients who meet the inclusion criteria and are seen by a physician practice randomized to receive the prompt:
This patient has reduced kidney function and is at risk for cardiovascular events and progression to kidney failure. The National Kidney Foundation recommends:
1. Measure random urine albumin to creatinine (Alb:Cr) ratio
2. Institute an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) in patients with diabetes, or those with an Alb:Cr &gt;35 mg/mmol
3. Referral to a nephrologist if GFR &lt;30 ml/min/1.73 m^2
4. Assess  and treat modifiable risk factors for cardiovascular (CV) and renal disease:
a. Target blood pressure (BP) less than 130/80 mmHg
b. Target low-density lipoprotein cholesterol(LDL-C) &lt;2.5 mmol/l
c. If diabetic, target hemoglobin A1C (HbA1C) &lt;7.0%

The above recommendations are general in nature and may not apply to all patients. Further information is available at  http://www.akdn.info
The control group will receive usual care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder14759-0</funderId>
      <contactId>Contact52528_14759</contactId>
      <sponsorId>Sponsor51051</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52528_14759">
    <title>Dr</title>
    <forename>Bruce</forename>
    <surname>Culleton</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>1403-29th St NW
Calgary</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T2N 2T9</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1403 944 8166</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bruce.culleton@calgaryhealthregion.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51051">
    <organisation>Alberta Heritage Foundation for Medical Research (Canada)</organisation>
    <website>http://www.ahfmr.ab.ca</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Suite 1500
10104-103 Avenue</address>
      <city>Edmonton</city>
      <country>Canada</country>
      <zip>T5J 4A7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 780 423 5727</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ahfmrinfo@ahfmr.ab.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.484182.3</gridId>
    <rorId>https://ror.org/006b2g567</rorId>
  </sponsor>
  <funder id="Funder14759-0">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-05-23T00:00:00.000Z">77101807</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, controlled, multicenter, pilot study comparing qigong and back school for elderly patients with chronic neck pain</title>
      <scientificTitle/>
      <acronym>QIBANE</acronym>
      <studyHypothesis>Primary hypothesis: there is a significant difference between the qigong and the waiting list groups for the primary outcome (visual analogue scale [VAS]) after 3 months.
Secondary hypothesis: there is a significant difference between the qigong and the back school groups for the primary outcome (VAS) after 3 months.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain measured on the VAS (visual analogue scale) after three months</primaryOutcome>
      <secondaryOutcome>1. Neck pain (Neck Pain and Disability Scale, Wheeler)
2. Depression (Depression Scale, Hautzinger)
3. Quality of life (Short-form Questionnaire-36 [SF-36], Bullinger)
4. Frequency of falls and anxiety to fall
5. Sleep quality and satisfaction
6. Overall treatment effect (OTE) (Wiklund)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Yes, date of approval: 23/02/06; reference number: EA1/265/05</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77101807</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicenter, three-armed, randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-09T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="41001a1b-3ff5-4639-9b23-1513da4cd7a8">
	  <name>Institute for Social Medicine</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10098</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age ≥55 years of age
2. Chronic neck pain (duration &gt;6 months)
3. Average pain during the last 7 days before randomisation ≥20 mm on 100 mm VAS
4. Informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120 (40 per group)</totalTarget>
      <exclusion>1. Serious acute or chronic disease which would not allow the exercises to be performed
2. Planned start of physiotherapy for chronic neck pain during study participation
3. Participation in another study during the last 6 months before study entry</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-09T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic neck pain</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Chronic neck pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomized into the qigong and back school exercise groups (each 24 sessions of 45 min over a period of three months)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15058-0</funderId>
      <contactId>Contact52883_15058</contactId>
      <sponsorId>Sponsor51433</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52883_15058">
    <title>Dr</title>
    <forename>Claudia </forename>
    <surname>Witt</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute for Social Medicine
Charité University Medical Center</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51433">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de/epidemiologie</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Medical Center 
Institute for Social Medicine</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10098</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder15058-0">
    <name>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin), Institute for Social Medicine, University Medical Center (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-15T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-03-31T00:00:00.000Z">95821329</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre prospective randomised clinical trial to compare the safety and efficacy of outpatient treatment with oral amoxicillin with that of injectable ampicillin in children aged 3 to 59 months: APPIS II Randomised Controlled Trial (RCT), Pakistan</title>
      <scientificTitle/>
      <acronym>APPIS II</acronym>
      <studyHypothesis>The proportion of children aged 3 to 59 months with World Health Organization (WHO) defined severe pneumonia who fail treatment in the oral amoxicillin group will not be greater than the proportion of those who fail in the parenteral ampicillin group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Clinical deterioration occurring any time after enrolment
2. Inability to take oral medication due to persisting vomiting as assessed by study physician
3. Change or addition of antibiotics</primaryOutcome>
      <secondaryOutcome>1. Treatment failure between day 6 and 14
2. Clinical deterioration (development of danger signs) between day 6 and 14
3. Development of lower chest indrawing or fast breathing, which is non responsive to three trials of nebulisation with bronchodilator between day 6 and 14</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from:
1. Local ethics board on the 2nd December 2004
2. WHO Ethics Research Committee (ERC) on the 23rd March 2005</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN95821329</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00227331</clinicalTrialsGovNumber>
      <protocolSerialNumber>RPC116</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-02-24T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Pakistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="209b5f7d-d67a-4b5f-a0a8-2f9eb8528bf9">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 3 to 59 months with severe pneumonia. Severe pneumonia is defined as Lower Chest Indrawing (LCI) in children with cough and/or difficult breathing, who are able to drink and do not have central cyanosis, regardless of the respiratory rate
2. Known Human Immunodeficiency Virus (HIV) infected patients in clinical category N or A (Centers for Disease Control [CDC]) will be included
3. Informed consent by a legal guardian</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="3.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>2100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2100</totalTarget>
      <exclusion>Children with any of the following conditions will be excluded:
1. Very severe pneumonia/disease
2. Known prior episodes of asthma or three or more prior episodes of wheezing
3. LCI that resolves after three doses of bronchodilator therapy
4. Severe malnutrition (visible severe wasting or oedema)
5. Known anaphylactic reaction to penicillin or amoxicillin
6. Hospitalisation in the last two weeks
7. Other diseases requiring antibiotic therapy at presentation, such as meningitis, dysentery, osteomyelitis, septic arthritis, evident tuberculosis etc.
8. Persistent vomiting
9. Previous inclusion in the study
10. Living outside a pre-defined area
11. Parental or caretaker refusal to participate in the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-02-24T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>World Health Organization (WHO) defined severe pneumonia</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Pneumonia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Parenteral Ampicillin for 2 days then sent home on oral amoxicillin for 3 days
2. Oral Amoxicillin for 5 days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Amoxicillin, ampicillin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18177775 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a9a4ab8-01fd-4876-aedf-5f5ae396864c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-05T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18177775"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14959-0</funderId>
      <funderId>Funder14959-1</funderId>
      <contactId>Contact52762_14959</contactId>
      <sponsorId>Sponsor51305</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52762_14959">
    <title>Dr</title>
    <forename>Shamim Ahmad</forename>
    <surname>Qazi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4853</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.in</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51305">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4853</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">qazis@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14959-0">
    <name>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14959-1">
    <name>US Agency for International Development (USAID) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-02-14T00:00:00.000Z">25180151</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized phase III study in previously untreated patients with biological high-risk CLL: fludarabine and cyclophosphamide (FC) versus FC and low-dose alemtuzumab</title>
      <scientificTitle/>
      <acronym>HOVON 68 CLL</acronym>
      <studyHypothesis>The hypothesis to be tested is that the outcome in arm B is better than in arm A.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Progression free survival (i.e. time from registration to disease progression, relapse or death due to CLL whichever occurs first)</primaryOutcome>
      <secondaryOutcome>1. Event free survival (i.e. time from registration to induction failure, progression, relapse or death whichever occurs first); the time to failure of patients with induction failure is set at one day
2. Clinical, flow cytometric and molecular response rate
3. Overall survival
4. Disease free survival (i.e. time from CR to relapse)
5. Toxicity</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25180151</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HO68</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, multicenter, randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4b05e13a-f146-499a-9481-4be2bb68f570">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Biological high-risk CLL
2. Patients with symptomatic stage A, symptomatic stage B or stage C
3. Age 18-75 years inclusive
4. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="75.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. WHO performance status &gt;/= 3, unless related to CLL
2. Intolerance of exogenous protein administration
3. Severe cardiac dysfunction (New York Heart Association [NYHA] classification III-IV)
4. Significant renal dysfunction (serum creatinine &gt;/= 150 micromol/l or creatinine clearance &lt;30 ml/min)
5. Significant hepatic dysfunction (total bilirubin or transaminases &gt;2 times upper limit of normal [ULN]), unless related to CLL
6. Suspected or documented central nervous system (CNS) involvement by CLL
7. Known HIV positivity
8. Active, uncontrolled infections
9. Uncontrolled asthma or allergy requiring systemic steroid treatment
10. Previously treated with chemotherapy, radiotherapy or immunotherapy for CLL
11. History of active cancer during the past 5 years, except non-melanoma skin cancer or stage 0 cervical carcinoma
12. Clinically significant auto-immune hemolytic anemia (AIHA)
13. Female patients who are pregnant or nursing
14. Male and female patients of reproductive potential who are not practicing effective means of contraception, these include oral contraceptives, intrauterine device, depot injection of gestagen, subdermal implantation, hormonal vaginal ring and transdermal depot plaster. These methods must be applied for the entire protocol treatment period, and for patients treated with alemtuzumab until at least 6 months after the end of alemtuzumab administration.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic Lymphocytic Leukemia (CLL)</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Leukaemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All eligible patients will be randomized on entry between:
Arm A: 6 cycles of oral FC 
Arm B: 6 cycles of oral FC combined with sc alemtuzumab</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Fludarabine and cyclophosphamide (FC) and low-dose alemtuzumab</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14786-0</funderId>
      <contactId>Contact52556_14786</contactId>
      <sponsorId>Sponsor51080</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52556_14786">
    <title>Prof</title>
    <forename>M.H.J.</forename>
    <surname>Oers, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Department of Hematologie
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5665785</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.h.vanoers@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51080">
    <organisation>Rigshospitalet (Denmark)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Hematology</address>
      <city>Copenhagen</city>
      <country>Denmark</country>
      <zip>DK-2100</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.475435.4</gridId>
    <rorId>https://ror.org/03mchdq19</rorId>
  </sponsor>
  <funder id="Funder14786-0">
    <name>Dutch Cancer Society and Schering AG (Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-01-27T00:00:00.000Z">14751416</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Clopidose trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>150 mg/day maintenance dose will increase the biological effect of clopidogrel in clopidogrel low responders</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Biological effect of clopidogrel</primaryOutcome>
      <secondaryOutcome>Genetic association study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This protocol has been approved by the ethics committee of the internal medicine department in November 2005</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14751416</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open labelled clinical study with patients admitted for coronary angioplasty</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3464b3b5-cd29-4d0e-8788-242768423001">
	  <name>Geneva University Hospital</name>
	  <address/>
	  <city>Geneva</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cardiovascular outpatients on 75 mg/day clopidogrel</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>Anticoagulation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular outpatients</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After a loading dose of clopidogrel (600 mg), patients will take a standard dose of clopidogrel 75 mg once a day for 15 days.


At day 15, adenosine diphosphate (ADP) induced platelet aggregation and measurement of phosphorylated vasodilator-stimulated phosphoprotein (VASP-P) by a flow cytometric technique will be performed. If patients are clopidogrel resistant, they will receive 150 mg (2x75) once a day during the next 15 days. ADP-induced platelet aggregation and measurement of VASP-P will be performed at day 30.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Clopidogrel</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14633-0</funderId>
      <funderId>Funder14633-1</funderId>
      <contactId>Contact52391_14633</contactId>
      <sponsorId>Sponsor50904</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52391_14633">
    <title>Prof</title>
    <forename>François</forename>
    <surname>Mach</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Geneva University Hospital
Cardiology Division
24 Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 382 7234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">francois.mach@medecine.unige.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50904">
    <organisation>Geneva University Hospital (Switzerland)</organisation>
    <website>http://www.cardiology-geneva.ch</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Cardiology Division
24 Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 382 7234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marjorie.burkhard@hcuge.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.150338.c</gridId>
    <rorId>https://ror.org/01m1pv723</rorId>
  </sponsor>
  <funder id="Funder14633-0">
    <name>University of Geneva Cardiology Foundation (GECOR)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14633-1">
    <name>Geneva University Hospital Internal Medicine Department</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-07T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-11-28T00:00:00.000Z">86717853</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Inhaled Fluticasone in Wheezy Infants</title>
      <scientificTitle/>
      <acronym>IFWIN</acronym>
      <studyHypothesis>1. Can the early introduction of inhaled corticosteroids (ICS) prevent the progressive fall in lung function seen in asthmatics?
2. Can early introduction of inhaled corticosteroids in children with asthma modify the natural history of the disease or prevent recurrence of asthma later in life?
3. Does treatment with ICS reduce symptoms in non-asthmatic wheezy children and improve their lung function at age 6 years?
4. Do inhaled corticosteroids improve the quality of life of families with wheezing children?
5. Is continuous treatment with ICS at this dose in young children associated with any local or systemic side effects?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Occurrence of asthma at age 5 and 6
2. Lung function at age 5
3. Non-specific bronchial hyper-reactivity at age 5
4. Number of courses and total dose of add-on fluticasone propionate required</primaryOutcome>
      <secondaryOutcome>1. Rescue and added asthma medication
2. Number of exacerbations
3. Safety parameters &#150; length/height, weight
4. Symptom scores
5. Adrenal function</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>ERP/97/023, 21st April 1997</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86717853</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A randomized double blind placebo controlled study investigating the effects of early intervention with low dose inhaled corticosteroids (fluticasone propionate) in young children with wheeze</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e62e832d-7637-46ca-bb73-100d7d766a0b">
	  <name>North West Lung Research Centre</name>
	  <address/>
	  <city>Manchester</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>M23 9LT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 6 months to 4 years
2. Two episodes of doctor verified wheeze or one episode continuous for more than 4 weeks</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="4.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Pre-term less than 34 weeks gestation
2. Neonatal lung disease or other lung disease
3. Other chronic disease
4. Children already or previously used an inhaled corticosteroid
5. Children who cannot use the spacer device</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Asthma in children</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Low dose inhaled corticosteroids (fluticasone propionate) versus placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone propionate</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16935686 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a4a20e32-9608-4c4f-859a-d172f2821efd" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-26T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16935686"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14186-0</funderId>
      <contactId>Contact51895_14186</contactId>
      <sponsorId>Sponsor50321</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51895_14186">
    <title>Dr</title>
    <forename>Clare</forename>
    <surname>Murray</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>North West Lung Research Centre

Wythenshawe Hospital

Southmoor Road</address>
      <city>Manchester</city>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 291 4199</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cmurray@fs1.with.man.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50321">
    <organisation>Wythenshawe Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Andrew Maines

R&amp;D Directorate

ERC Building

Wythenshawe Hospital

Southmoor Road</address>
      <city>Manchester</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>M23 9LT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)161 291 5775</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">amaines@fs1.with.man.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.417286.e</gridId>
    <rorId>https://ror.org/05vpsdj37</rorId>
  </sponsor>
  <funder id="Funder14186-0">
    <name>GlaxoSmithKline (UK)</name>
    <fundRef>http://dx.doi.org/10.13039/100004330</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-29T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">86632774</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II, double blind randomised, placebo controlled study to assess the safety reactogenicity and immunogenicity of three doses of GSK Biologicals (South Africa)</title>
      <scientificTitle/>
      <acronym>Rota014</acronym>
      <studyHypothesis>This study was undertaken to identify whether the immunogenicity of live Oral Poliovirus (OPV) vaccine was affected by the concomitant administration of the candidate Human Rotavirus (HRV) vaccine and also to assess the safety of the candidate HRV vaccine given concomitantly with poliovirus vaccine (OPV or IPV). The study was conducted in two parts, the first part (subset enrolled before the start of the 2002 Rotavirus [RV] season) and the second part of the study (subset enrolled after the end of the 2002 rotavirus season).

Objective:
To demonstrate that co-administering HRV vaccine with OPV does not induce a significant decrease in poliovirus immune response one month after the third dose of polio vaccine.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Seroprotection for each polio serotype:
1. Proportion of subjects with anti-poliovirus type 1 antibody titre greater than or equal to 1:8 one month after the third dose
2. Proportion of subjects with anti-poliovirus type 2 antibody titre greater than or equal to 1:8 one month after the third dose
3. Proportion of subjects with anti-poliovirus type 3 antibody titre greater than or equal to 1:8 one month after the third dose</primaryOutcome>
      <secondaryOutcome>1. Proportion of subjects with vaccine take one month after each dose of study vaccine at visits 2 and 3 for subset before RV season
2. Proportion of subjects with vaccine take one month after each dose of study vaccine at visits 3 and 4 for subset after RV season*
3. Viral shedding in a subset of subjects
4. Presence of rotavirus in diarrhoeal stools collected between visits 1 and 3 for subset before RV season, and between visits 1 and 4 for subset after RV season
5. Antibody titres for anti-poliovirus type 1, anti-poliovirus type 2, anti-poliovirus type 3 one month after the third dose
6. Serum anti-rotavirus IgA (immunoglobulin A) antibody titres in subjects in the subset before RV season at study visits 1 to 3
7. Serum anti-rotavirus IgA antibody titres in subjects in the subset after RV season at study visits 2 to 4
8. For each type of solicited symptom, occurrence of the symptom within the 15-day (day 0-14) solicited follow-up period after each study vaccine dose
9. Occurrence of unsolicited adverse events within 43 (day 0&#150;42) days after each study vaccine dose, according to World Health Organization (WHO) classification
10. Occurrence of serious adverse events (SAEs) throughout the entire study period (including long term follow-up for 6 months after Dose 2 of HRV vaccine/placebo)

*Not done since no stool samples were collected after RV season</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received in 2001</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN86632774</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled study with three parallel groups with balanced allocation (1:1:1).</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0732331b-b1be-4eff-b683-3e2a676c3b5d">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents/guardians of subjects who could comply with the protocol requirements (e.g. completion of diary cards, return for follow-up visits)
2. Male or female 6 - 10 weeks of age at the time of first vaccination
3. Written informed consent from parents/guardians
4. Born after a gestation period of 36 - 42 weeks</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Weeks" value="6.0"/>
      <upperAgeLimit unit="Weeks" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>271</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>271</totalTarget>
      <exclusion>1. Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period
2. Previous routine vaccination except Bacillus Calmette-Guerin (BCG) and hepatits B virus (HBV)
3. Clinically significant history of chronic Gastrointestinal Tract (GIT) disease including any incorrected congenital malformation of GIT
4. History of allergic disease or reaction likely to be exacerbated by any component of the vaccine
5. Acute illness at the time of enrolment
6. Diarrhoea with in 7 days preceding the study vaccination
7. Administration of immunoglobulins and/or blood products since birth or planned during study period
8. Use of any investigational or non-registered drug or vaccine other than study vaccines during the study period</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunisation</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two doses of GSK Biologicals&#146; oral live attenuated human rotavirus (HRV) vaccine (RIX4414) at 106.5 CCID50 viral concentration, one dose of placebo
Control: three doses of placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Live attenuated human rotavirus vaccine (RIX4414), oral poliovirus vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14240-0</funderId>
      <funderId>Funder14240-1</funderId>
      <contactId>Contact51963_14240</contactId>
      <sponsorId>Sponsor50393</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51963_14240">
    <title>Dr</title>
    <forename>Duncan</forename>
    <surname>Steele</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3752</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steeled@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50393">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14240-0">
    <name>RAPID trials (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14240-1">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-28T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-11-25T00:00:00.000Z">37373664</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A double blind, randomised placebo controlled study of the safety, reactogenicity and immunogenicity of two doses of orally administered human rotavirus vaccine (RIX4414) in healthy infants in South Africa</title>
      <scientificTitle/>
      <acronym>Rota013</acronym>
      <studyHypothesis>The aim of this study was to determine if there was a difference in immune response between the two different schedules that were tested.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of subjects who seroconverted at visit 4 (2 months after dose 3) in the vaccine groups.</primaryOutcome>
      <secondaryOutcome>Immunogenicity:
1. Proportion of subjects with vaccine take at visit 2 (dose 2) and visit 4 in a subset of subjects
2. Serum rotavirus IgA (immunoglobulin A) antibody concentrations in all subjects at visits 1, 2 and 4
3. Proportion of subjects with anti-poliovirus type 1, 2 and 3 antibody titre greater than or equal to 1:8, at visit 4
4. Antibody titres for anti-poliovirus types 1, 2 and 3, at visit 4
5. Viral shedding in a subset of subjects

Safety:
1. For each type of solicited symptom, occurrence of the symptom within the 15-day (day 0-14) solicited follow-up period after each dose
2. Occurrence of unsolicited adverse events within 43 days (day 0 - 42) after each dose, according to MedDRA (medical dictionary for adverse events) classification
3. Presence of rotavirus in diarrhoeal stool collected until visit 4
4. Occurrence of serious adverse events throughout the entire study period

Efficacy:
1. Occurrence of rotavirus gastroenteritis/severe rotavirus gastroenteritis during the period starting from dose 1 up to visit 5
2. Occurrence of severe rotavirus gastroenteritis during the entire study period</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved prior to 2002</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37373664</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC103</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A double blind, randomised placebo controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5cb4fcb-8be7-4e53-b035-d013406a0be0">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents/guardians of subjects who could comply with the protocol requirements (e.g. completion of diary cards, return for follow-up visits)
2. Male or female 6 - 10 weeks of age at the time of first vaccination
3. Written informed consent from parents/guardians
4. Born after a gestation period of 36 - 42 weeks</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Weeks" value="6.0"/>
      <upperAgeLimit unit="Weeks" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>285</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>285</totalTarget>
      <exclusion>1. Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period
2. Previous routine vaccination except Bacillus Calmette-Guerin (BCG) and hepatits B virus (HBV)
3. Clinically significant history of chronic gastrointestinal tract (GIT) disease including any incorrected congenital malformation of GIT
4. History of allergic disease or reaction likely to be exacerbated by any component of the vaccine
5. Acute illness at the time of enrolement
6. Diarrhoea with in 7 days preceding the study vaccination
7. Administration of immunoglobulins and/or blood products since birth or planned during study period
8. Use of any investigational or non-registered drug or vaccine other than study vaccines during the study period</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vaccine/immunization</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two doses of GSK Biologicals&#146; oral live attenuated human rotavirus (HRV) vaccine (RIX4414) at 106.5 CCID50 viral concentration
Control: placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Human rotavirus vaccine (RIX4414)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14241-0</funderId>
      <funderId>Funder14241-1</funderId>
      <contactId>Contact51964_14241</contactId>
      <sponsorId>Sponsor50394</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51964_14241">
    <title>Dr</title>
    <forename>Duncan</forename>
    <surname>Steele</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3752</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">steeled@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50394">
    <organisation>World Health Organization (WHO)/Department of Immunisation, Vaccines and Biologicals (IVB) (Switzerland) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14241-0">
    <name>RAPID trials (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14241-1">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-10-21T00:00:00.000Z">72633488</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intraarticular Application of Opioids versus Glucocorticoids versus Placebo in Gonarthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Assessment of efficacy and safety of intraarticular applicated Morphine versus Dexamethasone versus Placebo in gonarthritis in inflammatory rheumatic disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Improvement of VAS pain of at least 20 mm on a 0-100 scale.</primaryOutcome>
      <secondaryOutcome>Impovement of a numeric pain scale, sleep quality, global daily activity, knee mobility with Lysholm and Gilquist Score, Western Ontario McMaster Universities Osteoarthritis (WOMAC) index, relief of pain on a numeric scale from 0-3.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72633488</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f0f27f7d-dbb6-49ea-bce3-31ed8139a115">
	  <name>Charité Campus Benjamin Franklin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>12200</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 19-70
2. Gonarthritis with sonographically evident effusion in inflammatory rheumatic disease
3. Visual analogue score (VAS) pain &gt;30 mm
4. Body weight 50-90 kg
5. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Pregnancy, lactation
2. Severe or opportunistic infection, infection of the knee
3. Malignant diseases
4. Any other severe diseases
5. Platelets &lt;100/nl, Quick &lt;50
6. Significant findings during clinical examination
7. Participation in a clinical trial within 30 days before inclusion
8. Abuse of hard drugs, benzodiacepines, analgesics, alcohol
9. Therapy with anticoagulants</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gonarthritis in inflammatory rheumatic disease</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Gonarthritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Single injection of Morphine 3 mg or Dexamethasone 4 mg or Placebo during needle arthroscopy. Rearthroscopy after 7 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Morphine, Dexamethasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13412-0</funderId>
      <contactId>Contact51048_13412</contactId>
      <sponsorId>Sponsor49442</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51048_13412">
    <title>Prof</title>
    <forename>Joachim</forename>
    <surname>Sieper</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité Campus Benjamin Franklin
Dept of Rheumatology
Hindenburgdamm 30</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)3084454414</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joachim.sieper@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49442">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Benjamin Franklin Campus 
Department of Rheumatology
Hindenburgdamm 30</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>12200</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)3084454414</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">joachim.sieper@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder13412-0">
    <name>German Research Foundation  (Deutsche Forschungsgemeinschaft) KFO 100</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-10-19T00:00:00.000Z">05087777</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety and immunogenicity of one and two doses of the live, attenuated oral ETEC candidate vaccine BB01 in healthy adults - a phase I, randomized, double-blind study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Vaccination with an oral live attenuated EnteroToxigenic Escherichia Coli (ETEC) candidate vaccine is safe and well tolerated and immunogenic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety as measured by the incidence of adverse events reported post-vaccination.</primaryOutcome>
      <secondaryOutcome>1. Seroconversion rates as determined by antibody titers pre- and post-vaccination against ETEC candidate vaccine antigens  
2. Responder rates as determined by the number of antibody secreting cells pre- and post-vaccination against ETEC candidate vaccine antigens 
3. Shedding of ETEC candidate vaccine strain post-vaccination as measured by duration and number of bacteria shedded</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05087777</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-05-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-01-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="928f2ed1-7968-4cb5-8384-edce375c5b39">
	  <name>Center for Immunization Research</name>
	  <address/>
	  <city>Baltimore</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>21205</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Healthy adults between 18 and 45 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>Any confirmed or suspected immunosuppressive or immunodeficient condition or prior exposure to ETEC.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-05-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-01-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>ETEC disease.</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Enterotoxigenic E. coli infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Single dose of ETEC candidate vaccine 
2. Two doses of ETEC candidate vaccine</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>Vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13718-0</funderId>
      <contactId>Contact51395_13718</contactId>
      <sponsorId>Sponsor49799</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51395_13718">
    <title>Dr</title>
    <forename>Robin</forename>
    <surname>McKenzie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Immunization Research
Department of International Health
Johns Hopkins University
Bloomberg School of Public Health</address>
      <city>Baltimore</city>
      <country>United States of America</country>
      <zip>21205</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49799">
    <organisation>Berna Biotech Ltd (Switzerland)</organisation>
    <website>http://www.bernabiotech.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Rehhagstrasse 79A</address>
      <city>Bern</city>
      <country>Switzerland</country>
      <zip>3018</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.432742.4</gridId>
  </sponsor>
  <funder id="Funder13718-0">
    <name>Berna Biotech Ltd (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-10-06T00:00:00.000Z">49873657</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A  double blind, randomised, vehicle-controlled, safety and tolerance study of topical PSK 3841 solution at 5% administered twice daily over four weeks to healthy Caucasian males with androgenetic alopecia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the systemic and local safety and tolerance of 5% PSK 3841 solution versus vehicle (70% ethanol) when administered topically twice-a-day over 4 weeks on the scalp of Caucasian males with androgenic alopecia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety and tolerability based on pharmacodynamic endocrine profile (gonadotropins, steroids) on day 1, 15 and 28 of treatment.</primaryOutcome>
      <secondaryOutcome>1. To characterize the pharmacokinetics of PSK 3841 and its metabolites in alopecic males treated twice daily with topical applications on the scalp over a 4-week period
2. To assess whether an eventual exposure to PSK 3841 in untreated female partners occurred under real life conditions during the study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN49873657</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PSK 3841/1011</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-09-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5bb7354d-b21a-4c74-aaa2-ae1443e08d30">
	  <name>7-9 Rue Jean Louis Bertrand</name>
	  <address/>
	  <city>Rennes</city>
	  <state/>
	  <country>France</country>
	  <zip>35000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>For male subjects:
1. Caucasian healthy male subjects aged between 18 and 50 years old with an androgenic alopecia graded as IIIa, IIIv, IV, IVa or V according to Norwood-Hamilton classification
2. Subjects cohabiting with their female partner during all the study treatment

For their female partners:
1. Healthy female subjects</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>A total of 30 couples (30 treated males, 30 untreated females).</totalTarget>
      <exclusion>For male subjects: 
1. Mobile working activities preventing sleeping at home on a regular basis
2. Baldness due to medical illness, alopecia aerata, trichotillomania or any other form of pathologic alopecia other than androgenetic alopecia
3. Any pathology or abnormality of the skin in the areas to be treated
4. History of skin allergy
5. Regular use of medication which might interfere with the results of the study

For their female partners:
1. Mobile working activities preventing sleeping at home on a regular basis
2. Pregnant or lactating female
3. Female of childbearing potential without adequate efficacious contraception</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-09-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Androgenetic alopecia.</description>
	<diseaseClass1>Skin and Connective Tissue Diseases</diseaseClass1>
	<diseaseClass2>Androgenetic alopecia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>5% PSK 3841 solution or vehicle.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>PSK 3841</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13617-0</funderId>
      <contactId>Contact51289_13617</contactId>
      <sponsorId>Sponsor49690</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51289_13617">
    <title>Dr</title>
    <forename>Evelyne</forename>
    <surname>Guénolé</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>7-9 Rue Jean Louis Bertrand</address>
      <city>Rennes</city>
      <country>France</country>
      <zip>35000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor49690">
    <organisation>ProStrakan Pharmaceuticals (France)</organisation>
    <website>http://www.prostrakan.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>102 Route de Noisy
Romainville</address>
      <city>Paris</city>
      <country>France</country>
      <zip>93230</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487449.2</gridId>
    <rorId>https://ror.org/03bvd4t69</rorId>
  </sponsor>
  <funder id="Funder13617-0">
    <name>Proskelia Pharmaceuticals - a part of ProStrakan Pharmaceuticals.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">93119886</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Effect of Subcutaneous Ghrelin On Appetite And Nutritional Status In Patients Receiving Maintenance Peritoneal Dialysis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The short term administration of ghrelin to patients with anorexia with end stage kidney disease will result in increased appetite and calorie intake</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN93119886</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0016148177</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised double blind cross over study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-13T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0e867452-9098-4023-851f-b91c4f2ec2c4">
	  <name>6th Floor, Commonwealth Bldg.</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>W12 0HS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with end stage kidney disease</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>12</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12 volunteers</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-13T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urological and Genital Diseases: Kidney disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Kidney disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ghrelin vs placebo</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Subcutaneous Ghrelin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/15888560 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d9ac8ffd-c1ea-4dfa-b38e-9614f74fea06" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/15888560"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13832-0</funderId>
      <contactId>Contact51788_13832</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51788_13832">
    <title>Prof</title>
    <forename>Stephen</forename>
    <surname>Bloom</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>6th Floor, Commonwealth Bldg.
Imperial College School of Medicine
Hammersmith Hospital
Du Cane Road</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>W12 0HS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 8383 3242</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bloom@imperial.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13832-0">
    <name>Hammersmith Hospital NHS Trust (UK) - NHS R&amp;D Support</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-30T00:00:00.000Z">19439616</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of local anaesthetic techniques in cataract surgery.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the pain patients experience during cataract surgery with three different types of local anaesthesia, using two types of pain questionnaires (McGill pain questionnaire and visual analoque scale).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Quality of pain control through cataract surgery with different types of anaesthetic.  Assessment of pain the patients have with anaesthetic administration.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19439616</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0065149380</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="33c8e441-5f61-410e-8a87-c427ad355fe3">
	  <name>Department of Ophthalmology</name>
	  <address/>
	  <city>Sunderland</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SR2 9HP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 patients in each arm - 300</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Surgery: Cataract</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Cataract</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A randomised, controlled trial comparing three types of anaesthesia: peribulbar, sub-tenon and topical.</description>
	<interventionType>Procedure/Surgery</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Abstract results in http://www.ncbi.nlm.nih.gov/pubmed/16113395 publication in Br J Ophthalmol.  Sep;89(9):1228 entitled "Patient satisfaction with anaesthesia comparing sub-Tenon's block and topical anaesthesia" but no abstract available</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="7d39d0c8-73ea-43d1-905b-90937c846fa8" outputType="abstract" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16113395"/>
	<description>publication in Br J Ophthalmol.  Sep;89(9):1228 entitled "Patient satisfaction with anaesthesia comparing sub-Tenon's block and topical anaesthesia" but no abstract available</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13906-0</funderId>
      <funderId>Funder13906-1</funderId>
      <contactId>Contact51717_13906</contactId>
      <sponsorId>Sponsor50215</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51717_13906">
    <title>Mr</title>
    <forename>RWD</forename>
    <surname>Bell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Ophthalmology
Sunderland Eye Infirmary
Queen Alexandra Road
Sunderland</address>
      <city>Sunderland</city>
      <country>United Kingdom</country>
      <zip>SR2 9HP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor50215">
    <organisation>Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Richmond House
79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13906-0">
    <name>City Hospitals Sunderland NHS Trust R&amp;D Department</name>
    <fundRef/>
  </funder>
  <funder id="Funder13906-1">
    <name>NHS R&amp;D Support Funding</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-23T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-09-26T00:00:00.000Z">92707862</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of hypnosis to improve pain management during voluntary interruption of pregnancy</title>
      <scientificTitle/>
      <acronym>Hyp_IVG</acronym>
      <studyHypothesis>The growing interest of women for complementary and alternative medicines underlines the need to explore new approaches. By the hypnosis technique, it is possible to modify the subjective experiment of pain by suitable suggestions of analgesia. The interruption of pregnancy is a painful intervention with high prevalence. Following a pilot study carried out at the planning Department of Saint-François d&#146;Assise Hospital, the main objective is to evaluate by a randomized clinical trial if a short intervention of hypnosis before and during the intervention has a direct impact on the anxiety and the pain perceived by the women at the time of the abortion. The patients who wish to take part in the study will benefit, according to the randomization, of usual care or an intervention of hypnosis. All women, independently of the group, will have access, at their request, to the analgesics usually proposed to the women at the time of abortion. Hypnosis could be a clinical alternative for the relief of pain at the time of the abortion. Its use in acute pain, if it is effective, could constitute an example of integration of a more individualized care among standardized care of high quality.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Duration of procedure
2. Susceptibility of hypnosis
3. Belief in hypnosis
4. Expected pain and relief</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Comité d'éthique de la recherche clinique de l'Hopital St-François d'Assise, Quebec (Canada) on the 11th November 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN92707862</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MCT-68538</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="83d12d0c-810e-457b-94db-b49404063708">
	  <name>Hôpital Saint-François d'Assise-CHUQ</name>
	  <address/>
	  <city>Québec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>G1L 3L5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women of 18 years old and older
2. Pregnancy term greater than or equal to 6 weeks and less than 14 weeks
3. Signature of consent form for the pregnancy interruption
4. Signature of consent form for the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>350</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>350</totalTarget>
      <exclusion>1. Incapacity to complete consent form
2. Medical indication of fentanyl premedication
3. Use of antidepressants
4. Consumption of drugs the day of abortion
5. Incapacity to understand the French language</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Voluntary interruption of pregnancy</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Voluntary interruption</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Hypnosis versus standard care.

Standard care group: 
After randomization, patients in the standard care group will wait in a comfortable chair for 20 minutes before the procedure, usually in the company of a relative or a friend. The family planning nurse will be available to provide attention to the patient during those 20 minutes. Then the patient will enter the operating room with the nurse and lie supine on a gynecological table. As the abortion will be performed by the physician, the family planning nurse will provide attention and support to the patient, talking and listening to her, giving positive encouragement, reassurance, instructions for relaxation (abdominal and pelvic area) and deep breathing. There will be no instructions for imagery and no suggestions directed at decreasing pain or anxiety.  

Hypnosis group: 
A medical doctor will complete 30 hours of training in hypnosis prior to conducting the study (Introductory Sessions, Société Québécoise d&#146;Hypnose). This training will focus on the basic skills of induction, hypnosis theory, and the integration of hypnosis into clinical practice. Demonstrations and opportunities for practice will be provided to enable participants to begin utilizing hypnosis in their clinical practice. The specific script used in this study will be developed with the collaboration of the co-investigators and psychologists in charge of the training. Practice will then be centered on the needs of the current project and the written script will be tested on five female volunteers for acceptability. 

Pre-surgical hypnotic intervention: 
After randomization, and for the 20 minutes leading up to the procedure, patients in the hypnosis group will sit in a comfortable chair in a different room from the waiting area, where they will meet with the hypnosis provider. First, misconceptions about hypnosis will be cleared up to facilitate a positive attitude. The practitioner will then induce hypnosis by reading from a script prepared for this purpose. Physical and mental relaxation will be initiated by a suggestion of deep breathing, fixation on a part of the hand, and a sensation of floating or heaviness. Several analgesic strategies will then be tried with suggestions generally phrased to facilitate dissociation (e.g. 'the hand' instead of 'your hand'). Focal anesthesia suggestions inducing numbness of the hand (glove anesthesia) will be given to the patient with additional suggestions to transfer the numbness to the abdominal area by placing the hand on the abdomen. Suggestions for imagery will be introduced, including feelings of a warm or a cold wave of light spreading in the body, and relaxation in a safe and pleasant place that they particularly like. Direct suggestions to decrease pain intensity (like a rheostat) and unpleasantness (feeling more comfortable) during the surgical procedure will also be introduced. The patient will also be told that she is able to ask for anything that would increase her comfort during the surgical procedure. The total duration of the pre-surgical hypnotic induction was 20 minutes. 

Surgical hypnotic intervention: 
The patient will then be asked to walk to the surgery room with the hypnotist. The patient will be told that if she 'comes out' of hypnosis, she will be able to get back into this state once in the surgery room. Once she will be positioned supine on the surgical table, the hypnotist practitioner will suggest that she goes back deeper into hypnosis. Hypnosis will continue throughout the procedure to buffer response to painful stimuli using the same suggestions of well-being and imagery, and emphasizing decreased intensity and unpleasantness of pain using the preferred analgesic strategies that were introduced during the pre-surgical induction. The patient will be told again that she can ask for anything that would increase her comfort at any time during the procedure. At the end of the surgical procedure (removal of the speculum), the patient will receive suggestions to end hypnosis and become alert.

Surgical procedure: 
The surgical procedure will be similar to the ones outlined in the clinical policy guidelines and the paper by Burnhill. In the operating room, the standard procedure will begin by a brief preoperative discussion with the physician performing the abortion. The procedure will be performed by one of four physicians involved in this study. The patient will then lie back on the gynecological table. After a manual pelvic examination, the surgeon will insert a sterile vaginal speculum (Step 1) and will then inject 1 to 2 cc of  0.5% lidocaine at 12 o&#146;clock on the cervix and an additional 5 cc each at 4 and 8 o&#146;clock at 1 to 2 cm-deep for a total volume of 12 cc of lidocaine. Dilators will be used to dilate the cervix sufficiently (Step 2, maximal dilatation) to admit a rigid vacuum cannula of 8 to 12 mm depending of the gestational age (typically a 9 mm cannula is used for a 9 week gestational age). The uterine contents will be evacuated with suction (Step 3) with a uterine aspirator at maximum vacuum. Suction will follow by a sharp curetage (Step 4) to confirm that the uterus was empty. If necessary, a re-aspiration of the uterine contents will be performed. The patient will recover for a few minutes on the table and will then walk to the recovery room. Most of the patients will be discharged within 1-2 hours after the end of the procedure. 

At each step of the procedure, women usually experience pain, the most painful step being the suction of the uterine contents (Step 3). Cervical dilatation is also a painful and difficult part of surgical evacuation, and cervical priming may have a very important effect on the amount of pain that the patient experiences. Furthermore, women often experience pain before the surgical procedure. To help with cervical dilatation, laminaria tents will be used, 4 to 20 hours before the abortion. Indications for the use of laminaria tents will include women whose pregnancies were greater than or equal to 9 weeks, stenosis and surgical history of the cervix, age less than 20, gravida greater than or equal to 5. 

During the surgical procedure, patients will be monitored continuously by pulse oxymetry for oxygen desaturation and for changes in blood pressure and heart rate.

Initial assessment on arrival: 
Self reported anxiety and pain. Patient self-reported anxiety and pain will be assessed before randomization. In both the hypnosis group and the control group, the practitioner will ask the patient to rate her anxiety and pain on an 11-point verbal numerical scale. Anxiety levels will be assessed on scales from 0 to 10 (0 = not anxious at all; 10 = the most anxious that you can be). Intensity of pain will be rated on separate scale from 0 to 10 (0 = no pain at all; 10 = the most intense pain possible). These verbal scales have been validated for pain and anxiety.

Other measurements: Furthermore, before randomization, expected pain intensity will be assessed. The Pain Catastrophizing Scales (PCS) will be used to assess emotions previously shown to affect pain. A questionnaire assesses the belief in hypnosis in the two groups before randomisation. 

During the surgical procedure: 
Assessment of medication requirement. Intravenous sedation during abortion will be assessed as a dichotomous variable (requested or not requested by the patient) at any step of the surgical procedure: insertion of speculum, maximum dilation, suction, and end of curettage abortion. Irrespective of her group, each patient will be allowed to receive sedation as she wants and whenever she wants during the procedure. 
Assessment of pain and anxiety. Patient self-reported anxiety and pain (intensity and unpleasantness) will be assessed using the same 11-point verbal scales described above at each of the 3rd step of the procedure (aspiration). 

During recovery: 
Once again, patient self-reported anxiety and intensity of pain and relief will be assessed using the same scales described above. Additional questionnaires will be administered to obtain demographic information (maternal age, gestational age, parity, previous history of abortion). The physician who will perform the abortion will also complete a questionnaire describing oral medication administered before or after the abortion and the pre-surgical use of a laminaria tent to facilitate cervical dilation. His appreciation of the overall success of the procedure will be assessed with a short series of questions regarding surgical difficulties on a ten-point scales (ranging from the worse to the best). The duration of the procedure will be calculated from the total time spent by the women in the surgical room.

Trial details received: 12 Sept 2005</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13789-0</funderId>
      <contactId>Contact51481_13789</contactId>
      <sponsorId>Sponsor49885</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51481_13789">
    <title>Dr</title>
    <forename>Sylvie</forename>
    <surname>Dodin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hôpital Saint-François d'Assise-CHUQ
Centre de recherche
10, rue de l'Espinay
Local D6-702</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1L 3L5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 525 4348</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">sylvie.dodin@ogy.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49885">
    <organisation>University Laval, Manon Guillemette (Canada)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Coordonnatrice des opérations financières
Service des finances
Pavillon Jean-Charles-Bonenfant
Local 3413</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1K 7P4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 2131 poste 6513</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Manon.Guillemette@sf.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.23856.3a</gridId>
    <rorId>https://ror.org/04sjchr03</rorId>
  </sponsor>
  <funder id="Funder13789-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MCT-68538)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-09-12T00:00:00.000Z">46249783</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>MEMO study: Mental health in Elderly Maintained with Omega-3</title>
      <scientificTitle/>
      <acronym>MEMO</acronym>
      <studyHypothesis>Counteract the process of mental deterioration in elderly people through enhancement of their EPA-DHA status</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cognitive function and mental well-being</primaryOutcome>
      <secondaryOutcome>Quality of life</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46249783</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2005_05/08</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7462927a-c5f8-4d6d-acd0-a8f68ccd6d26">
	  <name>Division of Human Nutrition</name>
	  <address/>
	  <city>Wageningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6700 EV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women
2. Aged 65 years and over
3. Informed consent signed</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. A score of &gt; 16 on the CES-D (Centre for Epidemiological Studies-Depression Scale
2. A score of &lt; 21 points on MMSE (Mini-Mental State Examination) 
3. Current or recent (&lt;4 weeks) use of fish oil supplements or intake of more than 4 times fish/ week; 24.35 g of EPA-DHA from fish per month (800 mg/day) as judged by a fish consumption questionnaire
4. Current use of pharmacological antidepressants
5. Current use of dementia (Alzheimer) medication
6. Serious liver disease 
7. Use of more than 4 glasses of alcohol per day 
8. Unable to participate as judged by the responsible medical physician
9. Allergy to fish(oil)
10. Swallowing problems
11. Participation in another clinical trial less than 2 months before the start of the trial or at the same time</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depressive disorders, Depression, Cognitive decline</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 400 mg EPA-DHA in capsules
2. 1.8 g EPA-DHA in capsules
3. Placebo oil capsules</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>EPA-DHA</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13662-0</funderId>
      <contactId>Contact51344_13662</contactId>
      <sponsorId>Sponsor49739</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51344_13662">
    <title>Ms</title>
    <forename>Ondine</forename>
    <surname>Rest, van de</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Division of Human Nutrition
Wageningen University
Postbus 8129</address>
      <city>Wageningen</city>
      <country>Netherlands</country>
      <zip>6700 EV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)317 485867</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Ondine.vandeRest@wur.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49739">
    <organisation>Wageningen University (Nethelands)</organisation>
    <website>http://www.wur.nl/UK/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Division of Human Nutrition
Costerweg 50 / P.O.Box 9101</address>
      <city>Wageningen</city>
      <country>Netherlands</country>
      <zip>6700 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)317 489111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@wur.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4818.5</gridId>
    <rorId>https://ror.org/04qw24q55</rorId>
  </sponsor>
  <funder id="Funder13662-0">
    <name>ZON-MW, The Netherlands Organization for Health Research and Development</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-15T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2005-09-09T00:00:00.000Z">83029072</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Trying to improve the compliance to colorectal cancer screening: type of test provider (GP versus hospital) and type of faecal occult blood test (Guaiac versus immunochemical)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The efficacy of colorectal cancer screening (CRCS) using faecal occult blood test (FOBT) in reducing colorectal cancer (CRC) mortality in a population at generic risk, has been shown in several large randomized trials.

The screening programs need to contact the whole target population and involve as many people as possible in order to be actually effective. The scientific literature about the reasons for non-compliance have generated few definitive operational recommendations. 

Two types of FOBT are now available: the Guaiac and the Immunochemical test. The sensitivity and specificity of the two tests are similar and do not clearly indicate which one is better for screening. The price of the immunochemical test is actually about 1.5 times higher than the Guaiac, but there are no data about the costs per person screened. The Guaiac test recommends three different evacuations, and requires the patient to store the samples, and follow dietary restrictions. The immunochemical test is recommended on a single evacuation and does not require dietary restrictions. The discomfort and embarrassment of faecal sampling and the dietary restrictions have been hypothesized to be determinants of non-compliance. This background may determine lower compliance to the Guaiac test.
 
Several guidelines for screening programme implementation recommend the involvement of general practitioners (GP) and family practitioners (FP); nevertheless the role of the GPs and FPs varies between countries and health service organizations, making this recommendation hard to implement. The Agency for Public Health of Lazio, Italy, decided to design a trial phase in order to plan an evidence-based implementation of the CRCS program. The aim of this approach is to guarantee that the efficacy of CRCS can be translated to effectiveness in a public health intervention. The screening strategy adopted was: yearly FOB testing for 50&#150;74 year olds and, for positives, colonoscopy. A special focus was how to obtain a high compliance to screening; the topics studied were: GPs&#146; attitudes and practices, type of FOBT, test provider, and the individual reasons. 

Studies included: a survey, a randomized factorial trial nested in the survey, and a case&#150;control study nested in the trial.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Compliance to screening: (number of returned faeces samples)/(total number of invited subjects)</primaryOutcome>
      <secondaryOutcome>Positivity rate; variability of the positivity rate; rate of inadequate samples; positive predictive value.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83029072</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b8dfcea6-2a7a-49ba-a6ad-9d8276eb7584">
	  <name>Agency for Public Health, Lazio Region</name>
	  <address/>
	  <city>Rome</city>
	  <state/>
	  <country>Italy</country>
	  <zip>00198</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>We selected 13 hospitals, out of 20 to participate in the screening programme, in order to represent all types of gastroenterology units (5 university hospitals, 2 large research hospitals, 6 local hospitals) and all geographic areas (7 in the metropolitan area of Rome, 2 in the outskirts of Rome, 4 in towns and small cities of the province). We included in a survey about screening attitudes all the GPs with an office in the 13 selected hospital districts. During the survey, all the GPs were asked to participate in a trial to evaluate the best strategies to enhance the compliance to CRCS. The conditions for eligibility of the GPs were: more than 100 people aged 50&#150;74 in the practice population; a personal computer in the office; and consent to participate.

For each of the 13 districts we sampled 10 eligible GPs. The sampled GPs, primary sampling units, were randomised as follows: for each district, five to the immunochemical test and five to the Guaiac test. We sampled 2/10 of the target practice population for each GP; 1/10 of the population was randomised to the GP arm and 1/10 to the hospital arm.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>7320</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>We randomised 7320 subjects</totalTarget>
      <exclusion>We analysed the lists of randomised patients: the second member of a pair with the same telephone number was rejected and substituted, if assigned to a different arm.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colorectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Faecal occult blood test:
Two types of test: guaiac versus immunochemical
Two types of provider: General Practitioner versus Hospital gastroenterology centre</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15949119 Cluster results
2005 Other publications in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15911466 Study design
2005 Other publications in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15916990 Survey
2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16372903 Case controlled study results
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16411052 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="59a0dbb8-083f-4281-bb81-f6b9c1d56e4f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15949119"/>
	<description>Cluster results</description>
	<productionNotes/>
      </output>
      <output id="db452cae-69e8-4899-b8ed-8ff79c99b579" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15911466"/>
	<description>Study design</description>
	<productionNotes/>
      </output>
      <output id="ffc6ff77-603f-463c-8811-2cacecfefa3d" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15916990"/>
	<description>Survey</description>
	<productionNotes/>
      </output>
      <output id="d338f2db-94ec-4630-95a5-f05c32479473" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16372903"/>
	<description>Case controlled study results</description>
	<productionNotes/>
      </output>
      <output id="79d5e0ef-1a9b-4fd4-9468-2ae3de2ce8af" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16411052"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13486-0</funderId>
      <contactId>Contact51137_13486</contactId>
      <sponsorId>Sponsor49535</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51137_13486">
    <title>Mr</title>
    <forename>Paolo</forename>
    <surname>Giorgi Rossi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Agency for Public Health, Lazio Region
via S Costanza 53</address>
      <city>Rome</city>
      <country>Italy</country>
      <zip>00198</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)683060438</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">giorgirossi@asplazio.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49535">
    <organisation>Agency for Public Health, Lazio Region, Italy (Agenzia di Sanita Pubblica della Regione Lazio)</organisation>
    <website>http://www.asplazio.it</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>via S Costanza 53</address>
      <city>Rome</city>
      <country>Italy</country>
      <zip>00198</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)683060300</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">splendori@asplazio.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder13486-0">
    <name>The study is funded exclusively by the Agency for Public Health of the Lazio Region (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-07-07T00:00:00.000Z">89131885</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An evaluation of the relative effectiveness of interventions based on the transtheoretical model (TTM) of behaviour change (stages of change) compared with standard care in helping women to stop smoking in pregnancy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>That interventions based on the TTM would help more pregnant smokers stop smoking than standard care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Biochemically confirmed continuous abstinence for 10 weeks at the end of pregnancy.</primaryOutcome>
      <secondaryOutcome>Point prevalence abstinence, self-reported abstinence.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN89131885</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MREC 99/7/50</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="97f81849-3b82-459f-9c2c-b75aecf1adb4">
	  <name>Department of Primary Care &amp; General Practice</name>
	  <address/>
	  <city>Birmingham</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>B15 2TT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Pregnant, aged at least 16 years of age, smoking at the time of booking for maternity care, able to read English.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>918</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>918</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking in pregnancy</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Smoking in pregnancy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A cluster randomized trial of three interventions:
1. Standard care
2. Self-help manual and enhanced stage-based counselling
3. Self-help manual, enhanced stage-based counselling and use of an interactive computer program</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12773727 Results
2003 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12930219 Cohort results:
2005 Abstract results in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15598198
2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15749141 Results
2005 Results article in https://pubmed.ncbi.nlm.nih.gov/16053527 Results
2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16643698 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="fb798043-6a14-4846-a6fa-09d1b13c8aac" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12773727"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="a8e9f5b2-189a-4670-8d4f-8e79e1f6376b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2003-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12930219"/>
	<description>Cohort results:</description>
	<productionNotes/>
      </output>
      <output id="810d5a2d-0e39-465b-971c-9ea4ef1348fe" outputType="abstract" artefactType="ExternalLink" dateCreated="2005-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="false" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15598198"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="62e40012-e203-41f7-9cb7-bf1664643d2f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15749141"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="d1f7d169-4486-48b0-965d-6528eea2b0a0" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-07-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16053527"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="c2ffd52b-030d-4836-a3fe-745516acc346" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16643698"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13208-0</funderId>
      <contactId>Contact50788_13208</contactId>
      <sponsorId>Sponsor49177</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50788_13208">
    <title>Dr</title>
    <forename>Paul</forename>
    <surname>Aveyard</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Primary Care &amp; General Practice

University of Birmingham</address>
      <city>Birmingham</city>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 8529</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.n.aveyard@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49177">
    <organisation>University of Birmingham (UK)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Dr Brendan Laverty

Research &amp; Enterprise Services

University of Birmingham</address>
      <city>Birmingham</city>
      <state>England</state>
      <country>United Kingdom</country>
      <zip>B15 2TT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)121 414 7618</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.w.laverty@bham.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.6572.6</gridId>
    <rorId>https://ror.org/03angcq70</rorId>
  </sponsor>
  <funder id="Funder13208-0">
    <name>West Midlands Health Authorities (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-15T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-06-07T00:00:00.000Z">68386084</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase III multicentre, randomised, controlled, clinical trial to assess the safety and efficacy of injectable paromomycin in patients with visceral leishmaniasis (India)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The aim of this trial is to assess the safety and efficacy of injectable paromomycin in patients with Visceral Leishmaniasis (VL).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Safety:
1. Reported adverse events
2. Protocol-defined nephrotoxicity and ototoxicity
3. Laboratory evaluations
4. Vital signs</primaryOutcome>
      <secondaryOutcome>Efficacy:
1. Parasite density 
2. Final cure 
3. Relapse
4. Treatment failure</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the independent ethics committee at each of the four participating centers, the Drug Controller General of India, and the Steering Committee on Research Involving Human Subjects of the World Health Organization.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68386084</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber>NCT00216346</clinicalTrialsGovNumber>
      <protocolSerialNumber>A20643, A20485, A20648, A20599</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="00bb4ffb-f6db-415d-8d42-18da01e315c8">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva -27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 5 to 55 years (inclusive) of either gender
2. Confirmed diagnosis by spleen or bone marrow aspirate
3. Clinical signs and symptoms compatible with VL
4. Lab tests:
4.1. Haemoglobin more than 5.0/100 ml
4.2. White Blood Cell (WBC) count more than 1 x 10^9 l
4.3. Platelet count more than 50 x 10^9 l
4.4. Aspartate transaminase (AST), alanine transaminase (ALT) and Alkaline Phosphatase less than three times upper normal limit
4.5. Prothrombin time less than five seconds above control
4.6. Serum creatinine within normal limits
4.7. Serum potassium within normal limits
5. Human Immunodeficiency Virus (HIV) negative</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>667</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>667</totalTarget>
      <exclusion>1. History of intercurrent or concurrent diseases that may introduce variable that affect the outcome of the study
2. Any condition which the investigator thinks may prevent the patient from completing the study therapy
3. An abnormal baseline audiogram and/or a history of vestibular or auditory dysfunction
4. Proteinuria (more than 2 g/day)
5. A history of hypersensitivity or allergy to aminoglycosides
6. History of major surgery within last two weeks
7. Pregnancy or lactation
8. Previous treatment for VL within two weeks of enrolment into the study
9. Prior treatment failures with paromomycin or amphotericin B</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Visceral leishmaniasis (VL)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Visceral leishmaniasis (VL)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group (500 patients): 
Injectable paromomycin sulphate 15 mg/kg intramuscular per day x 30 days.

Control group (167 patients): 
Injectable amphotericin B 1 mg/kg continuous intravenous infusion every other day, total 15 doses.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Paromomycin, amphotericin B</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17582067 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a9053317-c51a-4821-acfc-676b36c2e746" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-21T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17582067"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder12974-0</funderId>
      <contactId>Contact50497_12974</contactId>
      <sponsorId>Sponsor48875</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50497_12974">
    <title>Dr</title>
    <forename>Juntra</forename>
    <surname>Karbwang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">karbwangj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48875">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva -27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder12974-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-14T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2005-05-11T00:00:00.000Z">55452501</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Illumination in human aging: sleep and mood effects</title>
      <scientificTitle/>
      <acronym>LRX</acronym>
      <studyHypothesis>Bright white light would reduce depression and improve sleep disorders related to circadian rhythm disturbance.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mood scales
2. Light recording
3. Wrist actigraphy
4. Assays of urine for aMT6s 
5. Assays of saliva for melatonin</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol and consent form were approved by the University of California and San Diego (UCSD) Human Research Protection Program.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55452501</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>5 RO1 AG12364-11A1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bd049d56-a1f0-450d-b10b-7e94fb02fbb4">
	  <name>9500 Gillman Drive</name>
	  <address/>
	  <city>La Jolla, CA</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>92093-0667</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Humans aged 60 - 79 years 
2. No history of mania
3. No diagnosis of bipolar disorder</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>81</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>81</totalTarget>
      <exclusion>Lifetime history of mania.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Depression and disturbed sleep</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>One hour bright white light compared to one hour dim red light at three different times of day.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/pubmed/16283925 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="28cb18df-968f-48f5-b77b-782ee3c4a87c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-11-09T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/16283925"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder13059-0</funderId>
      <contactId>Contact50592_13059</contactId>
      <sponsorId>Sponsor48975</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50592_13059">
    <title>Prof</title>
    <forename>Daniel</forename>
    <surname>Kripke</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>9500 Gillman Drive</address>
      <city>La Jolla, CA</city>
      <country>United States of America</country>
      <zip>92093-0667</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor48975">
    <organisation>National Institutes of Health (NIH)/National Institute of Aging (NIA) (USA) </organisation>
    <website>http://www.nia.nih.gov/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>7201 Wisconsin Ave.</address>
      <city>Bethesda, MD</city>
      <country>United States of America</country>
      <zip>20892</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419475.a</gridId>
    <rorId>https://ror.org/049v75w11</rorId>
  </sponsor>
  <funder id="Funder13059-0">
    <name>National Institutes of Health (NIH)/National Institute of Aging (NIA) (USA) (ref: 5 RO1 AG12364-11A1)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-06T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2005-05-05T00:00:00.000Z">43522674</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of intraperitoneal application of taurolidine on the perioperative metastases, tumor recurrence and survival rate after surgical resection of colorectal cancer</title>
      <scientificTitle/>
      <acronym>IPAT-MET</acronym>
      <studyHypothesis>Recurrence rates after colon resection for cancer are 16% to 18% (Surgical Therapy Study Group). The study hypothesis is that the intraoperative intraperitoneal lavage with taurolidine reduces the 5-year recurrence rate from 16% to 10%.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to local and distant tumor relapse (disease free survival).</primaryOutcome>
      <secondaryOutcome>Global survival time.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN43522674</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e62bfb46-4e20-45eb-8ce2-926e6ae8b806">
	  <name>Charité - University Medicine Berlin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with colorectal cancer and curative resection, age over 18 years, American Society of Anesthesiologists (ASA) classification &lt;IV.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>2000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2000</totalTarget>
      <exclusion>1. Ileus 
2. Peritoneal carcinomatosis 
3. Intraperitoneal abscess formation 
4. Intestinal perforation 
5. Peritonitis 
6. Sepsis 
7. Organ falure 
8. ASA classification IV
9. R1 or R2 resection</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colorectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>2000 patients with colorectal cancer will be randomised to receive either taurolidine or NaCl solution during resection. Tumor recurrence, metastases and survival rates will be investigated up to 5 years.

Intraoperative instillation of 1% taurolidine versus 0.9% NaCl solution, evaluation of morbidity and mortality, side-effects, long-term follow-up after 3, 6, 12 month and 2, 3, 4 and 5 years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Taurolidine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder12936-0</funderId>
      <contactId>Contact50455_12936</contactId>
      <sponsorId>Sponsor48830</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact50455_12936">
    <title>Prof</title>
    <forename>Christoph Andreas</forename>
    <surname>Jacobi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Charité - University Medicine Berlin
Department of Surgery
Schumannstraße 20/21</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 30450522031</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">christoph.jacobi@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor48830">
    <organisation>Charité - University Medicine Berlin (Charité - Universitätsmedizin Berlin) (Germany) </organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Surgery 
Schumannstraße 20/21</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder12936-0">
    <name>Funding of the Insurance (Gehrling-Konzern) Vers.Nr.: 70-5644584-4 by Böhringer Ingelheim (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-11T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2004-11-22T00:00:00.000Z">34265870</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34265870</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NEO-I-22</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="43a80cb2-42fc-4319-a703-1f35145494e3">
	  <name>via Ampere 126</name>
	  <address/>
	  <city>Milano</city>
	  <state/>
	  <country>Italy</country>
	  <zip>20131</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Seventy five patients presenting with diffuse proliferative lupus nephritis</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>75</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>75</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lupus nephritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Lupus nephritis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Administration of 3 intravenous methylprednisolone pulses followed by a 2-3 month treatment with prednisone and oral cyclophosphamide. Patients with serum creatinine ≤1.5 mg/dl, proteinuria ≥0.5 g per day and diastolic blood pressure &lt;90 mmHg were then randomized to receive cyclosporine or azathioprine for two years.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/pubmed/17699309 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4640759c-190f-4a9a-a7d5-ea71266d84ab" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/17699309"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11276-0</funderId>
      <contactId>Contact41725_11276</contactId>
      <sponsorId>Sponsor39470</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41725_11276">
    <title>Prof</title>
    <forename>Claudio</forename>
    <surname>Ponticelli</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>via Ampere 126</address>
      <city>Milano</city>
      <country>Italy</country>
      <zip>20131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor39470">
    <organisation>Novartis Farma (Italy)</organisation>
    <website>http://www.novartis.com/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Largo U. Boccioni 1</address>
      <city>Origgio</city>
      <country>Italy</country>
      <zip>21040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)2 9654 2351</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">simona.greco@pharma.novartis.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.15585.3c</gridId>
    <rorId>https://ror.org/04rcxhq50</rorId>
  </sponsor>
  <funder id="Funder11276-0">
    <name>The study was sponsored by Novartis and monitored by an external society. The steering committee approved the study protocol, case report forms, statistical analysis plan, progress of the study and analysis, as well as the reporting of the data, whatever the outcome of the study. The sponsors could comment on the manuscript before submission, but the final version was the sole responsibility of the authors. In addition, the steering committee had full access to the data files of the study.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-28T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-07-07T00:00:00.000Z">36133252</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised double blind placebo controlled internet trial of probiotics and ankylosing spondylitis (PAS- trial)</title>
      <scientificTitle/>
      <acronym>PAS trial</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration, information added 28/01/08: ethical approval granted by London MREC ref 04/2/18 in 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN36133252</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>04/2/018</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United Kingdom</country>
	<country>Wales</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2b08bf81-45b3-4c72-8f59-08a62ef96d7a">
	  <name>Clinical School</name>
	  <address/>
	  <city>Swansea</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SA2 8PP</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with a diagnosis of ankylosing spondylitis or other spondyloarthropathy</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>140</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>140</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Ankylosing spondylitis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Ankylosing Spondylitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Probiotic versus placebo
Participants are recruited through the internet (confirmation of diagnosis by general practitioner/rheumatologist) and assessed by weekly internet questionnaires.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Probiotics</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18190710 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="13349871-4437-41d0-94c0-ca6704a7adbc" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-11T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18190710"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder11238-0</funderId>
      <contactId>Contact41679_11238</contactId>
      <sponsorId>Sponsor39424</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact41679_11238">
    <title>Dr</title>
    <forename>Stephen</forename>
    <surname>Allen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical School
University of Wales, Swansea
Singleton Park</address>
      <city>Swansea</city>
      <country>United Kingdom</country>
      <zip>SA2 8PP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1792 513483</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.j.allen@swansea.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor39424">
    <organisation>University of Wales, Swansea (UK)</organisation>
    <website>http://www.swansea.ac.uk</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Singleton Park</address>
      <city>Swansea</city>
      <state xmlns:isrctn="http://www.67bricks.com/isrctn">Wales</state>
      <country>United Kingdom</country>
      <zip>SA2 8PP</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)1792 602058</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.j.allen@swansea.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4827.9</gridId>
    <rorId>https://ror.org/053fq8t95</rorId>
  </sponsor>
  <funder id="Funder11238-0">
    <name>National Ankylosing Spondylitis Society (NASS)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-07T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2004-04-21T00:00:00.000Z">80116232</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Strategies for the introduction and implementation of a guideline for the treatment by family physicians of diabetics in the Lazio region of Italy</title>
      <scientificTitle/>
      <acronym>IMPLEMEG</acronym>
      <studyHypothesis>The primary objective of the study is to assess the effectiveness of different strategies for the implementation of an evidence-based guideline for the management of non-complicated type 2 diabetes mellitus (DM) among GPs of the Lazio region.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The proportion of patients who were prescribed three measurements of glycosylated haemoglobin with at least two months&#146; interval per year.</primaryOutcome>
      <secondaryOutcome>1. Process of care variables on metabolic control and prevention of micro-macrovascular complications (ie proportion of overweight/obese diabetics who were prescribed methformin in monotherapy as first-choice therapy)
2. Proportion of diabetics with a complete lipid assessment per year
3. Proportion of diabetics with an eye examination or a fundus per year)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN80116232</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="53cefecf-0daf-4e82-a8bc-4005c2338e0a">
	  <name>Via di Santa Costanza 53</name>
	  <address/>
	  <city>Rome</city>
	  <state/>
	  <country>Italy</country>
	  <zip>00198</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>252 General Practitioners (GPs) taking part in an electronically-linked diseases surveillance network.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>252</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>252 GPs</totalTarget>
      <exclusion>1. Patients aged less than 40
2. Patients with complications
3. Diabetic pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 non-complicated diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Different strategies for the implementation of a guideline of non-complicated type 2 diabetes mellitus in the region of Lazio (Italy).
Eighty four GPs in each arm were randomised in the care of type 2 diabetes mellitus to:
Arm 1. Undergo a training module and administration of the guideline.
Arm 2. Receive the guideline without training.
Arm 3. Continue current practice.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Protocol article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15196307 Protocol
2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17547760 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a40ea5d0-3546-4ca2-9e7d-eaf2f7c806b1" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2004-06-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15196307"/>
	<description>Protocol</description>
	<productionNotes/>
      </output>
      <output id="0882e6a5-2fc9-4f6e-8fc2-fbf621469b31" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-04T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17547760"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder8210-0</funderId>
      <contactId>Contact19642_8210</contactId>
      <sponsorId>Sponsor16386</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact19642_8210">
    <title>Dr</title>
    <forename>Amina</forename>
    <surname>Pasquarella</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Via di Santa Costanza 53</address>
      <city>Rome</city>
      <country>Italy</country>
      <zip>00198</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor16386">
    <organisation>Agency for Public Health, Lazio Region, Italy (Agenzia di Sanità Pubblica della Regione Lazio)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Via di Santa Costanza 53</address>
      <city>Rome</city>
      <country>Italy</country>
      <zip>00198</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)6 83060429</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">segrdir@asplazio.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder8210-0">
    <name>Ministry of Health Lazio Region (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2004-03-22T00:00:00.000Z">06161544</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Honey as Adjuvant Leg ulcer Therapy: A randomised controlled trial of a honey-impregnated dressing for venous leg ulcers</title>
      <scientificTitle/>
      <acronym>HALT</acronym>
      <studyHypothesis>The HALT trial is an open-label, multi-centre, randomised,
controlled clinical trial assessing the effect of manuka honey on ulcer
healing, in patients with venous ulcers. Patients will be randomised to receive either manuka honey dressings or usual care (dressing of clinician's choice) for 12 weeks or until the ulcer has healed, whichever is sooner.
This intervention will be against a background of standard compression
therapy. Allocation is by central telephone randomisation. The sample is
stratified by ulcer size, ulceration duration and study centre. The objective of the study is to determine the effectiveness of manuka honey as an adjuvant to compression therapy in community-based patients with venous leg ulcers. Where the participant has more than one leg ulcer, the largest ulcer is selected as the reference ulcer.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of participants with completely healed reference ulcers at 12 weeks</primaryOutcome>
      <secondaryOutcome>Time to healing, percentage change in ulcer size, recurrence at six months, health related quality of life, number of dressing changes, costs, and adverse events.</secondaryOutcome>
      <trialWebsite>http://www.ctru.auckland.ac.nz/research/halt/index.html</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Auckland Ethics Committee (Committee X). Date of approval: 09/12/2003 (ref: AKX/03/09/232)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06161544</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Multi-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-08-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f9c1b165-521f-4e57-a054-44f245500cc6">
	  <name>Clinical Trials Research Unit</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1003</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>400 community-based participants treated by district nurses, each with venous leg ulcer (clinical history, ABI &gt;0.8) or mixed venous/arterial ulcer (clinical history, ABI &gt;0.7), and being treated with compression bandaging.
ABI = Ankle Brachial Index</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>400</totalTarget>
      <exclusion>1. Unable to provide informed consent
2. Have pre-exisiting diagnosis of diabetes
3. Have pre-existing diagnosis of rheumatoid arthritis
4. Have allergy to honey</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-08-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Venous or mixed venous/arterial leg ulcers</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Venous ulcers</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Honey-impregnated calcium alginate dressing as an adjuvant to compression bandaging versus usual care (compression bandaging plus dressing of clinician's choice).</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Manuka honey</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2008 Results article in http://www.ncbi.nlm.nih.gov/pubmed/18161896 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e0617481-9313-4698-b464-1e878df74a8d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/18161896"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6196-0</funderId>
      <funderId>Funder6196-1</funderId>
      <contactId>Contact7629_6196</contactId>
      <sponsorId>Sponsor5367</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7629_6196">
    <title>Mr</title>
    <forename>Andrew</forename>
    <surname>Jull</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Trials Research Unit
University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 9 373-7599 extn 84744</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.jull@ctru.auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5367">
    <organisation>Health Research Council of New Zealand</organisation>
    <website/>
    <sponsorType>Research council</sponsorType>
    <contactDetails>
      <address>PO Box 5541
Wellesley St</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 9 379 8227</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bscoggins@hrc.govt.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452999.a</gridId>
    <rorId>https://ror.org/00zbf3d93</rorId>
  </sponsor>
  <funder id="Funder6196-0">
    <name>Primary funder: Health Research Council of New Zealand, grant No: 03/087.</name>
    <fundRef/>
  </funder>
  <funder id="Funder6196-1">
    <name>Additional support: ApiMed Medical Honey Ltd and USL Medical Ltd</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-30T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">26342763</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evidence based secondary prevention of heart disease in primary care: a randomised controlled trial of three methods of implementation.</title>
      <scientificTitle/>
      <acronym>ASSIST trial</acronym>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN26342763</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Imp 10-11 Moher</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8b58e1b3-71af-423d-9069-5789e17e8659">
	  <name>Institute of Health Sciences</name>
	  <address/>
	  <city>Oxford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>OX3 7LF</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients with ischaemic heart disease</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular diseases: Heart disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Ischaemic heart disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Audit: audit of notes with summary feedback to primary health care team
2. Recall to general practitioner (GP): assistance with setting up a disease register and systematic patient recall to GP
3. Recall to nurse: assistance with setting up a disease register and systematic patient recall to practice nurse clinic</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2001 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11387182 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="a3128fb7-fe7e-44ac-b28b-94260c0e5f5d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2001-06-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11387182"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder5814-0</funderId>
      <contactId>Contact7232_5814</contactId>
      <sponsorId>Sponsor5354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7232_5814">
    <title>Dr</title>
    <forename>Michael</forename>
    <surname>Moher</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Health Sciences
University of Oxford</address>
      <city>Oxford</city>
      <country>United Kingdom</country>
      <zip>OX3 7LF</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">michael.moher@dphpc.ox.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5354">
    <organisation>Record Provided by the NHS R&amp;D 'Time-Limited' National Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder5814-0">
    <name>NHS Evaluation of Methods to Promote the Implementation of Research Findings (National Programme) - UK</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-01-30T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">24866285</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of transurethral microwave thermotherapy (TUMT)</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN24866285</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1995-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="3608bd05-c693-47c9-9222-403b7e3edf9a">
	  <name>Department of Urology</name>
	  <address/>
	  <city>London</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>SE1 9RT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men with symptoms of bladder outlet obstruction and benign prostatic hyperplasia (BPH), in whom no complications could be found and where there was no suspicion of malignancy.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Male</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1995-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Urological and genital diseases: Benign prostatic hyperplasia (BPH)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Benign prostatic hyperplasia (BPH)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Standard TUMT
2. Simulated treatment identical to group 1 but with no emission of microwaves
3. No treatment</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1997 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9117220 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50f23c8f-ffd8-4332-9033-80cc447a502f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1997-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9117220"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6006-0</funderId>
      <contactId>Contact7502_6006</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7502_6006">
    <title>Mr</title>
    <forename>JD</forename>
    <surname>Nawrocki</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Urology
Guy's Hospital
St Thomas Street</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SE1 9RT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6006-0">
    <name>NHS Executive London (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-11T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">34683285</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The Watcombe Housing Project</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34683285</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2000-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1623dc4e-65eb-44f4-ae66-4baa058f2ad6">
	  <name>Research and Development Support Unit</name>
	  <address/>
	  <city>Plymouth</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>PL6 8BX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Houses on an estate in Watcombe, Torbay</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2000-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Not applicable</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Improvement of houses (n=50) (including insulation, double-glazing, re-roofing, heating, ventilation and electrical rewiring) vs wait-list control</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2002 Results article in http://www.ncbi.nlm.nih.gov/pubmed/12031053 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="bc59b430-7a13-4ded-bacc-faaf07e6c7c2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2002-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/12031053"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6066-0</funderId>
      <contactId>Contact7305_6066</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7305_6066">
    <title>Dr</title>
    <forename>Magaret</forename>
    <surname>Somerville</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Research and Development Support Unit
Room N1
ITTC Building
Tamar Science Park
1 Davy Road</address>
      <city>Plymouth</city>
      <country>United Kingdom</country>
      <zip>PL6 8BX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">margaret.somerville@sw-devon-ha.swest.nhs.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6066-0">
    <name>NHS Executive South West (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">32282466</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Specialist treatment for alcohol problems presenting in an A&amp;E setting.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32282466</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>942010/RBB 94XX3</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1996-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1996-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0481d570-c4d5-4844-9214-9858065cc9ec">
	  <name>School of Health and Related Research</name>
	  <address/>
	  <city>Sheffield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>S1 4DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Not provided at time of registration</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>0</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Not provided at time of registration</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1996-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1996-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mental and behavioural disorders: Addiction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Alcohol addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Not provided at time of registration</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1998 Results article in http://www.ncbi.nlm.nih.gov/pubmed/9684397 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5c2e8566-38f4-4fdd-b461-233d41998d2b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1998-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/9684397"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6158-0</funderId>
      <contactId>Contact7331_6158</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7331_6158">
    <title>Prof</title>
    <forename>Charlie</forename>
    <surname>Brooker</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>School of Health and Related Research
University of Sheffield
Regent Court
30 Regent Street</address>
      <city>Sheffield</city>
      <country>United Kingdom</country>
      <zip>S1 4DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)114 222 5454</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.g.brooker@sheffield.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6158-0">
    <name>NHS Executive Trent (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2008-02-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2004-01-23T00:00:00.000Z">30555166</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomized Controlled Trial of Cardiotocography Versus Umbilical Artery Doppler in the Management of Small-for-Gestational-Age Fetuses</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Not provided at time of registration</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Not provided at time of registration</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN30555166</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1995-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1995-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="19169fee-a2cd-4f90-80e4-64b74c5653c8">
	  <name>Bradford Royal Infirmary</name>
	  <address/>
	  <city>Bradford</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BD9 6RJ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Women delivered of small for gestational age infants</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>Not provided at time of registration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1995-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1995-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neonatal diseases</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Doppler ultrasound versus cardiotocography</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1997 Results article in http://www.ncbi.nlm.nih.gov/pubmed/9141579 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="3e2c418b-ad25-47ab-9b73-540874aeee92" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="1997-04-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/pubmed/9141579"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder6169-0</funderId>
      <contactId>Contact7496_6169</contactId>
      <sponsorId>Sponsor5355</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact7496_6169">
    <title>Mr</title>
    <forename>D</forename>
    <surname>Tuffnell</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bradford Royal Infirmary
Duckworth Lane</address>
      <city>Bradford</city>
      <country>United Kingdom</country>
      <zip>BD9 6RJ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor5355">
    <organisation>NHS R&amp;D Regional Programme Register - Department of Health (UK)</organisation>
    <website>http://www.doh.gov.uk</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health
Richmond House
79 Whitehall</address>
      <city>London</city>
      <state/>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder6169-0">
    <name>NHS Executive Northern and Yorkshire (UK)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>